


09330446 0525722

JC03 Rec'd PCT/PTO 27 APR 2001

FORM PTO-1390 (Modified) (REV 5-93)		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 032931/0251	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371					
				U. S. APPLICATION NO. (If known, see 37 CFR 1.46) To be assigned 09/830446	
INTERNATIONAL APPLICATION NO. PCT/CA99/00992		INTERNATIONAL FILING DATE 28 October 1999		PRIORITY DATE CLAIMED 28 October 1998	
TITLE OF INVENTION CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF					
APPLICANT(S) FOR DO/EO/US Andrew D. MURDIN, Raymond P. OOMEN and Joe WANG					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.					
3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).					
4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date.					
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)					
6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).					
7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made.					
8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
11. <input type="checkbox"/> Applicant claims small entity status under 37 CFR 1.27.					
Items 12. to 17. below concern other document(s) or information included:					
12. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
14. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.					
15. <input type="checkbox"/> A substitute specification.					
16. <input type="checkbox"/> A change of power of attorney and/or address letter.					
17. <input type="checkbox"/> Other items or information:					

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.50) To be assigned 09/830446		INTERNATIONAL APPLICATION NO PCT/CA99/00992		ATTORNEY'S DOCKET NUMBER 032931/0251	
18. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATION	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO \$860.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$690.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00					
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,000.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))					
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	39	-	20	= 19	\$18.00
Independent Claims	8	-	3	= 5	\$80.00
Multiple dependent claim(s) (if applicable)				\$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$1602.00	
Reduction by 1/2 for filing by small entity, if applicable.				\$0.00	
SUBTOTAL =				\$1602.00	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
TOTAL NATIONAL FEE =				\$1602.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	
TOTAL FEES ENCLOSED =				\$1602.00	
				Amount to be: refunded \$	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$1602.00 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
FOLEY & LARDNER 3000 K Street, N.W., Suite 500 Washington, DC 20007				SIGNATURE 	
				NAME BERNHARD D. SAXE	
				REGISTRATION NUMBER 28,665	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No: 032931/0251

In re patent application of
MURDIN, Andrew D. *et al.*

Serial No.: Not Assigned
(U.S Entry of PCT/CA99/00992)

Group Art Unit: Not Assigned

Filed: October 28, 1999 (International Filing Date) Examiner: Not Assigned
US Entry Date: April 27, 2001

For: CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

AMENDMENT ACCOMPANYING SUBMISSION OF SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In order to comply with the requirements for patent applications containing amino acid and/or sequence disclosures, please amend the application as follows:

IN THE SPECIFICATION:

At the end of the specification, please insert the printed Sequence Listing submitted concurrently herewith.

REMARKS

Applicants submit this Amendment to insert the required references to SEQ ID NOS of the Sequence Listing filed concurrently herewith, and to indicate the insertion point for the Sequence Listing. Applicants respectfully request examination on the merits of this application.

Respectfully submitted;

June 22, 2001
Date

Joy D. Morrow
Joy D. Morrow
Reg. No. 30,911

09530446 052705
21 SEP 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No: 032931/0251

In re patent application of
MURDIN, Andrew D. *et al.*

Serial No.: U.S. National Entry
of PCT/CA99/00992

Group Art Unit: 1643

Filed: October 28, 1999

Examiner: Not assigned

For: CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND
USES THEREOF

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE with 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith,
the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. §
1.821(g), does not include new matter; and
2. the content of the attached paper copy and the attached computer
readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §
1.821(c) and (e), respectively, are the same.

Respectfully submitted,

25 May 2001
Date

Joy D. Morrow
Joy D. Morrow
Reg. No. 30,911

09 FEB 2001 09/830446

Attorney Docket No. 032931/0251

531 Rec'd PC

27 APR 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrew D. MURDIN
Title: CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS
AND USES THEREOF
Appl. No.: To be assigned
Filing Date: April 27, 2001
Examiner: Unassigned
Art Unit: Unassigned

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application, Applicants respectfully request that the following amendments be entered into the application:

IN THE CLAIMS:

Please cancel claims 1-24 in their entirety without prejudice or disclaimer and therefore insert new claims 25-63.

25. (New) A nucleic acid molecule comprising a nucleic acid sequence which encodes a polypeptide selected from any of:

(a) SEQ ID Nos: 27 to 45;

(b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and

(c) a polypeptide of (a) or (b) which has been modified without loss of immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

26. (New) A nucleic acid molecule comprising a nucleic acid sequence selected from any of:

(a) SEQ ID Nos: 1 to 26;

5 (b) a sequence which encodes a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(c) a sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (a) and (b); and

10 (d) a sequence which encodes a polypeptide which is at least 75% identical in amino acid sequence to any one of the polypeptides encoded by SEQ ID Nos: 1 to 26.

27. (New) A nucleic acid molecule comprising a nucleic acid sequence which is anti-sense to the nucleic acid molecule of claim 25.

28. (New) A nucleic acid molecule comprising a nucleic acid sequence which encodes a fusion protein, said fusion protein comprising a polypeptide encoded by a nucleic acid molecule
15 according to claim 25 and a second polypeptide.

29. (New) The nucleic acid molecule of claim 28 wherein the second polypeptide is a heterologous signal peptide.

30. (New) The nucleic acid molecule of claim 28 wherein the second polypeptide has adjuvant activity.

20 31. (New) A nucleic acid molecule according to claim 25, operatively linked to one or more expression control sequences.

32. (New) A vaccine comprising a vaccine vector and at least one first nucleic acid selected from any of:

(i) SEQ ID Nos: 1 to 26;

25 (ii) a nucleic acid sequence which encodes a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iii) a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (i) and (ii);

(iv) a nucleic acid sequence which encodes a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

5 (v) a nucleic acid sequence which encodes a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

(vi) a nucleic acid sequence which encodes an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

10 (vii) a nucleic acid sequence which encodes a polypeptide as defined in (v) or an immunogenic fragment as defined in (vi) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (v) or the corresponding fragment of (vi);

wherein each first nucleic acid is capable of being expressed.

33. 15 (New) A vaccine comprising a vaccine vector and at least one first nucleic acid encoding a fusion protein, wherein the fusion protein comprises:

(a) a first polypeptide selected from any of:

(i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 26;

20 (iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iv) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

(v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

25 (vi) a polypeptide as defined (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (iv) or the corresponding fragment of (v); and

(b) a second polypeptide;

wherein each first nucleic acid is capable of being expressed.

34. (New) The vaccine of claim 33 wherein the second polypeptide is a heterologous signal peptide.

5 35. (New) The vaccine of claim 33 wherein the second polypeptide has adjuvant activity.

36. (New) The vaccine of claim 32 wherein each first nucleic acid is operatively linked to one or more expression control sequences.

37. (New) A vaccine according to claim 32 wherein each first nucleic acid is expressed as a polypeptide, and wherein the vaccine comprises a second nucleic acid encoding an additional
10 polypeptide which enhances the immune response to the polypeptide expressed by the first nucleic acid.

38. (New) The vaccine of claim 37 wherein the second nucleic acid encodes an additional *Chlamydia* polypeptide.

39. (New) A pharmaceutical composition comprising a nucleic acid according to claim 25
15 and a pharmaceutically acceptable carrier.

40. (New) A pharmaceutical composition comprising a vaccine according to claim 32 and a pharmaceutically acceptable carrier.

41. (New) A unicellular host transformed with the nucleic acid molecule of claim 31.

42. (New) An isolated nucleic acid probe of 5 to 100 nucleotides which hybridizes under
20 stringent conditions to any one of nucleic acid molecules of SEQ ID Nos: 1 to 26, or to a complementary or anti-sense sequence of said nucleic acid molecule.

43. (New) A primer of 10 to 40 nucleotides which hybridizes under stringent conditions to any one of nucleic acid molecules of SEQ ID Nos: 1 to 26, or to a homolog or complementary or anti-sense sequence of said nucleic acid molecule.

25 44. (New) A polypeptide encoded by a nucleic acid sequence according to claim 26.

45. (New) A polypeptide comprising an amino acid sequence selected from any of:

(a) SEQ ID Nos: 27 to 45;

(b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and

5 (c) a polypeptide of (a) or (b) which has been modified without loss of immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

46. (New) A fusion protein comprising a polypeptide of claim 44 and a second polypeptide.

10 47. (New) The fusion protein of claim 46 wherein the second polypeptide is a heterologous signal peptide.

48. (New) The fusion protein of claim 46 wherein the second polypeptide has adjuvant activity.

15 49. (New) A method for producing a polypeptide, comprising the step of culturing a unicellular host of claim 41 and recovering the resultant polypeptide.

50. (New) An antibody against the polypeptide of claim 44.

51. (New) A vaccine comprising at least one first polypeptide selected from any of:

(i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

20 (ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 26;

(iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iv) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

25 (v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

(vi) a polypeptide as defined in (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or

fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (iv) or the corresponding fragment of (v).

52. (New) A vaccine comprising at least one fusion protein, wherein the fusion protein comprises:

5 (a) a first polypeptide selected from any of:

(i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 26;

10 (iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iv) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

(v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

15 (vi) a polypeptide as defined (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (iv) or the corresponding fragment of (v); and

(b) a second polypeptide.

53. (New) The vaccine of claim 52 wherein the second polypeptide is a heterologous
20 signal peptide.

54. (New) The vaccine of claim 52 wherein the second polypeptide has adjuvant activity.

55. (New) A vaccine comprising at least one first polypeptide according to claim 44 and an additional polypeptide which enhances the immune response to the first polypeptide.

56. (New) The vaccine of claim 55 wherein the additional polypeptide comprises a
25 *Chlamydia* polypeptide.

57. (New) A pharmaceutical composition comprising a polypeptide according to claim 44 and a pharmaceutically acceptable carrier.


Attorney Docket No. 032931/0251

(a) immunizing a mouse with a polypeptide of claim 44; and

(b) inoculating the immunized mouse with *Chlamydia*;

wherein the polypeptide which prevents or lessens the severity of *Chlamydia* infection in the immunized mouse compared to a non-immunized control mouse is identified.

The Examiner is respectfully requested to enter the above amendment prior to
5 examination of the instant application.

By 

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5414
Facsimile: (202) 672-5399

Bernhard D. Saxe
Attorney for Applicant
Registration No. 28,665

165/PRTS

09830446 09/830446

WO 00/24765

531 Rec'd PCT/F PCT/CA99/00893 27 APR 2001

TITLE OF INVENTION

**CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES
THEREOF**

5 REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S.
Provisional Application No. 60/106034, filed October 28, 1998,
U.S. Provisional Application No. 60/106039, filed October 28,
1998, U.S. Provisional Application No. 60/106042, filed October
10 28, 1998, U.S. Provisional Application No. 60/106044, filed
October 28, 1998, U.S. Provisional Application No. 60/106072,
filed October 29, 1998, U.S. Provisional Application No.
60/106073, filed October 29, 1998, U.S. Provisional Application
No. 60/106074, filed October 29, 1998, U.S. Provisional
15 Application No. 60/106087, filed October 29, 1998, U.S.
Provisional Application No. 60/106587, filed November 2, 1998,
U.S. Provisional Application No. 60/106588, filed November 2,
1998, U.S. Provisional Application No. 60/107089, filed November
2, 1998, U.S. Provisional Application No. 60/107034, filed
20 November 2, 1998 and U.S. Provisional Application No. 60/107035,
filed November 2, 1998.

FIELD OF INVENTION

The present invention relates to *Chlamydia* antigens
25 and corresponding DNA molecules, which can be used to prevent
and treat *Chlamydia* infection in mammals, such as humans.

BACKGROUND OF THE INVENTION

Chlamydiae are prokaryotes. They exhibit morphologic
30 and structural similarities to gram-negative bacteria including
a trilaminar outer membrane, which contains lipopolysaccharide
and several membrane proteins that are structurally and
functionally analogous to proteins found in *E coli*. They are
obligate intra-cellular parasites with a unique biphasic life

cycle consisting of a metabolically inactive but infectious extracellular stage and a replicating but non-infectious intracellular stage. The replicative stage of the life-cycle takes place within a membrane-bound inclusion which sequesters the bacteria away from the cytoplasm of the infected host cell.

C. pneumoniae is a common human pathogen, originally described as the TWAR strain of *Chlamydia psittaci* but subsequently recognised to be a new species. *C. pneumoniae* is antigenically, genetically and morphologically distinct from other chlamydia species (*C. trachomatis*, *C. pecorum* and *C. psittaci*). It shows 10% or less DNA sequence homology with either of *C. trachomatis* or *C. psittaci*.

C. pneumoniae is a common cause of community acquired pneumonia, only less frequent than *Streptococcus pneumoniae* and *Mycoplasma pneumoniae* (Grayston et al. (1995) Journal of Infectious Diseases 168:1231; Campos et al. (1995) Investigation of Ophthalmology and Visual Science 36:1477). It can also cause upper respiratory tract symptoms and disease, including bronchitis and sinusitis (Grayston et al. (1995) Journal of Infectious Diseases 168:1231; Grayston et al (1990) Journal of Infectious Diseases 161:618; Marrie (1993) Clinical Infectious Diseases. 18:501; Wang et al (1986) Chlamydial infections). Cambridge University Press, Cambridge. p. 329 The great majority of the adult population (over 60%) has antibodies to *C. pneumoniae* (Wang et al (1986) Chlamydial infections. Cambridge University Press, Cambridge. p. 329), indicating past infection which was unrecognized or asymptomatic.

C. pneumoniae infection usually presents as an acute respiratory disease (i.e., cough, sore throat, hoarseness, and fever; abnormal chest sounds on auscultation). For most patients, the cough persists for 2 to 6 weeks, and recovery is slow. In approximately 10% of these cases, upper respiratory tract infection is followed by bronchitis or pneumonia. Furthermore, during a *C. pneumoniae* epidemic, subsequent

co-infection with pneumococcus has been noted in about half of these pneumonia patients, particularly in the infirm and the elderly. As noted above, there is more and more evidence that *C. pneumoniae* infection is also linked to diseases other than
5 respiratory infections.

The reservoir for the organism is presumably people. In contrast to *C. psittaci* infections, there is no known bird or animal reservoir. Transmission has not been clearly defined. It may result from direct contact with secretions, from fomites, or
10 from airborne spread. There is a long incubation period, which may last for many months. Based on analysis of epidemics, *C. pneumoniae* appears to spread slowly through a population (case-to-case interval averaging 30 days) because infected persons are inefficient transmitters of the organism. Susceptibility to *C.*
15 *pneumoniae* is universal. Reinfections occur during adulthood, following the primary infection as a child. *C. pneumoniae* appears to be an endemic disease throughout the world, noteworthy for superimposed intervals of increased incidence (epidemics) that persist for 2 to 3 years. *C. trachomatis*
20 infection does not confer cross-immunity to *C. pneumoniae*. Infections are easily treated with oral antibiotics, tetracycline or erythromycin (2 g/d, for at least 10 to 14 d). A recently developed drug, azithromycin, is highly effective as a single-dose therapy against chlamydial infections.

25 In most instances, *C. pneumoniae* infection is often mild and without complications, and up to 90% of infections are subacute or unrecognized. Among children in industrialized countries, infections have been thought to be rare up to the age of 5 y, although a recent study (E Normann et al, Chlamydia
30 pneumoniae in children with acute respiratory tract infections, Acta Paediatrica, 1998, Vol 87, Iss 1, pp 23-27) has reported that many children in this age group show PCR evidence of infection despite being seronegative, and estimates a prevalence of 17-19% in 2-4 y olds. In developing countries, the

seroprevalence of *C. pneumoniae* antibodies among young children is elevated, and there are suspicions that *C. pneumoniae* may be an important cause of acute lower respiratory tract disease and mortality for infants and children in tropical regions of the

5 world.

From seroprevalence studies and studies of local epidemics, the initial *C. pneumoniae* infection usually happens between the ages of 5 and 20 y. In the USA, for example, there are estimated to be 30,000 cases of childhood pneumonia each 10 year caused by *C. pneumoniae*. Infections may cluster among groups of children or young adults (e.g., school pupils or military conscripts).

C. pneumoniae causes 10 to 25% of community-acquired lower respiratory tract infections (as reported from Sweden, Italy, Finland, and the USA). During an epidemic, *C. pneumoniae* infection may account for 50 to 60% of the cases of pneumonia. During these periods, also, more episodes of mixed infections with *S. pneumoniae* have been reported.

Reinfection during adulthood is common; the clinical presentation tends to be milder. Based on population seroprevalence studies, there tends to be increased exposure with age, which is particularly evident among men. Some investigators have speculated that a persistent, asymptomatic *C. pneumoniae* infection state is common.

25 In adults of middle age or older, *C. pneumoniae*
infection may progress to chronic bronchitis and sinusitis. A
study in the USA revealed that the incidence of pneumonia caused
by *C. pneumoniae* in persons younger than 60 years is 1 case per
1,000 persons per year; but in the elderly, the disease
30 incidence rose three-fold. *C. pneumoniae* infection rarely leads
to hospitalization, except in patients with an underlying
illness.

Of considerable importance is the association of atherosclerosis and *C. pneumoniae* infection. There are several

A number of recent studies have also indicated an association between *C. pneumoniae* infection and asthma. Infection has been linked to wheezing, asthmatic bronchitis, adult-onset asthma and acute exacerbations of asthma in adults, and small-scale studies have shown that prolonged antibiotic treatment was effective at greatly reducing the severity of the disease in some individuals (Hahn DL, et al. Evidence for *Chlamydia pneumoniae* infection in steroid-dependent asthma. Ann Allergy Asthma Immunol. 1998 Jan; 80(1): 45-49.; Hahn DL, et al. Association of *Chlamydia pneumoniae* IgA antibodies with recently symptomatic asthma. Epidemiol Infect. 1996 Dec;

WO 00/24765

PCT/CA99/00992

6

117(3): 513-517; Bjornsson E, et al. Serology of chlamydia in relation to asthma and bronchial hyperresponsiveness. Scand J Infect Dis. 1996; 28(1): 63-69.; Hahn DL. Treatment of *Chlamydia pneumoniae* infection in adult asthma: a before-after trial. J Fam Pract. 1995 Oct; 41(4): 345-351.; Allegra L, et al. Acute exacerbations of asthma in adults: role of *Chlamydia pneumoniae* infection. Eur Respir J. 1994 Dec; 7(12): 2165-2168.; Hahn DL, et al. Association of *Chlamydia pneumoniae* (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA. 1991 Jul 10; 266(2): 225-230).

In light of these results a protective vaccine against *C. pneumoniae* infection would be of considerable importance. There is not yet an effective vaccine for any human chlamydial infection. It is conceivable that an effective vaccine can be developed using physically or chemically inactivated *Chlamydiae*. However, such a vaccine does not have a high margin of safety. In general, safer vaccines are made by genetically manipulating the organism by attenuation or by recombinant means. Accordingly, a major obstacle in creating an effective and safe vaccine against human chlamydial infection has been the paucity of genetic information regarding *Chlamydia*, specifically *C. pneumoniae*.

Studies with *C. trachomatis* and *C. psittaci* indicate that safe and effective vaccine against *Chlamydia* is an attainable goal. For example, mice which have recovered from a lung infection with *C. trachomatis* are protected from infertility induced by a subsequent vaginal challenge (Pal et al. (1996) Infection and Immunity. 64:5341). Similarly, sheep immunized with inactivated *C. psittaci* were protected from subsequent chlamydial-induced abortions and stillbirths (Jones et al. (1995) Vaccine 13:715). Protection from chlamydial infections has been associated with Th1 immune responses, particularly the induction of INF γ - producing CD4+T-cells (Igiertsemes et al. (1993) Immunology 5:317). The adoptive

transfer of CD4+ cell lines or clones to nude or SCID mice conferred protection from challenge or cleared chronic disease (Igietseme et al (1993) Regional Immunology 5:317; Magee et al (1993) Regional Immunology 5: 305), and in vivo depletion of CD4+ T cells exacerbated disease post-challenge (Landers et al (1991) Infection & Immunity 59:3774; Magee et al (1995) Infection & Immunity 63:516). However, the presence of sufficiently high titres of neutralising antibody at mucosal surfaces can also exert a protective effect (Cotter et al. (1995) Infection and Immunity 63:4704).

Antigenic variation within the species *C. pneumoniae* is not well documented due to insufficient genetic information, though variation is expected to exist based on *C. trachomatis*. Serovars of *C. trachomatis* are defined on the basis of antigenic variation in MOMP, but published *C. pneumoniae* MOMP gene sequences show no variation between several diverse isolates of the organism (Campbell et al (1990) Infection and Immunity 58:93; McCafferty et al (1995) Infection and Immunity 63:2387-9; Knudsen et al (1996) Third Meeting of the European Society for Chlamydia Research, Vienna). Regions of the protein known to be conserved in other chlamydial MOMPs are conserved in *C. pneumoniae* (Campbell et al (1990) Infection and Immunity 58:93; McCafferty et al (1995) Infection and Immunity 63:2387-9). One study has described a strain of *C. pneumoniae* with a MOMP of greater than usual molecular weight, but the gene for this has not been sequenced (Grayston et al. (1995) Journal of Infectious Diseases 168:1231). Partial sequences of outer membrane protein 2 from nine diverse isolates were also found to be invariant (Ramirez et al (1996) Annals of Internal Medicine 125:979). The genes for HSP60 and HSP70 show little variation from other chlamydial species, as would be expected. The gene encoding a 76kDa antigen has been cloned from a single strain of *C. pneumoniae*. It has no significant similarity with other known

chlamydial genes (Marrie (1993) Clinical Infectious Diseases. 18:501).

Many antigens recognised by immune sera to *C. pneumoniae* are conserved across all *Chlamydiae*, but 98kDa, 76kDa and 54kDa proteins appear to be *C. pneumoniae*-specific (Campos et al. (1995) Investigation of Ophthalmology and Visual Science 36:1477; Marrie (1993) Clinical Infectious Diseases. 18:501; Wiedmann-Al-Ahmad M, et al. Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of *Chlamydia pneumoniae*. Clin Diagn Lab Immunol. 1997 Nov; 4(6): 700-704). A publication relevant to 98KDa proteins is Perez Melgosa et al. FEMS Microbiology Letters. 112(2): 199-204. 1993.

Immunoblotting of isolates with sera from patients does show variation of blotting patterns between isolates, indicating that serotypes *C. pneumoniae* may exist (Ref 1,16). However, the results are potentially confounded by the infection status of the patients, since immunoblot profiles of a patient's sera change with time post-infection. An assessment of the number and relative frequency of any serotypes, and the defining antigens, is not yet possible.

Accordingly, a need exists for identifying and isolating polynucleotide sequences of *C. pneumoniae* for use in preventing and treating *Chlamydia* infection.

SUMMARY OF THE INVENTION

The present invention provides purified and isolated polynucleotide molecules that encode *Chlamydia* polypeptides which can be used in methods to prevent, treat, and diagnose *Chlamydia* infection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode polypeptides CPN100397 (SEQ ID Nos: 1 and 2), CPN100421 (SEQ ID

invention, such vaccines and vaccine vectors being useful for, e.g., preventing and treating *Chlamydia* infection, in combination with a diluent or carrier, and related pharmaceutical compositions and associated therapeutic and/or prophylactic methods; (iii) a therapeutic and/or prophylactic use of an RNA or DNA molecule of the invention, either in a naked form or formulated with a delivery vehicle, a polypeptide or combination of polypeptides, or a monospecific antibody of the invention, and related pharmaceutical compositions; (iv) a method for diagnosing the presence of *Chlamydia* in a biological sample, which can involve the use of a DNA or RNA molecule, a monospecific antibody, or a polypeptide of the invention; and (v) a method for purifying a polypeptide of the invention by antibody-based affinity chromatography.

15

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further understood from the following description with reference to the drawings, in which:

Figure 1 shows the nucleotide sequence of the CPN100397 (SEQ ID No: 1 - entire sequence and SEQ ID No: 2 - coding sequence) and the deduced amino acid sequence of the CPN100397 protein from *Chlamydia pneumoniae* (SEQ ID No: 27 and 28).

Figure 2 shows the restriction enzyme analysis of the gene encoding the *C. pneumoniae* CPN100397 gene.

Figure 3 shows the nucleotide sequence of the CPN100421 (SEQ ID No: 3 - entire sequence and SEQ ID No: 4 - coding sequence) and the deduced amino acid sequence of the CPN100421 protein from *Chlamydia pneumoniae* (SEQ ID No: 29).

Figure 4 shows the restriction enzyme analysis of the gene encoding the *C. pneumoniae* CPN100421 gene.

Figure 5 shows the nucleotide sequence of the CPN100422 (SEQ ID No: 5 - entire sequence and SEQ ID No: 6 - coding sequence) and the deduced amino acid sequence of the CPN100422 protein from *Chlamydia pneumoniae* (SEQ ID No: 30).

Figure 6 shows the restriction enzyme analysis of the gene encoding the *C. pneumoniae* CPN100422 gene.

Figure 7 shows the nucleotide sequence of the CPN100424 (SEQ ID No: 7 - entire sequence and SEQ ID No: 8 - coding sequence) and the deduced amino acid sequence of the CPN100424 protein from *Chlamydia pneumoniae* (SEQ ID No: 31).

Figure 8 shows the restriction enzyme analysis of the gene encoding the *C. pneumoniae* CPN100424 gene.

Figure 9 shows the nucleotide sequence of the CPN100426 (SEQ ID No: 9 - entire sequence and SEQ ID No: 10 - coding sequence) and the deduced amino acid sequence of the CPN100426 protein from *Chlamydia pneumoniae* (SEQ ID No: 32).

Figure 10 shows the restriction enzyme analysis of the gene encoding the *C. pneumoniae* CPN100426 gene.

Figure 11 shows the nucleotide sequence of the CPN100508 (SEQ ID No: 11 - entire sequence and SEQ ID No: 12 - coding sequence) and the deduced amino acid sequence of the CPN100508 protein from *Chlamydia pneumoniae* (SEQ ID No: 33 - full length sequence and SEQ ID No: 34 - processed sequence).

Figure 12 shows the restriction enzyme analysis of the gene encoding the *C. pneumoniae* CPN100508 gene.

Figure 13 shows the nucleotide sequence of the CPN100515 (SEQ ID No: 13 - entire sequence and SEQ ID No: 14 - coding sequence) and the deduced amino acid sequence of the CPN100515 protein from *Chlamydia pneumoniae* (SEQ ID No: 35 - full length sequence and SEQ ID No: 36 - processed sequence).

Figure 14 shows the restriction enzyme analysis of the gene encoding the *C. pneumoniae* CPN100515 gene.

Figure 15 shows the nucleotide sequence of the CPN100538 (SEQ ID No: 15 - entire sequence and SEQ ID No: 16 - coding sequence) and the deduced amino acid sequence of the CPN100538 protein from *Chlamydia pneumoniae* (SEQ ID No: 37).

Figure 16 shows the restriction enzyme analysis of the gene encoding the *C. pneumoniae* CPN100538 gene.

The polynucleotide of the invention is either RNA or DNA (cDNA, genomic DNA, or synthetic DNA), or modifications, variants, homologs or fragments thereof. The DNA is either double-stranded or single-stranded, and, if single-stranded, is either the coding strand or the non-coding (anti-sense) strand. Any one of the sequences that encode the polypeptides of the invention as shown in SEQ ID Nos: 1 to 26 is (a) a coding sequence, (b) a ribonucleotide sequence derived from transcription of (a), or (c) a coding sequence which uses the redundancy or degeneracy of the genetic code to encode the same polypeptides. By "polypeptide" or "protein" is meant any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). Both terms are used interchangeably in the present application.

Consistent with the first aspect of the invention, amino acid sequences are provided which are homologous to any one of SEQ ID Nos: 27 to 45. As used herein, "homologous amino acid sequence" is any polypeptide which is encoded, in whole or in part, by a nucleic acid sequence which hybridizes at 25-35°C below critical melting temperature (T_m), to any portion of the nucleic acid sequences of SEQ ID Nos: 1 to 26. A homologous amino acid sequence is one that differs from an amino acid sequence shown in any one of SEQ ID Nos: 27 to 45 by one or more amino acid substitutions. Such a sequence also encompasses serotypic variants (defined below) as well as sequences containing deletions or insertions which retain inherent characteristics of the polypeptide such as immunogenicity. Preferably, such a sequence is at least 75%, more preferably 80%, and most preferably 90% identical to any one of SEQ ID Nos: 27 to 45. Homologous amino acid sequences include sequences that are identical or substantially identical to SEQ ID Nos: 27 to 45. By "amino acid sequence substantially identical" is meant a sequence that is at least 90%, preferably 95%, more preferably 97%, and most preferably 99% identical to

an amino acid sequence of reference and that preferably differs from the sequence of reference by a majority of conservative amino acid substitutions.

Conservative amino acid substitutions are substitutions among amino acids of the same class. These classes include, for example, amino acids having uncharged polar side chains, such as asparagine, glutamine, serine, threonine, and tyrosine; amino acids having basic side chains, such as lysine, arginine, and histidine; amino acids having acidic side chains, such as aspartic acid and glutamic acid; and amino acids having nonpolar side chains, such as glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, and cysteine.

Homology is measured using sequence analysis software such as Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705. Amino acid sequences are aligned to maximize identity. Gaps may be artificially introduced into the sequence to attain proper alignment. Once the optimal alignment has been set up, the degree of homology is established by recording all of the positions in which the amino acids of both sequences are identical, relative to the total number of positions.

Homologous polynucleotide sequences are defined in a similar way. Preferably, a homologous sequence is one that is at least 45%, more preferably 60%, and most preferably 85% identical to any one of coding sequences SEQ ID Nos: 1 to 26.

Consistent with the first aspect of the invention, polypeptides having a sequence homologous to any one of SEQ ID Nos: 27 to 45 include naturally-occurring allelic variants, as well as mutants or any other non-naturally occurring variants that retain the inherent characteristics of the polypeptide of SEQ ID Nos: 27 to 45.

primer is selected which consists of 10 to 40, preferably 15 to 25 nucleotides. It is advantageous to select primers containing C and G nucleotides in a proportion sufficient to ensure efficient hybridization; i.e., an amount of C and G nucleotides of at least 40%, preferably 50% of the total nucleotide content.

An alternative method for retrieving polynucleotides encoding homologous polypeptides or allelic variants is by hybridization screening of a DNA or RNA library. Hybridization procedures are well-known in the art and are described in Ausubel et al., (Ref 41), Silhavy et al. (Ref 43), and Davis et al. (ref 44). Important parameters for optimizing hybridization conditions are reflected in a formula used to obtain the critical melting temperature above which two complementary DNA strands separate from each other (Ref 45). For polynucleotides of about 600 nucleotides or larger, this formula is as follows:

$$T_m = 81.5 + 0.5 \times (\% \text{ G+C}) + 1.6 \log (\text{positive ion concentration}) - 0.6 \times (\% \text{ formamide}).$$

Under appropriate stringency conditions, hybridization temperature (T_h) is approximately 20 to 40°C, 20 to 25°C, or, preferably 30 to 40°C below the calculated T_m . Those skilled in the art will understand that optimal temperature and salt conditions can be readily determined.

For the polynucleotides of the invention, stringent conditions are achieved for both pre-hybridizing and hybridizing incubations (i) within 4-16 hours at 42°C, in 6 x SSC containing 50% formamide, or (ii) within 4-16 hours at 65°C in an aqueous 6 x SSC solution (1 M NaCl, 0.1 M sodium citrate (pH 7.0)).

Useful homologs and fragments thereof that do not occur naturally are designed using known methods for identifying regions of an antigen that are likely to tolerate amino acid sequence changes and/or deletions. As an example, homologous polypeptides from different species are compared; conserved sequences are identified. The more divergent sequences are the most likely to tolerate sequence changes. Alternatively, sequences are modified such that they become more reactive to T-

WO 00/24765

PCT/CA99/00992

18

and/or B-cells. (See Table below for identification of T- and B- epitopes.) Yet another alternative is to mutate a particular amino acid residue or sequence within the polypeptide *in vitro*, then screen the mutant polypeptides for their ability to prevent 5 or treat Chlamydia infection according to the method outlined below.

A person skilled in the art will readily understand that by following the screening process of this invention, it will be determined without undue experimentation whether a particular 10 homolog of any of SEQ ID Nos: 27 to 45 may be useful in the prevention or treatment of Chlamydia infection. The screening procedure comprises the steps:

- (i) immunizing an animal, preferably mouse, with the test homolog or fragment;
- 15 (ii) inoculating the immunized animal with Chlamydia; and
- (iii) selecting those homologs or fragments which confer protection against Chlamydia.

By "conferring protection" is meant that there is a 20 reduction in severity of any of the effects of Chlamydia infection, in comparison with a control animal which was not immunized with the test homolog or fragment.

It has been previously demonstrated (Yang *et. al.*, 1993) that mice are susceptible to intranasal infection with different 25 isolates of *C. pneumoniae*. Strain AR-39 (Grayston, 1989) was used in Balb/c mice as a challenge infection model to examine the capacity of chlamydia gene products delivered as naked DNA to elicit a protective response against a sublethal *C. pneumoniae* lung infection. Protective immunity is defined as an 30 accelerated clearance of pulmonary infection.

Groups of 7 to 9 week old male Balb/c mice (6 to 10 per group) were immunized intramuscularly (i.m.) plus intranasally (i.n.) with plasmid DNA containing the coding sequence of a *C.pneumoniae* polypeptide. Saline or the plasmid vector lacking

additional advantage of removing immunodominant regions of high variability among strains. Polynucleotides encoding polypeptide fragments and polypeptides having large internal deletions are constructed using standard methods (Ref 41). Such methods
5 include standard PCR, inverse PCR, restriction enzyme treatment of cloned DNA molecules, or the method of Kunkel et al. (Ref 42). Components for these methods and instructions for their use are readily available from various commercial sources such as Stratagene. Once the deletion mutants have been constructed,
10 they are tested for their ability to prevent or treat Chlamydia infection as described above.

As used herein, a fusion polypeptide is one that contains a polypeptide or a polypeptide derivative of the invention fused at the N- or C-terminal end to any other polypeptide
15 (hereinafter referred to as a peptide tail). A simple way to obtain such a fusion polypeptide is by translation of an in-frame fusion of the polynucleotide sequences, i.e., a hybrid gene. The hybrid gene encoding the fusion polypeptide is inserted into an expression vector which is used to transform or
20 transfect a host cell. Alternatively, the polynucleotide sequence encoding the polypeptide or polypeptide derivative is inserted into an expression vector in which the polynucleotide encoding the peptide tail is already present. Such vectors and instructions for their use are commercially available, e.g.
25 the pMal-c2 or pMal-p2 system from New England Biolabs, in which the peptide tail is a maltose binding protein, the glutathione-S-transferase system of Pharmacia, or the His-Tag system available from Novagen. These and other expression systems provide convenient means for further purification of
30 polypeptides and derivatives of the invention.

An advantageous example of a fusion polypeptide is one where the polypeptide or homolog or fragment of the invention is fused to a polypeptide having adjuvant activity, such as subunit B of either cholera toxin or *E. coli* heat-labile toxin. Another

cells used for recombinant protein expression also provide instructions for usage of the cells.

The choice of the expression system depends on the features desired for the expressed polypeptide. For example, it
5 may be useful to produce a polypeptide of the invention in a particular lipidated form or any other form.

One skilled in the art would readily understand that not all vectors and expression control sequences and hosts would be expected to express equally well the polynucleotides of this
10 invention. With the guidelines described below, however, a selection of vectors, expression control sequences and hosts may be made without undue experimentation and without departing from the scope of this invention.

In selecting a vector, the host must be chosen that is
15 compatible with the vector which is to exist and possibly replicate in it. Considerations are made with respect to the vector copy number, the ability to control the copy number, expression of other proteins such as antibiotic resistance. In selecting an expression control sequence, a number of variables
20 are considered. Among the important variable are the relative strength of the sequence (e.g. the ability to drive expression under various conditions), the ability to control the sequence's function, compatibility between the polynucleotide to be expressed and the control sequence (e.g. secondary structures
25 are considered to avoid hairpin structures which prevent efficient transcription). In selecting the host, unicellular hosts are selected which are compatible with the selected vector, tolerant of any possible toxic effects of the expressed product, able to secrete the expressed product efficiently if
30 such is desired, to be able to express the product in the desired conformation, to be easily scaled up, and to which ease of purification of the final product.

The choice of the expression cassette depends on the host system selected as well as the features desired for the

a mammalian cell and unable to integrate into the mammalian genome. Typically, such a DNA molecule is placed under the control of a promoter suitable for expression in a mammalian cell. The promoter functions either ubiquitously or tissue-specifically. Examples of non-tissue specific promoters include the early Cytomegalovirus (CMV) promoter (described in U.S. Patent No. 4,168,062) and the Rous Sarcoma Virus promoter (described in Norton & Coffin, *Molec. Cell Biol.* (1985) 5:281). An example of a tissue-specific promoter is the desmin promoter which drives expression in muscle cells (Li et al., *Gene* (1989) 78:243, Li & Paulin, *J. Biol. Chem.* (1991) 266:6562 and Li & Paulin, *J. Biol. Chem.* (1993) 268:10403). Use of promoters is well-known to those skilled in the art. Useful vectors are described in numerous publications, specifically WO 94/21797 and Hartikka et al., *Human Gene Therapy* (1996) 7:1205.

Polynucleotides of the invention which are used as a vaccine encode either a precursor or a mature form of the corresponding polypeptide. In the precursor form, the signal peptide is either homologous or heterologous. In the latter case, a eucaryotic leader sequence such as the leader sequence of the tissue-type plasminogen factor (tPA) is preferred.

As used herein, a composition of the invention contains one or several polynucleotides with optionally at least one additional polynucleotide encoding another *Chlamydia* antigen such as urease subunit A, B, or both, or a fragment, derivative, mutant, or analog thereof. The composition may also contain an additional polynucleotide encoding a cytokine, such as interleukin-2 (IL-2) or interleukin-12 (IL-12) so that the immune response is enhanced. These additional polynucleotides are placed under appropriate control for expression. Advantageously, DNA molecules of the invention and/or additional DNA molecules to be included in the same composition, are present in the same plasmid.

Standard techniques of molecular biology for preparing and purifying polynucleotides are used in the preparation of polynucleotide therapeutics of the invention. For use as a vaccine, a polynucleotide of the invention is formulated
5 according to various methods outlined below.

One method utilizes the polynucleotide in a naked form, free of any delivery vehicles. Such a polynucleotide is simply diluted in a physiologically acceptable solution such as sterile saline or sterile buffered saline, with or without a
10 carrier. When present, the carrier preferably is isotonic, hypotonic, or weakly hypertonic, and has a relatively low ionic strength, such as provided by a sucrose solution, e.g., a solution containing 20% sucrose.

An alternative method utilizes the polynucleotide in
15 association with agents that assist in cellular uptake. Examples of such agents are (i) chemicals that modify cellular permeability, such as bupivacaine (see, e.g., WO 94/16737), (ii) liposomes for encapsulation of the polynucleotide, or (iii) cationic lipids or silica, gold, or tungsten
20 microparticles which associate themselves with the polynucleotides.

Anionic and neutral liposomes are well-known in the art (see, e.g., Liposomes: A Practical Approach, RPC New Ed, IRL press (1990), for a detailed description of methods for making
25 liposomes) and are useful for delivering a large range of products, including polynucleotides. Cationic lipids are also known in the art and are commonly used for gene delivery. Such lipids include LipofectinTM also known as DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP
30 (1,2-bis(oleyloxy)-3-(trimethylammonio)propane), DDAB (dimethyldioctadecylammonium bromide), DOGS (dioctadecylamidologlycyl spermine) and cholesterol derivatives such as DC-Chol (3 beta-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol). A description of these cationic lipids

can be found in EP 187,702, WO 90/11092, U.S. Patent No. 5,283,185, WO 91/15501, WO 95/26356, and U.S. Patent No. 5,527,928. Cationic lipids for gene delivery are preferably used in association with a neutral lipid such as DOPE (dioleyl 5 phosphatidylethanolamine), as described in WO 90/11092 as an example.

Formulation containing cationic liposomes may optionally contain other transfection-facilitating compounds. A number of them are described in WO 93/18759, WO 93/19768, WO 94/25608, and 10 WO 95/2397. They include spermine derivatives useful for facilitating the transport of DNA through the nuclear membrane (see, for example, WO 93/18759) and membrane-permeabilizing compounds such as GALA, Gramicidine S, and cationic bile salts (see, for example, WO 93/19768).

15 Gold or tungsten microparticles are used for gene delivery, as described in WO 91/359, WO 93/17706, and Tang et al. (Nature (1992) 356:152). The microparticle-coated polynucleotide is injected via intradermal or intraepidermal routes using a needleless injection device ("gene gun"), such as 20 those described in U.S. Patent No. 4,945,050, U.S. Patent No. 5,015,580, and WO 94/24263.

The amount of DNA to be used in a vaccine recipient depends, e.g., on the strength of the promoter used in the DNA construct, the immunogenicity of the expressed gene product, the 25 condition of the mammal intended for administration (e.g., the weight, age, and general health of the mammal), the mode of administration, and the type of formulation. In general, a therapeutically or prophylactically effective dose from about 1 µg to about 1 mg, preferably, from about 10 µg to about 800 µg 30 and, more preferably, from about 25 µg to about 250 µg, can be administered to human adults. The administration can be achieved in a single dose or repeated at intervals.

The route of administration is any conventional route used in the vaccine field. As general guidance, a

polynucleotide of the invention is administered via a mucosal surface, e.g., an ocular, intranasal, pulmonary, oral, intestinal, rectal, vaginal, and urinary tract surface; or via a parenteral route, e.g., by an intravenous, subcutaneous, 5 intraperitoneal, intradermal, intraepidermal, or intramuscular route. The choice of administration route depends on the formulation that is selected. A polynucleotide formulated in association with bupivacaine is advantageously administered into muscles. When a neutral or anionic liposome or a cationic 10 lipid, such as DOTMA or DC-Chol, is used, the formulation can be advantageously injected via intravenous, intranasal (aerosolization), intramuscular, intradermal, and subcutaneous routes. A polynucleotide in a naked form can advantageously be administered via the intramuscular, intradermal, or sub- 15 cutaneous routes.

Although not absolutely required, such a composition can also contain an adjuvant. If so, a systemic adjuvant that does not require concomitant administration in order to exhibit an adjuvant effect is preferable such as, e.g., QS21, which is 20 described in U.S. Patent No. 5,057,546.

The sequence information provided in the present application enables the design of specific nucleotide probes and primers that are used for diagnostic purposes. Accordingly, a fifth aspect of the invention provides a nucleotide probe or 25 primer having a sequence found in or derived by degeneracy of the genetic code from a sequence shown in any one of SEQ ID Nos:1 to 26.

The term "probe" as used in the present application refers to DNA (preferably single stranded) or RNA molecules (or 30 modifications or combinations thereof) that hybridize under the stringent conditions, as defined above, to nucleic acid molecules having SEQ ID Nos: 1 to 26 or to sequences homologous to SEQ ID Nos:1 to 26, or to their complementary or anti-sense sequences. Generally, probes are significantly shorter than

full-length sequences . Such probes contain from about 5 to about 100, preferably from about 10 to about 80, nucleotides. In particular, probes have sequences that are at least 75%, preferably at least 85%, more preferably 95% homologous to a portion of any of SEQ ID Nos:1 to 26 or that are complementary to such sequences. Probes may contain modified bases such as inosine, methyl-5-deoxycytidine, deoxyuridine, dimethylamino-5-deoxyuridine, or diamino-2, 6-purine. Sugar or phosphate residues may also be modified or substituted. For example, a deoxyribose residue may be replaced by a polyamide (Nielsen et al., Science (1991) 254:1497) and phosphate residues may be replaced by ester groups such as diphosphate, alkyl, arylphosphonate and phosphorothioate esters. In addition, the 2'-hydroxyl group on ribonucleotides may be modified by including such groups as alkyl groups.

Probes of the invention are used in diagnostic tests, as capture or detection probes. Such capture probes are conventionally immobilized on a solid support, directly or indirectly, by covalent means or by passive adsorption. A detection probe is labelled by a detection marker selected from: radioactive isotopes, enzymes such as peroxidase, alkaline phosphatase, and enzymes able to hydrolyze a chromogenic, fluorogenic, or luminescent substrate, compounds that are chromogenic, fluorogenic, or luminescent, nucleotide base analogs, and biotin.

Probes of the invention are used in any conventional hybridization technique, such as dot blot (Maniatis et al., Molecular Cloning: A Laboratory Manual (1982) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), Southern blot (Southern, J. Mol. Biol. (1975) 98:503), northern blot (identical to Southern blot with the exception that RNA is used as a target), or the sandwich technique (Dunn et al., Cell (1977) 12:23). The latter technique involves the use of a specific capture probe and/or a specific detection probe with

in which it naturally occurs and/or that is free of the majority of the polypeptides that are present in the environment in which it was synthesized. For example, a substantially purified polypeptide is free from cytoplasmic polypeptides. Those skilled in the art would readily understand that the polypeptides of the invention may be purified from a natural source, i.e., a *Chlamydia* strain, or produced by recombinant means.

Consistent with the sixth aspect of the invention are polypeptides, homologs or fragments which are modified or treated to enhance their immunogenicity in the target animal, in whom the polypeptide, homolog or fragments are intended to confer protection against *Chlamydia*. Such modifications or treatments include: amino acid substitutions with an amino acid derivative such as 3-methylhistidine, 4-hydroxyproline, 5-hydroxylysine etc., modifications or deletions which are carried out after preparation of the polypeptide, homolog or fragment, such as the modification of free amino, carboxyl or hydroxyl side groups of the amino acids.

Identification of homologous polypeptides or polypeptide derivatives encoded by polynucleotides of the invention which have specific antigenicity is achieved by screening for cross-reactivity with an antiserum raised against the polypeptide of reference having an amino acid sequence of any one of SEQ ID Nos: 27 to 45. The procedure is as follows: a monospecific hyperimmune antiserum is raised against a purified reference polypeptide, a fusion polypeptide (for example, an expression product of MBP, GST, or His-tag systems), or a synthetic peptide predicted to be antigenic. Where an antiserum is raised against a fusion polypeptide, two different fusion systems are employed. Specific antigenicity can be determined according to a number of methods, including Western blot (Towbin et al., Proc. Natl. Acad. Sci. USA (1979) 76:4350), dot blot, and ELISA, as described below.

In a dot blot assay, a purified product is preferred, although a whole cell extract can also be used. Briefly, a solution of the product at about 100 µg/ml is serially two-fold diluted in 50 mM Tris-HCl (pH 7.5). 100 µl of each dilution are applied to a nitrocellulose membrane 0.45 µm set in a 96-well dot blot apparatus (Biorad). The buffer is removed by applying vacuum to the system. Wells are washed by addition of 50 mM Tris-HCl (pH 7.5) and the membrane is air-dried. The membrane is saturated in blocking buffer (50 mM Tris-HCl (pH 7.5) 0.15 M NaCl, 10 g/L skim milk) and incubated with an antiserum dilution from about 1:50 to about 1:5000, preferably about 1:500. The reaction is revealed according to standard procedures. For example, a goat anti-rabbit peroxidase conjugate is added to the wells when rabbit antibodies are used. Incubation is carried out 90 minutes at 37°C and the blot is washed. The reaction is developed with the appropriate substrate and stopped. The reaction is measured visually by the appearance of a colored spot, e.g., by colorimetry. Under the above experimental conditions, a positive reaction is shown once a colored spot is associated with a dilution of at least about 1:5, preferably of at least about 1:500.

Therapeutic or prophylactic efficacy of a polypeptide or derivative of the invention can be evaluated as described below. A seventh aspect of the invention provides (i) a composition of matter comprising a polypeptide of the invention together with a diluent or carrier; specifically (ii) a pharmaceutical composition containing a therapeutically or prophylactically effective amount of a polypeptide of the invention; (iii) a method for inducing an immune response against *Chlamydia* in a mammal, by administering to the mammal an immunogenically effective amount of a polypeptide of the invention to elicit a protective immune response to *Chlamydia*; and particularly, (iv) a method for preventing and/or treating a *Chlamydia* (e.g., *C. trachomatis*, *C. psittaci*, *C. pneumoniae*, or *C. pecorum*)

infection, by administering a prophylactic or therapeutic amount of a polypeptide of the invention to an infected individual. Additionally, the seventh aspect of the invention encompasses the use of a polypeptide of the invention in the preparation of
5 a medicament for preventing and/or treating *Chlamydia* infection.

As used herein, the immunogenic compositions of the invention are administered by conventional routes known the vaccine field, in particular to a mucosal (e.g., ocular, intranasal, pulmonary, oral, gastric, intestinal, rectal,
10 vaginal, or urinary tract) surface or via the parenteral (e.g., subcutaneous, intradermal, intramuscular, intravenous, or intraperitoneal) route. The choice of administration route depends upon a number of parameters, such as the adjuvant associated with the polypeptide. If a mucosal adjuvant is used,
15 the intranasal or oral route is preferred. If a lipid formulation or an aluminum compound is used, the parenteral route is preferred with the sub-cutaneous or intramuscular route being most preferred. The choice also depends upon the nature of the vaccine agent. For example, a polypeptide of the
20 invention fused to CTB or LTB is best administered to a mucosal surface.

As used herein, the composition of the invention contains one or several polypeptides or derivatives of the invention. The composition optionally contains at least one additional
25 *Chlamydia* antigen, or a subunit, fragment, homolog, mutant, or derivative thereof.

For use in a composition of the invention, a polypeptide or derivative thereof is formulated into or with liposomes, preferably neutral or anionic liposomes, microspheres, ISCOMS,
30 or virus-like-particles (VLPs) to facilitate delivery and/or enhance the immune response. These compounds are readily available to one skilled in the art; for example, see Liposomes: A Practical Approach (*supra*).

Adjuvants other than liposomes and the like are also used and are known in the art. Adjuvants may protect the antigen from rapid dispersal by sequestering it in a local deposit, or they may contain substances that stimulate the host to secrete factors that are chemotactic for macrophages and other components of the immune system. An appropriate selection can conventionally be made by those skilled in the art, for example, from those described below.

Treatment is achieved in a single dose or repeated as necessary at intervals, as can be determined readily by one skilled in the art. For example, a priming dose is followed by three booster doses at weekly or monthly intervals. An appropriate dose depends on various parameters including the recipient (e.g., adult or infant), the particular vaccine antigen, the route and frequency of administration, the presence/absence or type of adjuvant, and the desired effect (e.g., protection and/or treatment), as can be determined by one skilled in the art. In general, a vaccine antigen of the invention is administered by a mucosal route in an amount from about 10 μ g to about 500 mg, preferably from about 1 mg to about 200 mg. For the parenteral route of administration, the dose usually does not exceed about 1 mg, preferably about 100 μ g.

When used as vaccine agents, polynucleotides and polypeptides of the invention may be used sequentially as part of a multistep immunization process. For example, a mammal is initially primed with a vaccine vector of the invention such as a pox virus, e.g., via the parenteral route, and then boosted twice with the polypeptide encoded by the vaccine vector, e.g., via the mucosal route. In another example, liposomes associated with a polypeptide or derivative of the invention is also used for priming, with boosting being carried out mucosally using a soluble polypeptide or derivative of the invention in combination with a mucosal adjuvant (e.g., LT).

A polypeptide derivative of the invention is also used in accordance with the seventh aspect as a diagnostic reagent for detecting the presence of anti-*Chlamydia* antibodies, e.g., in a blood sample. Such polypeptides are about 5 to about 80, 5 preferably about 10 to about 50 amino acids in length. They are either labeled or unlabeled, depending upon the diagnostic method. Diagnostic methods involving such a reagent are described below.

Upon expression of a DNA molecule of the invention, a 10 polypeptide or polypeptide derivative is produced and purified using known laboratory techniques. As described above, the polypeptide or polypeptide derivative may be produced as a fusion protein containing a fused tail that facilitates purification. The fusion product is used to immunize a small 15 mammal, e.g., a mouse or a rabbit, in order to raise antibodies against the polypeptide or polypeptide derivative (monospecific antibodies). Accordingly, an eighth aspect of the invention provides a monospecific antibody that binds to a polypeptide or polypeptide derivative of the invention.

20 By "monospecific antibody" is meant an antibody that is capable of reacting with a unique naturally-occurring *Chlamydia* polypeptide. An antibody of the invention is either polyclonal or monoclonal. Monospecific antibodies may be recombinant, e.g., chimeric (e.g., constituted by a variable region of murine 25 origin associated with a human constant region), humanized (a human immunoglobulin constant backbone together with hypervariable region of animal, e.g., murine, origin), and/or single chain. Both polyclonal and monospecific antibodies may also be in the form of immunoglobulin fragments, e.g., F(ab)'2 30 or Fab fragments. The antibodies of the invention are of any isotype, e.g., IgG or IgA, and polyclonal antibodies are of a single isotype or a mixture of isotypes.

Antibodies against the polypeptides, homologs or fragments of the present invention are generated by immunization

of a mammal with a composition comprising said polypeptide, homolog or fragment. Such antibodies may be polyclonal or monoclonal. Methods to produce polyclonal or monoclonal antibodies are well known in the art. For a review, see

5 "Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Eds. E. Harlow and D. Lane (1988), and D.E. Yelton et al., 1981. Ann. Rev. Biochem. 50:657-680. For monoclonal antibodies, see Kohl and Milstein?..

The antibodies of the invention, which are raised to a

10 polypeptide or polypeptide derivative of the invention, are produced and identified using standard immunological assays, e.g., Western blot analysis, dot blot assay, or ELISA (see, e.g., Coligan et al., Current Protocols in Immunology (1994) John Wiley & Sons, Inc., New York, NY). The antibodies are used

15 in diagnostic methods to detect the presence of a *Chlamydia* antigen in a sample, such as a biological sample. The antibodies are also used in affinity chromatography for purifying a polypeptide or polypeptide derivative of the invention. As is discussed further below, such antibodies may

20 be used in prophylactic and therapeutic passive immunization methods.

Accordingly, a ninth aspect of the invention provides (i) a reagent for detecting the presence of *Chlamydia* in a biological sample that contains an antibody, polypeptide, or

25 polypeptide derivative of the invention; and (ii) a diagnostic method for detecting the presence of *Chlamydia* in a biological sample, by contacting the biological sample with an antibody, a polypeptide, or a polypeptide derivative of the invention, such that an immune complex is formed, and by detecting such complex

30 to indicate the presence of *Chlamydia* in the sample or the organism from which the sample is derived.

Those skilled in the art will readily understand that the immune complex is formed between a component of the sample and the antibody, polypeptide, or polypeptide derivative, whichever

is used, and that any unbound material is removed prior to detecting the complex. It is understood that a polypeptide reagent is useful for detecting the presence of anti-*Chlamydia* antibodies in a sample, e.g., a blood sample, while an antibody of the invention is used for screening a sample, such as a gastric extract or biopsy, for the presence of *Chlamydia* polypeptides.

For diagnostic applications, the reagent (i.e., the antibody, polypeptide, or polypeptide derivative of the invention) is either in a free state or immobilized on a solid support, such as a tube, a bead, or any other conventional support used in the field. Immobilization is achieved using direct or indirect means. Direct means include passive adsorption (non-covalent binding) or covalent binding between the support and the reagent. By "indirect means" is meant that an anti-reagent compound that interacts with a reagent is first attached to the solid support. For example, if a polypeptide reagent is used, an antibody that binds to it can serve as an anti-reagent, provided that it binds to an epitope that is not involved in the recognition of antibodies in biological samples. Indirect means may also employ a ligand-receptor system, for example, where a molecule such as a vitamin is grafted onto the polypeptide reagent and the corresponding receptor immobilized on the solid phase. This is illustrated by the biotin-streptavidin system. Alternatively, a peptide tail is added chemically or by genetic engineering to the reagent and the grafted or fused product immobilized by passive adsorption or covalent linkage of the peptide tail.

Such diagnostic agents may be included in a kit which also comprises instructions for use. The reagent are labeled with a detection means which allows for the detection of the reagent when it is bound to its target. The detection means may be a fluorescent agent such as fluorescein isocyanate or fluorescein isothiocyanate, or an enzyme such as horse radish

prophylactically effective amount of a monospecific antibody of the invention, and (iii) a method for treating or preventing a *Chlamydia* (e.g., *C. trachomatis*, *C. psittaci*, *C. pneumoniae* or *C. pecorum*) infection, by administering a therapeutic or

5 prophylactic amount of a monospecific antibody of the invention to an infected individual. Additionally, the eleventh aspect of the invention encompasses the use of a monospecific antibody of the invention in the preparation of a medicament for treating or preventing *Chlamydia* infection.

The monospecific antibody is either polyclonal or monoclonal, preferably of the IgA isotype (predominantly). In passive immunization, the antibody is administered to a mucosal surface of a mammal, e.g., the gastric mucosa, e.g., orally or intragastrically, advantageously, in the presence of a bicarbonate buffer. Alternatively, systemic administration, not requiring a bicarbonate buffer, is carried out. A monospecific antibody of the invention is administered as a single active component or as a mixture with at least one monospecific antibody specific for a different *Chlamydia* polypeptide. The amount of antibody and the particular regimen used are readily determined by one skilled in the art. For example, daily administration of about 100 to 1,000 mg of antibodies over one week, or three doses per day of about 100 to 1,000 mg of antibodies over two or three days, are effective regimens for most purposes.

Therapeutic or prophylactic efficacy are evaluated using standard methods in the art, e.g., by measuring induction of a mucosal immune response or induction of protective and/or therapeutic immunity, using, e.g., the *C. pneumoniae* mouse model. Those skilled in the art will readily recognize that the *C. pneumoniae* strain of the model may be replaced with another *Chlamydia* strain. For example, the efficacy of DNA molecules and polypeptides from *C. pneumoniae* is preferably evaluated in a mouse model using *C. pneumoniae* strain. Protection is

determined by comparing the degree of *Chlamydia* infection to that of a control group. Protection is shown when infection is reduced by comparison to the control group. Such an evaluation is made for polynucleotides, vaccine vectors, polypeptides and 5 derivatives thereof, as well as antibodies of the invention.

Adjuvants useful in any of the vaccine compositions described above are as follows.

Adjuvants for parenteral administration include aluminum compounds, such as aluminum hydroxide, aluminum phosphate, and 10 aluminum hydroxy phosphate. The antigen is precipitated with, or adsorbed onto, the aluminum compound according to standard protocols. Other adjuvants, such as RIBI (ImmunoChem, Hamilton, MT), is used in parenteral administration.

Adjuvants for mucosal administration include bacterial 15 toxins, e.g., the cholera toxin (CT), the *E. coli* heat-labile toxin (LT), the *Clostridium difficile* toxin A and the pertussis toxin (PT), or combinations, subunits, toxoids, or mutants thereof such as a purified preparation of native cholera toxin subunit B (CTB). Fragments, homologs, derivatives, and fusions 20 to any of these toxins are also suitable, provided that they retain adjuvant activity. Preferably, a mutant having reduced toxicity is used. Suitable mutants are described, e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627 (Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PT mutant). 25 Additional LT mutants that are used in the methods and compositions of the invention include, e.g., Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants, such as a bacterial monophosphoryl lipid A (MPLA) of, e.g., *E. coli*, *Salmonella minnesota*, *Salmonella typhimurium*, or *Shigella* 30 *flexneri*; saponins, or polylactide glycolide (PLGA) microspheres, is also be used in mucosal administration.

Adjuvants useful for both mucosal and parenteral administrations include polyphosphazene (WO 95/2415), DC-chol (3

b-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol; U.S. Patent No. 5,283,185 and WO 96/14831) and QS-21 (WO 88/9336).

Any pharmaceutical composition of the invention containing a polynucleotide, a polypeptide, a polypeptide derivative, or an antibody of the invention, is manufactured in a conventional manner. In particular, it is formulated with a pharmaceutically acceptable diluent or carrier, e.g., water or a saline solution such as phosphate buffer saline. In general, a diluent or carrier is selected on the basis of the mode and route of administration, and standard pharmaceutical practice. Suitable pharmaceutical carriers or diluents, as well as pharmaceutical necessities for their use in pharmaceutical formulations, are described in *Remington's Pharmaceutical Sciences*, a standard reference text in this field and in the USP/NF.

The invention also includes methods in which *Chlamydia* infection are treated by oral administration of a *Chlamydia* polypeptide of the invention and a mucosal adjuvant, in combination with an antibiotic, an antacid, sucralfate, or a combination thereof. Examples of such compounds that can be administered with the vaccine antigen and the adjuvant are antibiotics, including, e.g., macrolides, tetracyclines, and derivatives thereof (specific examples of antibiotics that can be used include azithromycin or doxycycline or immunomodulators such as cytokines or steroids). In addition, compounds containing more than one of the above-listed components coupled together, are used. The invention also includes compositions for carrying out these methods, i.e., compositions containing a *Chlamydia* antigen (or antigens) of the invention, an adjuvant, and one or more of the above-listed compounds, in a pharmaceutically acceptable carrier or diluent.

Amounts of the above-listed compounds used in the methods and compositions of the invention are readily determined by one skilled in the art. Treatment/immunization schedules are also

known and readily designed by one skilled in the art. For example, the non-vaccine components can be administered on days 1-14, and the vaccine antigen + adjuvant can be administered on days 7, 14, 21, and 28.

REFERENCES

1. Grayston et al. (1995) Journal of Infectious Diseases 168:1231
2. Campos et al. (1995) Investigation of Ophthalmology and
5 Visual Science 36:1477
3. Grayston et al (1990) Journal of Infectious Diseases 161:618
4. Marrie (1993) Clinical Infectious Diseases. 18:501
5. Wang et al (1986) Chlamydial infections. Cambridge
University Press, Cambridge. p. 329
- 10 6. Saikku et al.(1988) Lancet;ii:983
7. Thom et al. (1992) JAMA 268:68
8. Linnanmaki et al. (1993), Circulation 87:1030
9. Saikku et al. (1992)Annals Internal Medicine 116:273
10. Melnick et al(1993) American Journal of Medicine 95:499 11
- 15 Shor et al. (1992) South African. Medical Journal 82:158
12. Kuo et al. (1993) Journal of Infectious Diseases 167:841
13. Kuo et al. (1993) Arteriosclerosis and Thrombosis 13:1500
14. Campbell et al (1995) Journal of Infectious Diseases 172:585
15. Chiu et al. Circulation, 1997 (In Press).
- 20 16. Ramirez et al (1996) Annals of Internal Medicine 125:979
17. Jackson et al. Abst. K121, p272, 36th ICAAC, 15-18 Sept.
1996, New Orleans.
18. Fong et al (1997) Journal of Clinical Microbiology 35:48
19. Hahn DL, et al. Evidence for Chlamydia pneumoniae infection
25 in steroid-dependent asthma. Ann Allergy Asthma Immunol. 1998
Jan; 80(1): 45-49.
20. Hahn DL, et al. Association of Chlamydia pneumoniae IgA
antibodies with recently symptomatic asthma. Epidemiol Infect.
1996 Dec; 117(3): 513-517.
- 30 21. Bjornsson E, et al. Serology of chlamydia in relation to
asthma and bronchial hyperresponsiveness. Scand J Infect Dis.
1996; 28(1): 63-69.

22. Hahn DL. Treatment of *Chlamydia pneumoniae* infection in adult asthma: a before-after trial. J Fam Pract. 1995 Oct; 41(4): 345-351.
23. Allegra L, et al. Acute exacerbations of asthma in adults: role of *Chlamydia pneumoniae* infection. Eur Respir J. 1994 Dec; 7(12): 2165-2168.
24. Hahn DL, et al. Association of *Chlamydia pneumoniae* (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA. 1991 Jul 10; 266(2): 225-230.
25. Pal et al. (1996) Infection and Immunity. 64:5341
26. Jones et al. (1995) Vaccine 13:715
27. Igietsemes et al. (1993) Immunology 5:317
28. Igietseme et al (1993) Regional Immunology 5:317
29. Magee et al (1993) Regional Immunology 5: 305
30. Landers et al (1991) Infection & Immunity 59:3774
31. Magee et al (1995) Infection & Immunity 63:516
32. Cotter et al. (1995) Infection and Immunity 63:4704
33. Campbell et al (1990) Infection and Immunity 58:93
34. McCafferty et al (1995) Infection and Immunity 63:2387-9.
35. Knudsen et al (1996) Third Meeting of the European Society for *Chlamydia* Research, Vienna
36. Wiedmann-Al-Ahmad M, et al. Reactions of polyclonal and neutralizing anti-p54 monoclonal antibodies with an isolated, species-specific 54-kilodalton protein of *Chlamydia pneumoniae*. Clin Diagn Lab Immunol. 1997 Nov; 4(6): 700-704
37. Hughes et al., 1992. Infect. Immun. 60(9):3497,
38. Dion et al., 1990. Virology 179:474-477,
39. Snijders et al., 1991. J. Gen. Virol. 72:557-565,
40. Langeveld et al., Vaccine 12(15):1473-1480, 1994
41. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994
42. Kunkel et al. Proc. Natl. Acad. Sci. USA (1985) 82:448
43. Silhavy et al. Experiments with Gene Fusions, Cold Spring Harbor Laboratory Press, 1984

CLAIMS:

1. A nucleic acid molecule comprising a nucleic acid sequence which encodes a polypeptide selected from any of:

(a) SEQ ID Nos: 27 to 45;

5 (b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and

(c) a polypeptide of (a) or (b) which has been modified without loss of immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to
10 the corresponding polypeptide of (a) or (b).

2. A nucleic acid molecule comprising a nucleic acid sequence selected from any of:

(a) SEQ ID Nos: 1 to 26;

(b) a sequence which encodes a polypeptide encoded by
15 any one of SEQ ID Nos: 1 to 26;

(c) a sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (a) and (b); and

(d) a sequence which encodes a polypeptide which is
20 at least 75% identical in amino acid sequence to any one of the polypeptides encoded by SEQ ID Nos: 1 to 26.

3. A nucleic acid molecule comprising a nucleic acid sequence which is anti-sense to the nucleic acid molecule of claim 1.

25 4. A nucleic acid molecule comprising a nucleic acid sequence which encodes a fusion protein, said fusion protein comprising a polypeptide encoded by a nucleic acid molecule according to claim 1 and a second polypeptide.

5. The nucleic acid molecule of claim 4 wherein the second polypeptide is a heterologous signal peptide.

6. The nucleic acid molecule of claim 4 wherein the second polypeptide has adjuvant activity.

5 7. A nucleic acid molecule according to claim 1, operatively linked to one or more expression control sequences.

8. A vaccine comprising a vaccine vector and at least one first nucleic acid selected from any of:

(i) SEQ ID Nos: 1 to 26;

10 (ii) a nucleic acid sequence which encodes a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iii) a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (i) and (ii);

15 (iv) a nucleic acid sequence which encodes a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(v) a nucleic acid sequence which encodes a
20 polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

(vi) a nucleic acid sequence which encodes an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

25 (vii) a nucleic acid sequence which encodes a polypeptide as defined in (v) or an immunogenic fragment as defined in (vi) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the

corresponding polypeptide of (v) or the corresponding fragment of (vi);

wherein each first nucleic acid is capable of being expressed.

- 5 9. A vaccine comprising a vaccine vector and at least one first nucleic acid encoding a fusion protein, wherein the fusion protein comprises:

(a) a first polypeptide selected from any of:

10 (i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 26;

15 (iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iv) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

20 (v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

(vi) a polypeptide as defined (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or
25 fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (iv) or the corresponding fragment of (v); and

(b) a second polypeptide;

wherein each first nucleic acid is capable of being expressed.

10. The vaccine of claim 9 wherein the second polypeptide is a heterologous signal peptide.

5 11. The vaccine of claim 9 wherein the second polypeptide has adjuvant activity.

12. The vaccine of claim 8 wherein each first nucleic acid is operatively linked to one or more expression control sequences.

10 13. A vaccine according to claim 8 wherein each first nucleic acid is expressed as a polypeptide, and wherein the vaccine comprises a second nucleic acid encoding an additional polypeptide which enhances the immune response to the polypeptide expressed by the first nucleic acid.

15 14. The vaccine of claim 13 wherein the second nucleic acid encodes an additional *Chlamydia* polypeptide.

15. A pharmaceutical composition comprising a nucleic acid according to claim 1 and a pharmaceutically acceptable carrier.

20 16. A pharmaceutical composition comprising a vaccine according to claim 8 and a pharmaceutically acceptable carrier.

17. A unicellular host transformed with the nucleic acid molecule of claim 7.

18. An isolated nucleic acid probe of 5 to 100
25 nucleotides which hybridizes under stringent conditions to any one of nucleic acid molecules of SEQ ID Nos: 1 to 26, or to a complementary or anti-sense sequence of said nucleic acid molecule.

19. A primer of 10 to 40 nucleotides which hybridizes
30 under stringent conditions to any one of nucleic acid molecules

of SEQ ID Nos: 1 to 26, or to a homolog or complementary or anti-sense sequence of said nucleic acid molecule.

20. A polypeptide encoded by a nucleic acid sequence according to claim 2.

5 21. A polypeptide comprising an amino acid sequence selected from any of:

(a) SEQ ID Nos: 27 to 45;

(b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and

10 (c) a polypeptide of (a) or (b) which has been modified without loss of immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

22. A fusion protein comprising a polypeptide of claim 20
15 and a second polypeptide.

23. The fusion protein of claim 22 wherein the second polypeptide is a heterologous signal peptide.

24. The fusion protein of claim 22 wherein the second polypeptide has adjuvant activity.

20 25. A method for producing a polypeptide of claim 20, comprising the step of culturing a unicellular host of claim 17.

26. An antibody against the polypeptide of claim 20.

27. A vaccine comprising at least one first polypeptide
25 selected from any of:

(i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 26;

(iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iv) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

(v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

(vi) a polypeptide as defined in (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (iv) or the corresponding fragment of (v).

28. A vaccine comprising at least one fusion protein, wherein the fusion protein comprises:

(a) a first polypeptide selected from any of:

(i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 26;

(iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 26;

(iv) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 27 to 45;

(v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 27 to 45; and

(vi) a polypeptide as defined (iv) or an immunogenic
5 fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (iv) or the corresponding fragment of (v); and

10 (b) a second polypeptide.

29. The vaccine of claim 28 wherein the second polypeptide is a heterologous signal peptide.

30. The vaccine of claim 28 wherein the second polypeptide has adjuvant activity.

15 31. A vaccine comprising at least one first polypeptide according to claim 20 and an additional polypeptide which enhances the immune response to the first polypeptide.

32. The vaccine of claim 31 wherein the additional polypeptide comprises a *Chlamydia* polypeptide.

20 33. A pharmaceutical composition comprising a polypeptide according to claim 20 and a pharmaceutically acceptable carrier.

34. A pharmaceutical composition comprising a vaccine according to claim 27 and a pharmaceutically acceptable
25 carrier.

35. A pharmaceutical composition comprising an antibody according to claim 26 and a pharmaceutically acceptable carrier.

3. A nucleic acid molecule comprising a nucleic acid sequence which encodes a fusion protein, said fusion protein comprising a polypeptide encoded by a nucleic acid molecule according to claim 1 and an additional
5 polypeptide.
4. A nucleic acid molecule according to claim 1, operatively linked to one or more expression control sequences.
- 10
5. A vaccine comprising at least one first nucleic acid according to any one of claims 1 to 4 and a vaccine vector wherein each first nucleic acid is expressed as a polypeptide, the vaccine optionally comprising a second
15 nucleic acid encoding an additional polypeptide which enhances the immune response to the polypeptide expressed by said first nucleic acid.
6. The vaccine of claim 5 wherein the second nucleic acid
20 encodes an additional *Chlamydia* polypeptide.
7. A pharmaceutical composition comprising a nucleic acid according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising a polypeptide according to any one of claims 12 to 14 and a pharmaceutically acceptable carrier.
- 5
20. A pharmaceutical composition comprising a vaccine according to claim 17 or 18 and a pharmaceutically acceptable carrier.
- 10 21. A pharmaceutical composition comprising an antibody according to claim 16 and a pharmaceutically acceptable carrier.
22. A method for preventing or treating *Chlamydia*
- 15 infection using:
- (a) the nucleic acid of any one of claims 1 to 4;
 - (b) the vaccine of any one of claims 5, 6, 17 and 18;
 - (c) the pharmaceutical composition of any one of claims 7, 8, 19 to 21;
 - 20 (d) the polypeptide of any one of claims 12 to 14; or
 - (e) the antibody of claim 16.
23. A method of detecting *Chlamydia* infection comprising the step of assaying a body fluid of a mammal to be tested,
- 25 with a component selected from any one of:
- (a) the nucleic acid of any one of claims 1 to 4;

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 May 2000 (04.05.2000)

PCT

(10) International Publication Number
WO 00/24765 A3

(51) International Patent Classification⁷: C12N 15/62,
C07K 14/295, 16/12, A61K 39/118, G01N 33/53, C12Q
1/68, C12N 5/10

[CA/CA]; 51 Aspenwood Drive, Toronto, Ontario M2H
2E8 (CA).

(21) International Application Number: PCT/CA99/00992

(74) Agents: MORROW, Joy, D. et al.: Smart & Biggar,
900-55 Metcalfe Street, P.O. Box 2999, Station D, Ottawa,
Ontario K1P 5Y6 (CA).

(22) International Filing Date: 28 October 1999 (28.10.1999)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:

60/106,034	28 October 1998 (28.10.1998)	US
60/106,044	28 October 1998 (28.10.1998)	US
60/106,039	28 October 1998 (28.10.1998)	US
60/106,042	28 October 1998 (28.10.1998)	US
60/106,087	29 October 1998 (29.10.1998)	US
60/106,072	29 October 1998 (29.10.1998)	US
60/106,073	29 October 1998 (29.10.1998)	US
60/106,074	29 October 1998 (29.10.1998)	US
60/106,589	2 November 1998 (02.11.1998)	US
60/107,034	2 November 1998 (02.11.1998)	US
60/107,035	2 November 1998 (02.11.1998)	US
60/106,587	2 November 1998 (02.11.1998)	US
60/106,588	2 November 1998 (02.11.1998)	US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
9 November 2000

(71) Applicant (*for all designated States except US*): AVEN-
TIS PASTEUR LIMITED [CA/CA]; 1755 Steeles Av-
enue West, Toronto, Ontario M2R 3T4 (CA).

(48) Date of publication of this corrected version:
20 December 2001

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MURDIN, Andrew,
D. [CA/CA]; 11 Forest Hill Drive, Richmond Hill, Ontario
L4B 3C2 (CA). OOMEN, Raymond, P. [CA/CA]; RR
No. 1, Schomberg, Ontario L0G 1T0 (CA). WANG, Joe

(15) Information about Correction:
see PCT Gazette No. 51/2001 of 20 December 2001, Sec-
tion II

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

(57) Abstract: The present invention provides purified and isolated polynucleotide molecules that encode *Chlamydia* polypeptides which can be used in methods to prevent, treat, and diagnose *Chlamydia* infection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode polypeptides CPN100397 (SEQ ID Nos: 1 and 2), CPN100421 (SEQ ID Nos: 3 and 4), CPN100422 (SEQ ID Nos: 4 and 6), CPN100424 (SEQ ID Nos: 7 and 8), CPN100426 (SEQ ID Nos: 9 and 10), CPN100508 (SEQ ID Nos: 11 and 12), CPN100515 (SEQ ID Nos: 13 and 14), CPN100538 (SEQ ID Nos: 15 and 16), CPN100557 (SEQ ID Nos: 17 and 18), CPN100622 (SEQ ID Nos: 19 and 20), CPN100626 (SEQ ID Nos: 21 and 22), CPN100628 (SEQ ID Nos: 23 and 24) and CPN100630 (SEQ ID Nos: 25 and 26).

WO 00/24765 A3

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Figure 1: CPN100397

```

attttaacgt gcgtatcatt tgtgactaag agatagactt gctttcttta tctatcttct 60
gtattggaaa gaaagcccct tgagggaaaa aaagggttgtt atg aag att cca ctc 115
                                         Met Lys Ile Pro Leu
                                         1           5
cgc ttt tta ttg ata tca tta gta cct acg ctt tct atg tcg aat tta 163
Arg Phe Leu Leu Ile Ser Leu Val Pro Thr Leu Ser Met Ser Asn Leu
                        10                        15                        20
tta gga gct gct act acc gaa gag tta tcg gct agc aat agc ttc gat 211
Leu Gly Ala Ala Thr Thr Glu Glu Leu Ser Ala Ser Asn Ser Phe Asp
                        25                        30                        35
gga act aca tca aca aca agc ttt tct agt aaa aca tca tcg gct aca 259
Gly Thr Thr Ser Thr Thr Ser Phe Ser Ser Lys Thr Ser Ser Ala Thr
                        40                        45                        50
gat ggc acc aat tat gtt ttt aaa gat tct gta gtt ata gaa aat gta 307
Asp Gly Thr Asn Tyr Val Phe Lys Asp Ser Val Val Ile Glu Asn Val
                        55                        60                        65
ccc aaa aca ggg gaa act cag tct act agt tgt ttt aaa aat gac gct 355
Pro Lys Thr Gly Glu Thr Gln Ser Thr Ser Ser Cys Phe Lys Asn Asp Ala
                        70                        75                        80                        85
gca gct gga gat cta aat ttc tta gga ggg gga ttt tct ttc aca ttt 403
Ala Ala Gly Asp Leu Asn Phe Leu Gly Gly Gly Phe Ser Phe Thr Phe
                        90                        95                        100
agc aat atc gat gca acc acg gct tct gga gct gct att gga agt gaa 451
Ser Asn Ile Asp Ala Thr Thr Ala Ser Gly Ala Ala Ile Gly Ser Glu
                        105                        110                        115
gca gct aat aag aca gtc acg tta tca gga ttt tcg gca ctt tct ttt 499
Ala Ala Asn Lys Thr Val Thr Leu Ser Gly Phe Ser Ala Leu Ser Phe
                        120                        125                        130
ctt aaa tcc cca gca agt aca gtg act aat gga ttg gga gct atc aat 547
Leu Lys Ser Pro Ala Ser Thr Val Thr Asn Gly Leu Gly Ala Ile Asn
                        135                        140                        145
gtt aaa ggg aat tta agc cta ttg gat aat gat aag gta ttg att cag 595
Val Lys Gly Asn Leu Ser Leu Leu Asp Asn Asp Lys Val Leu Ile Gln
                        150                        155                        160                        165
gac aat ttc tca aca gga gat ggc gga gca att aat tgt gca ggc tcc 643
Asp Asn Phe Ser Thr Gly Asp Gly Gly Ala Ile Asn Cys Ala Gly Ser
                        170                        175                        180
ttg aag atc gca aac aat aag tcc ctt tct ttt att gga aat agt tct 691
Leu Lys Ile Ala Asn Asn Lys Ser Leu Ser Phe Ile Gly Asn Ser Ser
                        185                        190                        195

```


Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 1 (con't)

tca	aca	cgt	ggc	gga	gcg	att	cat	acc	aaa	aac	ctc	aca	cta	tct	tct	739
Ser	Thr	Arg	Gly	Gly	Ala	Ile	His	Thr	Lys	Asn	Leu	Thr	Leu	Ser	Ser	
		200					205					210				
ggg	ggg	gaa	act	cta	ttt	cag	ggg	aat	aca	gcg	cct	acg	gct	gct	ggg	787
Gly	Gly	Glu	Thr	Leu	Phe	Gln	Gly	Asn	Thr	Ala	Pro	Thr	Ala	Ala	Gly	
	215					220					225					
aaa	gga	ggg	gct	atc	gcg	att	gca	gac	tct	ggc	acc	cta	tcc	att	tct	835
Lys	Gly	Gly	Ala	Ile	Ala	Ile	Ala	Asp	Ser	Gly	Thr	Leu	Ser	Ile	Ser	
230					235					240					245	
gga	gac	agt	ggc	gac	att	atc	ttt	gaa	ggc	aat	acg	ata	gga	gct	aca	883
Gly	Asp	Ser	Gly	Asp	Ile	Ile	Phe	Glu	Gly	Asn	Thr	Ile	Gly	Ala	Thr	
			250						255					260		
gga	acc	gtc	tct	cat	agt	gct	att	gat	tta	gga	act	agc	gct	aag	ata	931
Gly	Thr	Val	Ser	His	Ser	Ala	Ile	Asp	Leu	Gly	Thr	Ser	Ala	Lys	Ile	
		265					270						275			
act	gcg	tta	cgt	gct	gcg	caa	gga	cat	acg	ata	tac	ttt	tat	gat	ccg	979
Thr	Ala	Leu	Arg	Ala	Ala	Gln	Gly	His	Thr	Ile	Tyr	Phe	Tyr	Asp	Pro	
	280					285						290				
att	act	gta	aca	gga	tcg	aca	tct	gtt	gct	gat	gct	ctc	aat	att	aat	1027
Ile	Thr	Val	Thr	Gly	Ser	Thr	Ser	Val	Ala	Asp	Ala	Leu	Asn	Ile	Asn	
	295					300					305					
agc	cct	gat	act	gga	gat	aac	aaa	gag	tat	acg	gga	acc	ata	gtc	ttt	1075
Ser	Pro	Asp	Thr	Gly	Asp	Asn	Lys	Glu	Tyr	Thr	Gly	Thr	Ile	Val	Phe	
310					315					320					325	
tct	gga	gag	aag	ctc	acg	gag	gca	gaa	gct	aaa	gat	gag	aag	aac	cgc	1123
Ser	Gly	Glu	Lys	Leu	Thr	Glu	Ala	Glu	Ala	Lys	Asp	Glu	Lys	Asn	Arg	
			330					335						340		
act	tct	aaa	tta	ctt	caa	aat	gtt	gct	ttt	aaa	aat	ggg	act	gta	gtt	1171
Thr	Ser	Lys	Leu	Leu	Gln	Asn	Val	Ala	Phe	Lys	Asn	Gly	Thr	Val	Val	
		345					350					355				
tta	aaa	ggg	gat	gtc	gtt	tta	agt	gcg	aac	ggg	ttc	tct	cag	gat	gca	1219
Leu	Lys	Gly	Asp	Val	Val	Leu	Ser	Ala	Asn	Gly	Phe	Ser	Gln	Asp	Ala	
		360					365					370				
aac	tct	aag	ttg	att	atg	gat	tta	ggg	acg	tcg	ttg	gtt	gca	aac	acc	1267
Asn	Ser	Lys	Leu	Ile	Met	Asp	Leu	Gly	Thr	Ser	Leu	Val	Ala	Asn	Thr	
	375					380					385					
gaa	agt	atc	gag	tta	acg	aat	ttg	gaa	att	aat	ata	gac	tct	ctc	agg	1315
Glu	Ser	Ile	Glu	Leu	Thr	Asn	Leu	Glu	Ile	Asn	Ile	Asp	Ser	Leu	Arg	
390					395					400					405	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/1830446

WO 00/24765

PCT/CA99/00992

Fig. 1 (con't)

aac ggg aaa aag ata aaa ctc agt gct gcc aca gct cag aaa gat att	1363
Asn Gly Lys Lys Ile Lys Leu Ser Ala Ala Thr Ala Gln Lys Asp Ile	
410 415 420	
cgt ata gat cgt cct gtt gta ctg gca att agc gat gag agt ttt tat	1411
Arg Ile Asp Arg Pro Val Val Leu Ala Ile Ser Asp Glu Ser Phe Tyr	
425 430 435	
caa aat ggc ttt ttg aat gag gac cat tcc tat gat ggg att ctt gag	1459
Gln Asn Gly Phe Leu Asn Glu Asp His Ser Tyr Asp Gly Ile Leu Glu	
440 445 450	
tta gat gct ggg aaa gac atc gtg att tct gca gat tct cgc agt ata	1507
Leu Asp Ala Gly Lys Asp Ile Val Ile Ser Ala Asp Ser Arg Ser Ile	
455 460 465	
gat gct gta caa tct ccg tat ggc tat cag gga aag tgg acg atc aat	1555
Asp Ala Val Gln Ser Pro Tyr Gly Tyr Gln Gly Lys Trp Thr Ile Asn	
470 475 480 485	
tgg tct act gat gat aag aaa gct acg gtt tct tgg gcg aag cag agt	1603
Trp Ser Thr Asp Asp Lys Lys Ala Thr Val Ser Trp Ala Lys Gln Ser	
490 495 500	
ttt aat ccc act gct gag cag gag gct ccg tta gtt cct aat ctt ctt	1651
Phe Asn Pro Thr Ala Glu Gln Glu Ala Pro Leu Val Pro Asn Leu Leu	
505 510 515	
tgg ggt tct ttt ata gat gtt cgt tcc ttc cag aat ttt ata gag cta	1699
Trp Gly Ser Phe Ile Asp Val Arg Ser Phe Gln Asn Phe Ile Glu Leu	
520 525 530	
ggg act gaa ggt gct cct tac gaa aag aga ttt tgg gtt gca ggc att	1747
Gly Thr Glu Gly Ala Pro Tyr Glu Lys Arg Phe Trp Val Ala Gly Ile	
535 540 545	
tcc aat gtt ttg cat agg agc ggt cgt gaa aat caa agg aaa ttc cgt	1795
Ser Asn Val Leu His Arg Ser Gly Arg Glu Asn Gln Arg Lys Phe Arg	
550 555 560 565	
cat gtg agt gga ggt gct gta gta ggt gct agc acg agg atg ccg ggt	1843
His Val Ser Gly Gly Ala Val Val Gly Ala Ser Thr Arg Met Pro Gly	
570 575 580	
ggg gat acc ttg tct ctg ggt ttt gct cag ctc ttt gcg cgt gac aaa	1891
Gly Asp Thr Leu Ser Leu Gly Phe Ala Gln Leu Phe Ala Arg Asp Lys	
585 590 595	
gac tac ttt atg aat acc aat ttc gca aag acc tac gca gga tct tta	1939
Asp Tyr Phe Met Asn Thr Asn Phe Ala Lys Thr Tyr Ala Gly Ser Leu	
600 605 610	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

WO 00/24765

PCT/CA99/00992

Fig. 1 (con't)

cgt ttg cag cac gat gct tcc cta tac tct gtg gtg agt atc ctt tta	1987
Arg Leu Gln His Asp Ala Ser Leu Tyr Ser Val Val Ser Ile Leu Leu	
615 620 625	
gga gag gga gga ctc cgc gag atc ctg ttg cct tat gtt tcc aag act	2035
Gly Glu Gly Gly Leu Arg Glu Ile Leu Leu Pro Tyr Val Ser Lys Thr	
630 635 640 645	
ctg ccg tgc tct ttc tat ggg cag ctt agc tac ggc cat acg gat cat	2083
Leu Pro Cys Ser Phe Tyr Gly Gln Leu Ser Tyr Gly His Thr Asp His	
650 655 660	
cgc atg aag acc gag tct cta ccc ccc ccc ccc ccg acg ctc tcg acg	2131
Arg Met Lys Thr Glu Ser Leu Pro Pro Pro Pro Pro Thr Leu Ser Thr	
665 670 675	
gat cat act tct tgg gga gga tat gtc tgg gct gga gag ctg gga act	2179
Asp His Thr Ser Trp Gly Gly Tyr Val Trp Ala Gly Glu Leu Gly Thr	
680 685 690	
cga gtt gct gtt gaa aat acc agc ggc aga gga ttt ttc caa gag tac	2227
Arg Val Ala Val Glu Asn Thr Ser Gly Arg Gly Phe Phe Gln Glu Tyr	
695 700 705	
act cca ttt gta aaa gtc caa gct gtt tac gct cgc caa gat agc ttt	2275
Thr Pro Phe Val Lys Val Gln Ala Val Tyr Ala Arg Gln Asp Ser Phe	
710 715 720 725	
gta gaa cta gga gct atc agt cgt gat ttt agt gat tcg cat ctt tat	2323
Val Glu Leu Gly Ala Ile Ser Arg Asp Phe Ser Asp Ser His Leu Tyr	
730 735 740	
aac ctt gcg att cct ctt gga atc aag tta gag aaa cgg ttt gca gag	2371
Asn Leu Ala Ile Pro Leu Gly Ile Lys Leu Glu Lys Arg Phe Ala Glu	
745 750 755	
caa tat tat cat gtt gta gcg atg tat tct cca gat gtt tgt cgt agt	2419
Gln Tyr Tyr His Val Val Ala Met Tyr Ser Pro Asp Val Cys Arg Ser	
760 765 770	
aac ccc aaa tgt acg act acc cta ctt tcc aac caa ggg agt tgg aag	2467
Asn Pro Lys Cys Thr Thr Thr Leu Leu Ser Asn Gln Gly Ser Trp Lys	
775 780 785	
acc aaa ggt tcg aac tta gca aga cag gct ggt att gtt cag gcc tca	2515
Thr Lys Gly Ser Asn Leu Ala Arg Gln Ala Gly Ile Val Gln Ala Ser	
790 795 800 805	
ggg ttt cga tct ttg gga gct gca gca gag ctt ttc ggg aac ttt ggc	2563
Gly Phe Arg Ser Leu Gly Ala Ala Ala Glu Leu Phe Gly Asn Phe Gly	
810 815 820	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 1 (con't)

```
ttt gaa tgg cgg gga tct tct cgt agc tat aat gta gat gcg ggt agc 2611
Phe Glu Trp Arg Gly Ser Ser Arg Ser Tyr Asn Val Asp Ala Gly Ser
      825                      830                      835


aaa atc aaa ttt tagcgatttc tctttcgatg ctatttttcc atggctattt 2663
Lys Ile Lys Phe
      840

ttaaaatgat agccatgggt atagatacgt agtccttatt tcaaagaaga cactgttgca 2723

ttagatacgc tctctgatcc ctcaaaa 2750
```

Figure 2 (RY-32)

Restriction Enzyme analysis of CPN100397



7/165

Fig. 2 (con't)





Fig. 2 (con't)



WO 00/24765

PCT/CA99/00992

Fig. 2 (con't)




Fig. 2 (con't)




Fig. 2 (con't)





Fig. 2 (con't)



[illegible]

```

                                     Hpy178III
                                     AluI
                                     CviJI
                               Sth132I
                               PstI
                               Fnu4HI
                               CviRI
    BseMII
    DpnI
Sau3AI
BbvI
MnlI
TaqI
                               TseI
                               Fnu4HI
                               SfcI
                               AluI
                               CviJI
                               TseI
                                     BbvI
                                     FauI
                                     Sth132I
                                     CviJI
                                     MboII
                                     BstYI
                                     Sau3AI
                                     DpnI
2521  TCGATCTTTGGGAGCTGCAGCAGAGCTTTTCGGAACCTTTGGCTTTGAATGGCGGGGATC
-----+-----+-----+-----+-----+-----+-----+-----+
AGCTAGAAACCCTCGACGTCGTCTCGAAAAGCCCTTGAAACCGAAACTTACCGCCCCCTAG
                                     2580

                               FauI
                               Sth132I
                               SfaNI
                               AluI
                               CviJI
    Pfl1108I
    AlwI
                               AciI
                               Tsp509I
                               SfaNI
                               TaqI
2581  TTCTCGTAGCTATAATGTAGATGCGGGTAGCAAAATCAAATTTTAGCGATTCTCTTTTCG
-----+-----+-----+-----+-----+-----+-----+
AAGAGCATCGATATTACATCTACGCCCATCGTTTTAGTTTAAATCGCTAAAGAGAAAGC
                                     2640

                               CviJI
                               NlaIII
                               BsaJI
                               BstDSI
                               NcoI
                               StyI
                               DraI
                               MseI
                               CviJI
                               NlaIII
                               BsaJI
                               BstDSI
                               NcoI
                               StyI
                               BsaAI
                               HaeIV
                               Hin4I
                               SnaBI
                               MaeII
2641  ATGCTATTTTTCCATGGCTATTTTTTAAAATGATAGCCATGGTTATAGATACGTAGTCCTT
-----+-----+-----+-----+-----+-----+-----+
TACGATAAAAAGGTACCGATAAAAATTTTACTATCGGTACCAATATCTATGCATCAGGAA
                                     2700

                               CviRI
                               MboII
                               TspRI
                               TaaI
                               BbsI
                               DpnI
                               Sau3AI
                               Hpy188IX
                               AlwI
                               Hin4I
2701  ATTTCAAAGAAGACACTGTTGCATTAGATACGCTCTCTGATCCCTCAAAA
-----+-----+-----+-----+-----+-----+-----+
TAAAGTTTCTCTGTGACAACGTAATCTATGCGAGAGACTAGGGAGTTTT

```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS

AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al

DOCKET NO.: 032931/0251

WO 00/24765

PCT/CA99/00992

Figure 3: CPN100421

```

ctcctgtccc tcgcgttgtc aacctacccc tctccctcg aattctaate ctttgaacgt 60
agtagaacag cctgttgctg catcgtcagt gccttcctac atg ccc cca ctg aat 115
                                         Met Pro Pro Leu Asn
                                         1 5

gct gat gat gtt ctc cct aga gac cat ctg tca gat gga agt ttc tca 163
Ala Asp Asp Val Leu Pro Arg Asp His Leu Ser Asp Gly Ser Phe Ser
                        10 15 20

gat acg tat cca gac att aca acg caa gcg atc atc tta att ttc ttg 211
Asp Thr Tyr Pro Asp Ile Thr Thr Gln Ala Ile Ile Leu Ile Phe Leu
                        25 30 35

gcc cta tcg cct ttc ctg gtc atg ttg ctc act tcg tat cta aag att 259
Ala Leu Ser Pro Phe Leu Val Met Leu Leu Thr Ser Tyr Leu Lys Ile
                        40 45 50

atc att act tta gtc tta tta cgt aac gcc tta gga gta caa caa aca 307
Ile Ile Thr Leu Val Leu Leu Arg Asn Ala Leu Gly Val Gln Gln Thr
                        55 60 65

cct ccc agt caa gtc ctc aat ggg att gca ctc atc cta tct att tat 355
Pro Pro Ser Gln Val Leu Asn Gly Ile Ala Leu Ile Leu Ser Ile Tyr
                        70 75 80 85

gtg atg ttc ccc acg gga gtg gct atg tat aaa gat gct cgc aag gaa 403
Val Met Phe Pro Thr Gly Val Ala Met Tyr Lys Asp Ala Arg Lys Glu
                        90 95 100

atc gaa gcc aat acc att cct caa agc ctc ttc act gca gaa ggt gct 451
Ile Glu Ala Asn Thr Ile Pro Gln Ser Leu Phe Thr Ala Glu Gly Ala
                        105 110 115

gaa aca gtg ttt gtc gct tta aac aaa tct aaa gaa cct ttg cgc tct 499
Glu Thr Val Phe Val Ala Leu Asn Lys Ser Lys Glu Pro Leu Arg Ser
                        120 125 130

ttc tta att cgc aac act cca aaa gca caa att caa agc ttt tac aag 547
Phe Leu Ile Arg Asn Thr Pro Lys Ala Gln Ile Gln Ser Phe Tyr Lys
                        135 140 145

atc tca cag aaa acc ttc cct tcg gaa att cga gcg cac ctc act gcc 595
Ile Ser Gln Lys Thr Phe Pro Ser Glu Ile Arg Ala His Leu Thr Ala
                        150 155 160 165

tcc gac ttt gta atc att att cct gct ttt att atg ggt cag ata aaa 643
Ser Asp Phe Val Ile Ile Ile Pro Ala Phe Ile Met Gly Gln Ile Lys
                        170 175 180

aat gct ttc gaa att gga gtc ttg atc tat cta cct ttc ttt gtt att 691
Asn Ala Phe Glu Ile Gly Val Leu Ile Tyr Leu Pro Phe Phe Val Ile
                        185 190 195

```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

WO 00/24765


PCT/CA99/00992

Fig. 3 (con't)

gat tta gtg act gct aac gtt ctt gta gcg atg cag atg atg atg tta	739
Asp Leu Val Thr Ala Asn Val Leu Val Ala Met Gln Met Met Met Leu	
200 205 210	
tcc cct cta tcg att tcg tta cct tta aag tta ctt ttg atc gtc atg	787
Ser Pro Leu Ser Ile Ser Leu Pro Leu Lys Leu Leu Leu Ile Val Met	
215 220 225	
gta gac gga tgg aca tta ctg ctc caa ggg ctt atg atc agc ttt aaa	835
Val Asp Gly Trp Thr Leu Leu Leu Gln Gly Leu Met Ile Ser Phe Lys	
230 235 240 245	
taaggacacg tgccgtgtta gcattttttcg caactagttt caaatctggt ctttttgagt	895
actcctacca atcattatta cttatttttga ttgttttcggc acctcccatc atcttagctt	955
ccatagtcgg gattatgggt gcgatcttcc aagccgcaac acaaa	1000

Figure 4 (RY-34)

Restriction enzyme analysis of CP100421



PCT/CA99/00992

MnlI
 Tth111111
 BmrI
 BsrI
 FokI
 CviRI
 MnlI
 Sth132I
 301
 ACAAACACCTCCCAGTCAAGTCCTCAATGGGATTGCACTCATCTATCTATTTATGTGAT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 360
 TGTTTGTGGAGGGTCAGTTCAGGAGTTACCCTAACGTGAGTAGGATAGATAAATACACTA
 SfaNI
 CviJI
 BstXI
 MslI
 BscGI
 BsaJI
 BstDSI
 BcgI
 Cac8I
 TaqI
 CjePI
 CviJI
 BcgI
 361
 GTTCCCCACGGGAGTGGCTATGTATAAAGATGCTCGCAAGGAAATCGAAGCCAATACCAT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 420
 CAAGGGGTGCCCTCACCGATACATATTTCTACGAGCGTTCCTTTAGCTTCGGTTATGGTA
 Tth111111
 BstAPI
 PstI
 TspRI
 CviRI
 MnlI
 BtsI
 SfcI
 EarI
 CjePI
 MnlI
 CviJI
 MboII
 MwoI
 TaaI
 TspRI
 DraI
 MseI
 421
 TCCTCAAAGCCTCTTCACTGCAGAAGGTGCTGAAACAGTGTGTTGTCGCTTTAAACAAATC
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 480
 AGGAGTTTCGGAGAAGTGACGTCTTCCACGACTTTGTCAAAACAGCGAAATTTGTTTGA
 Tth111111
 BstAPI
 PstI
 TspRI
 CviRI
 MnlI
 BtsI
 SfcI
 EarI
 CjePI
 MnlI
 CviJI
 MboII
 MwoI
 TaaI
 TspRI
 DraI
 MseI
 481
 TAAAGAACCTTTGCGCTCTTTCTTAATTCGCAACACTCCAAAAGCACAAATTCAAAGCTT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 540
 ATTTCTTGGAACGCGAGAAAGAATTAAGCGTTGTGAGGTTTTTCGTGTTTAAGTTTCGAA

DpnI
 BglII |
 BstYI |
 Sau3AI |
 XmnI |
 Hpy188IX |
 TaqI |
 Hin4I |
 BtsI |
 Hpy188IX |
 MnlI |
 TspRI |
 541
 TTACAAGATCTCACAGAAAACCTTCCCTTCGGAAATTCGAGCGCACCTCACTGCCTCCGA
 -----+-----+-----+-----+-----+-----+-----+-----+ 600
 AATGTTCTAGAGTGTCTTTTGAAGGGAAGCCTTTAAGCTCGCGTGGAGTGACGGAGGCT

 MnlI
 BplI |
 MmeI |
 Hpy188IX |
 SimI |
 Tsp509I
 NspV |
 TaqI |
 HinfI |
 601
 CTTTGTAATCATTATTCTGCTTTTATTATGGGTGAGATAAAAAATGCTTTCGAAATTGG
 -----+-----+-----+-----+-----+-----+-----+-----+ 660
 GAAACATTAGTAATAAGGACGAAAATAATACCCAGTCTATTTTTTACGAAAGCTTTAACC

 DpnI
 PleI
 Sau3AI |
 Hpy178III |
 Hin4I |
 MaeIII
 Tsp45I
 SfaNI
 AclI |
 MaeII |
 661
 AGTCTTGATCTATCTACCTTTCTTTGTTATTGATTTAGTGACTGCTAACGTTCTTGTAGC
 -----+-----+-----+-----+-----+-----+-----+-----+ 720
 TCAGAACTAGATAGATGGAAGAACAATAACTAAATCACTGACGATTGCAAGAACATCG

 MaeIII
 MnlI |
 ClaI |
 TaqI |
 MaeIII
 DraI |
 MseI |
 DpnI
 Sau3AI |
 CviRI
 721
 GATGCAGATGATGATGTTATCCCTCTATCGATTTTCGTTACCTTTAAAGTTACTTTTGAT
 -----+-----+-----+-----+-----+-----+-----+-----+ 780
 CTACGTCTACTACTACAATAGGGGAGATAGCTAAAGCAATGGAAATTTCAATGAAAACTA

 Bcefi
 DraI |
 MseI |
 AluI |
 CviJI |
 DpnI |
 BclI |
 Sau3AI |
 CviJI |
 MwoI |
 BsaJI |
 StyI |
 AccI
 NlaIII |
 BccI |
 FokI |
 781
 CGTCATGGTAGACGGATGGACATTACTGCTCCAAGGGCTTATGATCAGCTTTAAATAAGG
 -----+-----+-----+-----+-----+-----+-----+-----+ 840
 GCAGTACCATCTGCCTACCTGTAATGACGAGGTTCCCGAATACTAGTCGAAATTTATTCC

Fig. 4 (con't)

```

      BsaAI
      PmlI
      MaeII |
AflIII | | |
      MwoI |
      MwoI |
      BfaI |
      SpeI |
      RsaI
      ScaI
      TatI | |
ACACGTGCCGTGTTAGCATTTTTCGCAACTAGTTTCAAATCTGTTCTTTTTGAGTACTCC
841 -----+-----+-----+-----+-----+-----+-----+ 900
      TGTGCACGGCACAATCGTAAAAAGCGTTGATCAAAGTTTAGACAAGAAAAACTCATGAGG

      Sth132I
      AluI
      CviJI
      NlaIV
      BanI | |
      BccI |
      DdeI |
      MnlI | |
TACCAATCATTATTACTTATTTTGATTGTTTCGGCACCTCCCATCATCTTAGCTTCCATA
901 -----+-----+-----+-----+-----+-----+-----+ 960
      ATGGTTAGTAATAATGAATAAAACTAACAAAGCCGTGGAGGGTAGTAGAATCGAAGGTAT

      AcI
      DpnI
      Fnu4HI
      TauI
      CviJI |
      BsbI
      Hpy178III
      BslI | |
      MboII |
      Sau3AI | |
      GTCGGGATTATGGTTGCGATCTTCCAAGCCGCAACACAAA
961 -----+-----+-----+-----+-----+-----+ 1000
      CAGCCCTAATACCAACGCTAGAAGGTTTCGGCGTTGTGTTT

```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

PCT/CA99/00992

Figure 5:

```

tagctttata caaagtatag aaaaataaca cgacaataaa aggagcgggtg ttttctcttc 60

tgaggtaa at cagcctcaaa gatactacgc catagtaa atg aag ttt ttt agc 115
          Met Lys Phe Phe Ser
          1 5

tta att ttt aaa gat gat gat gtc tcc cca aat aag aag gtt tta tct 163
Leu Ile Phe Lys Asp Asp Asp Val Ser Pro Asn Lys Lys Val Leu Ser
          10 15 20

cct gaa gct ttc tct gct ttc ctt gat gcc aaa gag ctg tta gaa aaa 211
Pro Glu Ala Phe Ser Ala Phe Leu Asp Ala Lys Glu Leu Leu Glu Lys
          25 30 35

aca aaa gcc gat agc gaa gcc tat gtt gca gag aca gaa caa aag tgt 259
Thr Lys Ala Asp Ser Glu Ala Tyr Val Ala Glu Thr Glu Gln Lys Cys
          40 45 50

gca caa att cgt caa gaa gct aaa gat caa gga ttt aaa gag gga tct 307
Ala Gln Ile Arg Gln Glu Ala Lys Asp Gln Gly Phe Lys Glu Gly Ser
          55 60 65

gaa tcc tgg agc aag caa att gct ttc tta gaa gaa gaa act aaa aat 355
Glu Ser Trp Ser Lys Gln Ile Ala Phe Leu Glu Glu Glu Thr Lys Asn
          70 75 80 85

cta cgc ata aga gta cgc gag gcc ttg gtt cct ctg gca att gcg agt 403
Leu Arg Ile Arg Val Arg Glu Ala Leu Val Pro Leu Ala Ile Ala Ser
          90 95 100

gtg agg aaa atc att ggg aag gaa ctc gaa tta cat cct gaa act att 451
Val Arg Lys Ile Ile Gly Lys Glu Leu Glu Leu His Pro Glu Thr Ile
          105 110 115

gtc tct att att tct caa gca ttg aaa gag ctc aca caa aat aaa cat 499
Val Ser Ile Ile Ser Gln Ala Leu Lys Glu Leu Thr Gln Asn Lys His
          120 125 130

atc att atc tct gtc aat ccc aaa gat tta cct ctt gtt gag aaa agt 547
Ile Ile Ile Ser Val Asn Pro Lys Asp Leu Pro Leu Val Glu Lys Ser
          135 140 145

cgt cct gaa ctc aag aac atc gtg gag tat gct gac tcc tta att ctt 595
Arg Pro Glu Leu Lys Asn Ile Val Glu Tyr Ala Asp Ser Leu Ile Leu
          150 155 160 165

aca gca aaa cct gat gtt act cct ggg ggt tgc att atc gag act gaa 643
Thr Ala Lys Pro Asp Val Thr Pro Gly Gly Cys Ile Ile Glu Thr Glu
          170 175 180

gca ggg atc atc aat gcg cag ctt gat gta caa tta gat gcc tta gaa 691
Ala Gly Ile Ile Asn Ala Gln Leu Asp Val Gln Leu Asp Ala Leu Glu
          185 190 195

```

Fig. 5 (con't)

```
aaa gct ttc tcg act ata cta aaa gcg aag aac cct gta gac gag cca 739
Lys Ala Phe Ser Thr Ile Leu Lys Ala Lys Asn Pro Val Asp Glu Pro
      200                      205                      210


tct gag act tca tca tcc acg gat tct tct tct tta tct aat gat cag 787
Ser Glu Thr Ser Ser Ser Thr Asp Ser Ser Ser Leu Ser Asn Asp Gln
      215                      220                      225

gat aag aaa gaa taaaggtatt cactattatg cgatccattt ttcgattttc 839
Asp Lys Lys Glu
230

cctttgtttt tttacgctga gcgtctcatg ctgatttgct gacgccagtc tatatgaaaa 899

c 900
```

Restriction analysis of CPN100422



EcoRII
 AlwI
 HinfI
 TfiI
 BsaBI
 Hpy188IX
 DpnI
 BstYI
 Sau3AI
 Tsp509I
 Cac8I
 Tth111III
 BpmI
 DdeI
 MboII
 MboII
 GGGATCTGAATCCTGGAGCAAGCAAATTGCTTTCTTAGAAGAAGAAACTAAAAATCTACG
 301 -----+----- 360
 CCCTAGACTTAGGACCTCGTTCGTTTAAACGAAAGAATCTTCTTCTTTGATTTTATAGATGC
 BsaJI
 StyI
 CviJI
 HaeI
 HaeIII
 ThaI
 RsaI
 MnlI
 NlaIV
 MunI
 Tsp509I
 CjePI
 MnlI
 MnlI
 CATAAGAGTACGCGAGGCCTTGGTTCTCTGGCAATTGCGAGTGTGAGGAAAAATCATTTGG
 361 -----+----- 420
 GTATTCTCATGCGCTCCGGAACCAAGGAGACCGTTAACGCTCACACTCCTTTTAGTAACC
 Hpy178III
 CjePI
 Tsp509I
 FokI
 TaqI
 Bce83I
 BsmAI
 SmlI
 GAAGGAACTCGAATTACATCCTGAAACTATTGTCTCTATTATTCTCAAGCATTGAAAGA
 421 -----+----- 480
 CTTCTTTGAGCTTAATGTAGGACTTTGATAACAGAGATAATAAAGAGTTCGTAACTTTCT
 BanII
 BsiHKA
 Bsp1286I
 SacI
 Tth111III
 AluI
 CviJI
 MnlI
 GCTCACACAAAATAAACATATCATTATCTCTGTCAATCCCAAAGATTTACCTCTTGTTGA
 481 -----+----- 540
 CGAGTGTGTTTTATTGTATAGTAATAGAGACAGTTAGGGTTTCTAAATGGAGAACAAC

Fig. 6 (con't)




Fig. 6 (con't)

NlaIII
 Bpu1102I
 BsmAI
 BsmBI
 BsrI
 PshAI
 HgaI
 BseMII
 DdeI
 MwoI
 BsaHI
 HgaI

CTTTGTTTTTTTACGCTGAGCGTCTCATGCTGATTTGCTGACGCCAGTCTATATGAAAAC
 841 +-----+-----+-----+-----+-----+-----+-----+-----+ 900
 GAAACAAAAAATGCGACTCGCAGAGTACGACTAAACGACTGCGGTCTCAGATATACTTTTG

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

WO 00/24765

PCT/CA99/00992

Figure 7: CPN 100424

```

tggttcgcat tggcactaat cccccctttt gttatggtga ataaaaaggt atgcgtggat 60

catggttcgt cgatctatatt ctttttgctt gttctttcta atg aca ttg ctg tgc 115
                                     Met Thr Leu Leu Cys
                                     1 5

tgt aca agc tgt aac agc agg tct cta att gtg cac ggt ctt cct ggc 163
Cys Thr Ser Cys Asn Ser Arg Ser Leu Ile Val His Gly Leu Pro Gly
                10                15                20

aga gaa gcg aat gag att gtg gtg ctt ttg gta agc aaa ggg gtg gct 211
Arg Glu Ala Asn Glu Ile Val Val Leu Val Ser Lys Gly Val Ala
                25                30                35

gca caa aaa ttg cct caa gct gca gcg gct aca gcc gga gca gct act 259
Ala Gln Lys Leu Pro Gln Ala Ala Ala Ala Thr Ala Gly Ala Ala Thr
                40                45                50

gag caa atg tgg gat atc gcg gtt ccg tca gca caa atc aca gag gcc 307
Glu Gln Met Trp Asp Ile Ala Val Pro Ser Ala Gln Ile Thr Glu Ala
                55                60                65

ctt gcc att cta aat caa gcg ggt ctt cca cgt atg aaa ggg aca agc 355
Leu Ala Ile Leu Asn Gln Ala Gly Leu Pro Arg Met Lys Gly Thr Ser
                70                75                80                85

ctg tta gat ctt ttt gca aaa caa ggt ctt gtt cct tcc gag ctt cag 403
Leu Leu Asp Leu Phe Ala Lys Gln Gly Leu Val Pro Ser Glu Leu Gln
                90                95                100

gaa aaa atc cgt tat caa gaa ggc tta tca gaa cag atg gcc tct acg 451
Glu Lys Ile Arg Tyr Gln Glu Gly Leu Ser Glu Gln Met Ala Ser Thr
                105                110                115

att aga aaa atg gat ggc gtt gtc gat gcc tca gta cag att tcc ttc 499
Ile Arg Lys Met Asp Gly Val Val Asp Ala Ser Val Gln Ile Ser Phe
                120                125                130

act aca gaa aat gaa gat aat ctt cct tta aca gcc tct gtg tat att 547
Thr Thr Glu Asn Glu Asp Asn Leu Pro Leu Thr Ala Ser Val Tyr Ile
                135                140                145

aag cat cga ggg gtt ttg gac aat ccg aac agc att atg gtt tcc aaa 595
Lys His Arg Gly Val Leu Asp Asn Pro Asn Ser Ile Met Val Ser Lys
                150                155                160                165

att aag cgc ctt att gca agt gct gtt cca gga ctt gtg cca gag aac 643
Ile Lys Arg Leu Ile Ala Ser Ala Val Pro Gly Leu Val Pro Glu Asn
                170                175                180

gtc tct gta gtg agc gat cgc gca gct tat agt gat att aca att aat 691
Val Ser Val Val Ser Asp Arg Ala Ala Tyr Ser Asp Ile Thr Ile Asn
                185                190                195

```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

09/830446

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251


PCT/CA99/00992

Fig. 7 (con't)

ggt cct tgg gga tta aca gaa gaa atc gat tat gtt tct gtt tgg ggt	739
Gly Pro Trp Gly Leu Thr Glu Glu Ile Asp Tyr Val Ser Val Trp Gly	
200 205 210	
att att ctt gcg aag tct tcg ctc acc aaa ttc cgt ctc att ttt tat	787
Ile Ile Leu Ala Lys Ser Ser Leu Thr Lys Phe Arg Leu Ile Phe Tyr	
215 220 225	
gtc ttg att ctc att tta ttt gtt att tct tgt ggt ctc ctt tgg gtc	835
Val Leu Ile Leu Ile Leu Phe Val Ile Ser Cys Gly Leu Leu Trp Val	
230 235 240 245	
att tgg aaa act cat act ctc att atg act atg gga ggt aca aaa ggg	883
Ile Trp Lys Thr His Thr Leu Ile Met Thr Met Gly Gly Thr Lys Gly	
250 255 260	
ttc ttc aac cct aca cca tat aca aag aat gcc ttg gaa gcc aag aaa	931
Phe Phe Asn Pro Thr Pro Tyr Thr Lys Asn Ala Leu Glu Ala Lys Lys	
265 270 275	
gcc gag gga gca gct gct gac aaa gag aaa aaa gaa gat gca gat tca	979
Ala Glu Gly Ala Ala Ala Asp Lys Glu Lys Lys Glu Asp Ala Asp Ser	
280 285 290	
cag ggg gaa agc aaa aat gcg gaa acc agt gat aaa gac tct agt gat	1027
Gln Gly Glu Ser Lys Asn Ala Glu Thr Ser Asp Lys Asp Ser Ser Asp	
295 300 305	
aaa gat gct cca gaa gga agc aat gaa att gag ggt gct tagtgactgc	1076
Lys Asp Ala Pro Glu Gly Ser Asn Glu Ile Glu Gly Ala	
310 315 320	
caacactttt ggaactctag acatcttgat gaagcactcc aaggaagatg acctctccag	1136
gtttcttctt aaaaatcttc ttgttgaatc tctcatccc gaagaaatcc ctttaaaatc	1196
ttta	1200

Figure 8 (RY-36)

Restriction analysis of CPN100424






Fig. 8 (con't)





Fig. 8 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

WO 00/24765

09/830446

PCT/CA99/00992

Figure 9: CPN100426

```

ttgaacccta tggaaatgta tcttatttgt gctgggctat atttcttaat gacaacatca 60
ttttcctgta tttctagggt atcagaaaag agaaggagtt atg aca att aga gtc 115
                                         Met Thr Ile Arg Val
                                         1           5

cga aac ctt gcc tac tct gta aat aag aaa aag att cta gat ggt gta 163
Arg Asn Leu Ala Tyr Ser Val Asn Lys Lys Lys Ile Leu Asp Gly Val
                        10           15           20

act ttt tct tta gag cga ggg cac att aca ctg ttt gtt ggg aag agt 211
Thr Phe Ser Leu Glu Arg Gly His Ile Thr Leu Phe Val Gly Lys Ser
                        25           30           35

ggg tca gga aaa aca atg att tta cgt gct ttg gcg ggc tta gtc cag 259
Gly Ser Gly Lys Thr Met Ile Leu Arg Ala Leu Ala Gly Leu Val Gln
                        40           45           50

ccc act caa gga gat att tgg att gaa ggg gag gct cca gct cta gtt 307
Pro Thr Gln Gly Asp Ile Trp Ile Glu Gly Glu Ala Pro Ala Leu Val
                        55           60           65

ttc caa caa ccc gag tta ttt tcc cat atg aca gta tta gga aat tgc 355
Phe Gln Gln Pro Glu Leu Phe Ser His Met Thr Val Leu Gly Asn Cys
                        70           75           80           85

acc cat cca caa atc cat atc aag ggt cgt agt acc gaa gaa gct cga 403
Thr His Pro Gln Ile His Ile Lys Gly Arg Ser Thr Glu Glu Ala Arg
                        90           95           100

gaa aag gcg ttc gag ctt tta cat ttg ttg gat att gaa gag gtt gct 451
Glu Lys Ala Phe Glu Leu Leu His Leu Leu Asp Ile Glu Glu Val Ala
                        105           110           115

aag aat tat cct gac cag ctc tct ggg gga caa aaa caa cgt gtg gct 499
Lys Asn Tyr Pro Asp Gln Leu Ser Gly Gly Gln Lys Gln Arg Val Ala
                        120           125           130

att gta cgt tct tta tgt atg gat aaa cat aca tta ctt ttt gat gaa 547
Ile Val Arg Ser Leu Cys Met Asp Lys His Thr Leu Leu Phe Asp Glu
                        135           140           145

cct aca tcg gct tta gat cct ttt gct acg gca tcg ttc cga cat ctt 595
Pro Thr Ser Ala Leu Asp Pro Phe Ala Thr Ala Ser Phe Arg His Leu
                        150           155           160           165

tta gaa aca ctt cga gac cag gaa ctg act gta ggg tta act act cat 643
Leu Glu Thr Leu Arg Asp Gln Glu Leu Thr Val Gly Leu Thr Thr His
                        170           175           180

gac atg caa ttt gtt cat agt tgt ttg gat cgt atc tat ctt ata gat 691
Asp Met Gln Phe Val His Ser Cys Leu Asp Arg Ile Tyr Leu Ile Asp
                        185           190           195

```

Fig. 9 (con't)

```
caa gga act gtt gcg ggg gtc tat gac aag cgt gac gga gag ctc gat 739
Gln Gly Thr Val Ala Gly Val Tyr Asp Lys Arg Asp Gly Glu Leu Asp
      200                      205                      210

tct ggt cat cca tta tcg aaa tat atc cac tct gct caa taggactaca 788
Ser Gly His Pro Leu Ser Lys Tyr Ile His Ser Ala Gln
      215                      220                      225

gctgctagag cagctgtagt gatacttttag aatcctgacc agtggcagga atgagcggca 848
tg                                                                 850
```

Figure 10 (RY-37)
Restriction enzyme analysis of CPN100426





Fig. 10 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF


Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 10 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

04446 097830446

WO 00/24765

PCT/CA99/00992

Fig. 10 (con't)

```
Fnu4HI
TauI
AciI|
BsrBI|NlaIII
    |||
    GAGCGGCATG
841 -----+ 850
    CTCGCCGTAC
```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al

DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Figure 11: CPN100508

```

ctctgattta tggttaattct ttatttttcag agccgtcaag tcctttctat tctgttgaat 60
ttcctaataa cgtaagtaat aaacaatcaa aagtcgcgat atg aaa aga cct ttt 115
                                     Met Lys Arg Pro Phe
                                     1 5

ttt acc tat cta tgc atc atc ttc tac gga tct tgt gca tcg tta tct 163
Phe Thr Tyr Leu Cys Ile Ile Phe Tyr Gly Ser Cys Ala Ser Leu Ser
                                     10 15 20

tta cat gca gga ctc tct ttc cca gaa gta cgt gga gct acg gct gct 211
Leu His Ala Gly Leu Ser Phe Pro Glu Val Arg Gly Ala Thr Ala Ala
                                     25 30 35

gtt gtc cat gcc gac tct ggg aag gta ttc tat gat aaa gac ata gat 259
Val Val His Ala Asp Ser Gly Lys Val Phe Tyr Asp Lys Asp Ile Asp
Val Val His Ala Asp Ser Gly Lys Val Phe Tyr Asp Lys Asp Ile Asp
                                     40 45 50

gct gta atc tat cct gcc agc atg acg aaa atc gca act gcc ctc ttt 307
Ala Val Ile Tyr Pro Ala Ser Met Thr Lys Ile Ala Thr Ala Leu Phe
Ala Val Ile Tyr Pro Ala Ser Met Thr Lys Ile Ala Thr Ala Leu Phe
                                     55 60 65

atc cta aag cac tat ccc aca gtc ctc gat act ctc atc aaa gtc aaa 355
Ile Leu Lys His Tyr Pro Thr Val Leu Asp Thr Leu Ile Lys Val Lys
Ile Leu Lys His Tyr Pro Thr Val Leu Asp Thr Leu Ile Lys Val Lys
                                     70 75 80 85

caa gat gcg atc gct tcc atc act ccg caa gca aaa aaa caa tca gga 403
Gln Asp Ala Ile Ala Ser Ile Thr Pro Gln Ala Lys Lys Gln Ser Gly
Gln Asp Ala Ile Ala Ser Ile Thr Pro Gln Ala Lys Lys Gln Ser Gly
                                     90 95 100

tat cgt agt cct ccc cac tgg tta gaa act gat gga tct aca ata cag 451
Tyr Arg Ser Pro Pro His Trp Leu Glu Thr Asp Gly Ser Thr Ile Gln
Tyr Arg Ser Pro Pro His Trp Leu Glu Thr Asp Gly Ser Thr Ile Gln
                                     105 110 115

ctc cat ctt cga gaa gag ctt tta ggg tgg gac ctg ttc cac gcc tta 499
Leu His Leu Arg Glu Glu Leu Leu Gly Trp Asp Leu Phe His Ala Leu
Leu His Leu Arg Glu Glu Leu Leu Gly Trp Asp Leu Phe His Ala Leu
                                     120 125 130

ctg gtc tgt tct gct aat gat gct gcg aat gtc tta gct atg gca tgt 547
Leu Val Cys Ser Ala Asn Asp Ala Ala Asn Val Leu Ala Met Ala Cys
Leu Val Cys Ser Ala Asn Asp Ala Ala Asn Val Leu Ala Met Ala Cys
                                     135 140 145

tgc gga tct gta gag aag ttt atg gat aag ctg aac ttc ttc tta aaa 595
Cys Gly Ser Val Glu Lys Phe Met Asp Lys Leu Asn Phe Phe Leu Lys
Cys Gly Ser Val Glu Lys Phe Met Asp Lys Leu Asn Phe Phe Leu Lys
                                     150 155 160 165

gaa gaa atc ggc tgc act cat acc cat ttt aat aat ccc cat ggg tta 643
Glu Glu Ile Gly Cys Thr His Thr His Phe Asn Asn Pro His Gly Leu
Glu Glu Ile Gly Cys Thr His Thr His Phe Asn Asn Pro His Gly Leu
                                     170 175 180

```


Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 11 (con't)

cat cat ccg aat cac tat act aca acc cgt gat ctt att agc atc atg	691
His His Pro Asn His Tyr Thr Thr Thr Arg Asp Leu Ile Ser Ile Met	
His His Pro Asn His Tyr Thr Thr Thr Arg Asp Leu Ile Ser Ile Met	
185 190 195	
cg t tgc gct ctg aaa gaa cct cca ttt cga ggg gtc atc tcc acg aca	739
Arg Cys Ala Leu Lys Glu Pro Pro Phe Arg Gly Val Ile Ser Thr Thr	
Arg Cys Ala Leu Lys Glu Pro Pro Phe Arg Gly Val Ile Ser Thr Thr	
200 205 210	
agc tat aaa ata ggg gct aca aac ctg cat ggc gaa cgg atc cta tcc	787
Ser Tyr Lys Ile Gly Ala Thr Asn Leu His Gly Glu Arg Ile Leu Ser	
Ser Tyr Lys Ile Gly Ala Thr Asn Leu His Gly Glu Arg Ile Leu Ser	
215 220 225	
cca aca aac aaa ttg ctt ctt cct ggg tct acc tac cac tat ccc cca	835
Pro Thr Asn Lys Leu Leu Leu Pro Gly Ser Thr Tyr His Tyr Pro Pro	
Pro Thr Asn Lys Leu Leu Leu Pro Gly Ser Thr Tyr His Tyr Pro Pro	
230 235 240 245	
gct tta gga ggg aaa aca ggg acc acc aag act gca ggg aaa aat cta	883
Ala Leu Gly Gly Lys Thr Gly Thr Thr Lys Thr Ala Gly Lys Asn Leu	
Ala Leu Gly Gly Lys Thr Gly Thr Thr Lys Thr Ala Gly Lys Asn Leu	
250 255 260	
att atg gct gct gaa aaa aat aac cgc ctc ttg gta acg atc gca acg	931
Ile Met Ala Ala Glu Lys Asn Asn Arg Leu Leu Val Thr Ile Ala Thr	
Ile Met Ala Ala Glu Lys Asn Asn Arg Leu Leu Val Thr Ile Ala Thr	
265 270 275	
ggc tat tcg ggt cct gtg agt gat ctc tac caa gat gtc att gct cta	979
Gly Tyr Ser Gly Pro Val Ser Asp Leu Tyr Gln Asp Val Ile Ala Leu	
Gly Tyr Ser Gly Pro Val Ser Asp Leu Tyr Gln Asp Val Ile Ala Leu	
280 285 290	
tgt gaa acg gta ttt aac gag ccg cta tta aga aaa gag ctc gtc ccc	1027
Cys Glu Thr Val Phe Asn Glu Pro Leu Leu Arg Lys Glu Leu Val Pro	
Cys Glu Thr Val Phe Asn Glu Pro Leu Leu Arg Lys Glu Leu Val Pro	
295 300 305	
ccc tcc gac tgt ctc caa tta gaa ata gcg aat ctt ggg aag ctt tct	1075
Pro Ser Asp Cys Leu Gln Leu Glu Ile Ala Asn Leu Gly Lys Leu Ser	
Pro Ser Asp Cys Leu Gln Leu Glu Ile Ala Asn Leu Gly Lys Leu Ser	
310 315 320 325	
tgc cct ctt cct gag gga ctc tac tat gac ttc tat gcc tcc gaa gat	1123
Cys Pro Leu Pro Glu Gly Leu Tyr Tyr Asp Phe Tyr Ala Ser Glu Asp	
Cys Pro Leu Pro Glu Gly Leu Tyr Tyr Asp Phe Tyr Ala Ser Glu Asp	
330 335 340	
cgc gaa cct ctt tct gta tct ttt att gca cat gcg gac gcc ttc cct	1171
Arg Glu Pro Leu Ser Val Ser Phe Ile Ala His Ala Asp Ala Phe Pro	
Arg Glu Pro Leu Ser Val Ser Phe Ile Ala His Ala Asp Ala Phe Pro	
345 350 355	
att gaa caa gga gat ctt ctt ggt cat tgg gtt ttt tat gac gat gaa	1219
Ile Glu Gln Gly Asp Leu Leu Gly His Trp Val Phe Tyr Asp Asp Glu	
Ile Glu Gln Gly Asp Leu Leu Gly His Trp Val Phe Tyr Asp Asp Glu	
360 365 370	

Fig. 11 (con't)

```
ggc aag aaa att tct tcc cag cct ttc tat gcc cct tgt cgt ttt gag 1267
Gly Lys Lys Ile Ser Ser Gln Pro Phe Tyr Ala Pro Cys Arg Phe Glu
    375                      380                      385

cgc act atc aag cct tgg aaa ctc tat atg aaa cgt gtc ttc aca tcg 1315
Arg Thr Ile Lys Pro Trp Lys Leu Tyr Met Lys Arg Val Phe Thr Ser
    390                      395                      400                      405

tat aga acc tat atg tct ata acc atg ctg ctc atg tat ttt cgc atc 1363
Tyr Arg Thr Tyr Met Ser Ile Thr Met Leu Leu Met Tyr Phe Arg Ile
    410                      415                      420


cgc aag cac cgc aag tat aaa aat tta aaa cac tat tct aaa atc 1408
Arg Lys His Arg Lys Tyr Lys Asn Leu Lys His Tyr Ser Lys Ile
    425                      430                      435

taacttttttc ttttaattta taaaaaacca aagggtttatg taagatttgc gctttttcaat 1468

ccaacaagaa tcccttgtgc gcacattact tt 1500
```

Figure 12 (RY-39)

Restriction enzyme analysis of CPN100508



Tth111II
 BsiEI
 PvuI
 SgfI
 DpnI
 Sau3AI
 BccI
 AciI
 Cac8I
 Hpy178III
 Tth111II
 Pfl1108I
 EcoRV
 361
 TCGGATCGCTTCCATCACTCCGCAAGCAAAAAACAATCAGGATATCGTAGTCCTCCCCA
 -----+-----+-----+-----+-----+-----+-----+-----+ 420
 ACGCTAGCGAAGGTAGTGAGGCGTTTCGTTTTTTTGTAGTCCTATAGCATCAGGAGGGGT
 Hpy178III
 AceIII
 DpnI
 AluI
 TaqI
 BsrI
 BstYI
 CviJI
 EarI
 TspRI
 Sau3AI
 MboII
 SapI
 AluI
 MnlI
 BccI
 AlwI
 BccI
 CviJI
 MboII
 421
 CTGGTTAGAACTGATGGATCTACAATACAGCTCCATCTTCGAGAAGAGCTTTTAGGGTG
 -----+-----+-----+-----+-----+-----+-----+-----+ 480
 GACCAATCTTTGACTACCTAGATGTTATGTGCGAGGTAGAAGCTCTTCTCGAAATCCCAC
 NlaIV
 AvaII
 B0109I
 Psp5II
 Sau96I
 BsmFI
 BsrI
 BbvI
 SfaNI
 Fnu4HI
 TseI
 MwoI
 DdeI
 AluI
 CviJI
 481
 GGACCTGTTCCACGCCTTACTGGTCTGTTCTGCTAATGATGCTGCGAATGTCTTAGCTAT
 -----+-----+-----+-----+-----+-----+-----+-----+ 540
 CCTGGACAAGGTGCGGAATGACCAGACAAGACGATTACTACGACGCTTACAGAATCGATA
 SfcI
 DpnI
 BstYI
 Sau3AI
 AciI
 NlaIII
 NspI
 AlwI
 AluI
 CviJI
 MboII
 XmnI
 MseI
 BbvI
 BsgI
 541
 GGCATGTTGCGGATCTGTAGAGAAGTTTATGGATAAGCTGAACCTTCTTAAAGAAGA
 -----+-----+-----+-----+-----+-----+-----+-----+ 600
 CCGTACAACGCCTAGACATCTCTTCAAATACCTATTCGACTTGAAGAAGAATTTTCTTCT

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF


Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

WO 00/24765

PCT/CA99/00992

09/830446

Fig. 12 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 12 (con't)





Fig. 12 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Figure 13: CPN100515 -

```

aaggagcaaa tggagattgg ccaaataagac gagcaagggt ttgcataaga atagcctttt 60
tcgcaataat aacttgcccta aacgatcttg taaacgactt atg gct tct aat ccc 115
                                         Met Ala Ser Asn Pro
                                         1           5

att tta cag ata gag gat cta tcc ata acc ttg gca aaa caa cgc caa 163
Ile Leu Gln Ile Glu Asp Leu Ser Ile Thr Leu Ala Lys Gln Arg Gln
Ile Leu Gln Ile Glu Asp Leu Ser Ile Thr Leu Ala Lys Gln Arg Gln
                                         10           15           20

cag tac ccc atc gtc caa tct tta tcg ttt act atc aat gaa gga caa 211
Gln Tyr Pro Ile Val Gln Ser Leu Ser Phe Thr Ile Asn Glu Gly Gln
Gln Tyr Pro Ile Val Gln Ser Leu Ser Phe Thr Ile Asn Glu Gly Gln
                                         25           30           35

acc tta gca atc att gga gaa tca gga tca gga aaa tct gtc tct gcg 259
Thr Leu Ala Ile Ile Gly Glu Ser Gly Ser Gly Lys Ser Val Ser Ala
Thr Leu Ala Ile Ile Gly Glu Ser Gly Ser Gly Lys Ser Val Ser Ala
                                         40           45           50

cat gca atc ctt cga tta ctt cct tgc ccc cca ttt tct gtt tct ggc 307
His Ala Ile Leu Arg Leu Leu Pro Cys Pro Pro Phe Ser Val Ser Gly
His Ala Ile Leu Arg Leu Leu Pro Cys Pro Pro Phe Ser Val Ser Gly
                                         55           60           65

cag gtc aac ttc caa ggc cac aac tta ctt acg gct tcg cgc tct ata 355
Gln Val Asn Phe Gln Gly His Asn Leu Leu Thr Ala Ser Arg Ser Ile
Gln Val Asn Phe Gln Gly His Asn Leu Leu Thr Ala Ser Arg Ser Ile
                                         70           75           80           85

caa aaa aag att ata ggg aca gaa att tct atg atc ttt caa aac ccg 403
Gln Lys Lys Ile Ile Gly Thr Glu Ile Ser Met Ile Phe Gln Asn Pro
Gln Lys Lys Ile Ile Gly Thr Glu Ile Ser Met Ile Phe Gln Asn Pro
                                         90           95           100

caa gca tct cta aac ccc gtg ttt act att gaa cag cag ttt cga gaa 451
Gln Ala Ser Leu Asn Pro Val Phe Thr Ile Glu Gln Gln Phe Arg Glu
Gln Ala Ser Leu Asn Pro Val Phe Thr Ile Glu Gln Gln Phe Arg Glu
                                         105           110           115

att att cat acc cac cta gcc tta act gca gaa gtt gct aaa gaa aag 499
Ile Ile His Thr His Leu Ala Leu Thr Ala Glu Val Ala Lys Glu Lys
Ile Ile His Thr His Leu Ala Leu Thr Ala Glu Val Ala Lys Glu Lys
                                         120           125           130

atg tta tac gct ctt gaa gaa aca ggg ttt cat gat ccc agg ctg tgc 547
Met Leu Tyr Ala Leu Glu Glu Thr Gly Phe His Asp Pro Arg Leu Cys
Met Leu Tyr Ala Leu Glu Glu Thr Gly Phe His Asp Pro Arg Leu Cys
                                         135           140           145

ttg aat ctc tac ccc cac caa ctc tct gga ggg atg ctt caa aga att 595
Leu Asn Leu Tyr Pro His Gln Leu Ser Gly Gly Met Leu Gln Arg Ile
Leu Asn Leu Tyr Pro His Gln Leu Ser Gly Gly Met Leu Gln Arg Ile
                                         150           155           160           165

```


Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

097830446

WO 00/24765

PCT/CA99/00992

Fig. 13 (con't)

tgc att gcc atg gcg ctc ctc tgt tct cct aaa ctt ctt att gct gat	643
Cys Ile Ala Met Ala Leu Leu Cys Ser Pro Lys Leu Leu Ile Ala Asp	
Cys Ile Ala Met Ala Leu Leu Cys Ser Pro Lys Leu Leu Ile Ala Asp	
170 175 180	
 gaa cct acg act gct tta gat gtt tct gtt cag tat cag att cta caa	691
Glu Pro Thr Thr Ala Leu Asp Val Ser Val Gln Tyr Gln Ile Leu Gln	
Glu Pro Thr Thr Ala Leu Asp Val Ser Val Gln Tyr Gln Ile Leu Gln	
185 190 195	
 tta cta aaa aca cta cag aaa aaa acg gga atg agc ctt ctt att att	739
Leu Leu Lys Thr Leu Gln Lys Lys Thr Gly Met Ser Leu Leu Ile Ile	
Leu Leu Lys Thr Leu Gln Lys Lys Thr Gly Met Ser Leu Leu Ile Ile	
200 205 210	
 acc cat aat atg gga gtc gtt gca gaa act gct gat gac gtg ctc gtg	787
Thr His Asn Met Gly Val Val Ala Glu Thr Ala Asp Asp Val Leu Val	
Thr His Asn Met Gly Val Val Ala Glu Thr Ala Asp Asp Val Leu Val	
215 220 225	
 ctc tat gca gga cgc atg gta gaa tgt gcc cct gcg gtt caa atg ttc	835
Leu Tyr Ala Gly Arg Met Val Glu Cys Ala Pro Ala Val Gln Met Phe	
Leu Tyr Ala Gly Arg Met Val Glu Cys Ala Pro Ala Val Gln Met Phe	
230 235 240 245	
 cat aat cct tct cat ccc tat acc cga gat ctt tta gca tcc aga ccc	883
His Asn Pro Ser His Pro Tyr Thr Arg Asp Leu Leu Ala Ser Arg Pro	
His Asn Pro Ser His Pro Tyr Thr Arg Asp Leu Leu Ala Ser Arg Pro	
250 255 260	
 tct cta caa ccg caa caa cta ggt tcc ttc aac ccc att cca gga cag	931
Ser Leu Gln Pro Gln Gln Leu Gly Ser Phe Asn Pro Ile Pro Gly Gln	
Ser Leu Gln Pro Gln Gln Leu Gly Ser Phe Asn Pro Ile Pro Gly Gln	
265 270 275	
 ccc cca cac tac acg gcc ttt ccc tcg gga tgt cgc tat cac cct aga	979
Pro Pro His Tyr Thr Ala Phe Pro Ser Gly Cys Arg Tyr His Pro Arg	
Pro Pro His Tyr Thr Ala Phe Pro Ser Gly Cys Arg Tyr His Pro Arg	
280 285 290	
 tgc tca aaa att tta aat cga tgt tct gcg gaa gct cca gaa atc tat	1027
Cys Ser Lys Ile Leu Asn Arg Cys Ser Ala Glu Ala Pro Glu Ile Tyr	
Cys Ser Lys Ile Leu Asn Arg Cys Ser Ala Glu Ala Pro Glu Ile Tyr	
295 300 305	
 ccg gta cgc gaa ggt cac aaa gta agg gtt ggc tgt atg acg act aat	1075
Pro Val Arg Glu Gly His Lys Val Arg Val Gly Cys Met Thr Thr Asn	
Pro Val Arg Glu Gly His Lys Val Arg Val Gly Cys Met Thr Thr Asn	
310 315 320 325	
 ttt ccc caa cct tta att caa gca acc tca tta aca aag cac tat tac	1123
Phe Pro Gln Pro Leu Ile Gln Ala Thr Ser Leu Thr Lys His Tyr Tyr	
Phe Pro Gln Pro Leu Ile Gln Ala Thr Ser Leu Thr Lys His Tyr Tyr	
330 335 340	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

09/830446

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

Fig. 13 (con't)

aag cgt tcc ttt tgg ttt cag gga aag aca att gcc agt cgt cct gtt	1171
Lys Arg Ser Phe Trp Phe Gln Gly Lys Thr Ile Ala Ser Arg Pro Val	
Lys Arg Ser Phe Trp Phe Gln Gly Lys Thr Ile Ala Ser Arg Pro Val	
345 350 355	
gac gac gtc tct ttt tca cta tac tcc aga cgt gct gtc gga ctt att	1219
Asp Asp Val Ser Phe Ser Leu Tyr Ser Arg Arg Ala Val Gly Leu Ile	
Asp Asp Val Ser Phe Ser Leu Tyr Ser Arg Arg Ala Val Gly Leu Ile	
360 365 370	
gga gaa tct gga tca ggg aaa agt acc ctg gcg tta gct ctc gca ggt	1267
Gly Glu Ser Gly Ser Gly Lys Ser Thr Leu Ala Leu Ala Leu Ala Gly	
Gly Glu Ser Gly Ser Gly Lys Ser Thr Leu Ala Leu Ala Leu Ala Gly	
375 380 385	
ctc cta cct ctc acc tct ggg ttc tta act ttt aac ggc acc cca atc	1315
Leu Leu Pro Leu Thr Ser Gly Phe Leu Thr Phe Asn Gly Thr Pro Ile	
Leu Leu Pro Leu Thr Ser Gly Phe Leu Thr Phe Asn Gly Thr Pro Ile	
390 395 400 405	
aag ttg cat tct aaa cac gga cgc cat caa tta cga tct caa gta cgg	1363
Lys Leu His Ser Lys His Gly Arg His Gln Leu Arg Ser Gln Val Arg	
Lys Leu His Ser Lys His Gly Arg His Gln Leu Arg Ser Gln Val Arg	
410 415 420	
ttg gtc ttt caa aat cca caa gct tca tta aac ccg cga aaa act atc	1411
Leu Val Phe Gln Asn Pro Gln Ala Ser Leu Asn Pro Arg Lys Thr Ile	
Leu Val Phe Gln Asn Pro Gln Ala Ser Leu Asn Pro Arg Lys Thr Ile	
425 430 435	
cta gat agt tta ggc cac tct ctg ctt tac cat aaa ctc gtc cca aaa	1459
Leu Asp Ser Leu Gly His Ser Leu Leu Tyr His Lys Leu Val Pro Lys	
Leu Asp Ser Leu Gly His Ser Leu Leu Tyr His Lys Leu Val Pro Lys	
440 445 450	
gaa aaa gta cta gca acg gta agg gaa tat tta gaa ttg gta ggg tta	1507
Glu Lys Val Leu Ala Thr Val Arg Glu Tyr Leu Glu Leu Val Gly Leu	
Glu Lys Val Leu Ala Thr Val Arg Glu Tyr Leu Glu Leu Val Gly Leu	
455 460 465	
tct gag gag tat ttt tat cgt tat cct cac cag ctt tct gga gga caa	1555
Ser Glu Glu Tyr Phe Tyr Arg Tyr Pro His Gln Leu Ser Gly Gly Gln	
Ser Glu Glu Tyr Phe Tyr Arg Tyr Pro His Gln Leu Ser Gly Gly Gln	
470 475 480 485	
caa caa cga gtc tct ata gcg aga gcc cta tta gga gtc cct cag tta	1603
Gln Gln Arg Val Ser Ile Ala Arg Ala Leu Leu Gly Val Pro Gln Leu	
Gln Gln Arg Val Ser Ile Ala Arg Ala Leu Leu Gly Val Pro Gln Leu	
490 495 500	
att att tgt gac gaa att gtt tct gct cta gat tta tct att caa gca	1651
Ile Ile Cys Asp Glu Ile Val Ser Ala Leu Asp Leu Ser Ile Gln Ala	
Ile Ile Cys Asp Glu Ile Val Ser Ala Leu Asp Leu Ser Ile Gln Ala	
505 510 515	
caa att ctg aat atg ctt gcc gag ctg caa aaa aaa ctc agc ctc aca	1699
Gln Ile Leu Asn Met Leu Ala Glu Leu Gln Lys Lys Leu Ser Leu Thr	
Gln Ile Leu Asn Met Leu Ala Glu Leu Gln Lys Lys Leu Ser Leu Thr	
520 525 530	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765


PCT/CA99/00992

Fig. 13 (con't)

tat ctc ttc att tcg cat gat ctt gcc gtt gta cgc tcg ttc tgc aca	1747
Tyr Leu Phe Ile Ser His Asp Leu Ala Val Val Arg Ser Phe Cys Thr	
Tyr Leu Phe Ile Ser His Asp Leu Ala Val Val Arg Ser Phe Cys Thr	
535 540 545	
gag gta ttc att atg tat aag ggg caa att gta gaa aaa gga aat aca	1795
Glu Val Phe Ile Met Tyr Lys Gly Gln Ile Val Glu Lys Gly Asn Thr	
Glu Val Phe Ile Met Tyr Lys Gly Gln Ile Val Glu Lys Gly Asn Thr	
550 555 560 565	
aaa cgc att ttt tct gat cca caa cat cct tat acg cgc atg ttg tta	1843
Lys Arg Ile Phe Ser Asp Pro Gln His Pro Tyr Thr Arg Met Leu Leu	
Lys Arg Ile Phe Ser Asp Pro Gln His Pro Tyr Thr Arg Met Leu Leu	
570 575 580	
aat gcc caa ctt cca gag act cct gat caa agg caa tct aaa cct ata	1891
Asn Ala Gln Leu Pro Glu Thr Pro Asp Gln Arg Gln Ser Lys Pro Ile	
Asn Ala Gln Leu Pro Glu Thr Pro Asp Gln Arg Gln	
585 590 595	
ttc caa gaa tat cac aaa gat tct gaa gaa tct tgc tct aca gga tgc	1939
Phe Gln Glu Tyr His Lys Asp Ser Glu Glu Ser Cys Ser Thr Gly Cys	
600 605 610	
tac ttt tac aat cgt tgt cca caa aaa caa gaa gct tgc aag tca gag	1987
Tyr Phe Tyr Asn Arg Cys Pro Gln Lys Gln Glu Ala Cys Lys Ser Glu	
615 620 625	
atc atc cca aat caa gga gac gcg cac cat aca tac cgt tgt atc cat	2035
Ile Ile Pro Asn Gln Gly Asp Ala His His Thr Tyr Arg Cys Ile His	
630 635 640 645	
tgattcgtcc tctacgctat tcttaagcta ccattaagga atcccaaggg agagggtctgc	2095
tctat	2100

Figure 14 (RY-40)

Restriction enzyme analysis of CPN 100515



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF


Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992


Fig. 14 (cont)



097830446

[illegible]

Fig. 14 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

097830446

WO 00/24765

PCT/CA99/00992

Fig. 14 (cont')




Fig. 14 (con't)




Fig. 14 (con't)





Fig. 14 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Figure 15:

```

cgaagagcaa acctccacag ttacagagaa agacgtccaa cctaaaacac aagcaacacc 60
acacgcttcg aagaaaaacg ttgcaagtcc ttcgacctct atg cca gga atc gag 115
                                         Met Pro Gly Ile Glu
                                         1           5

aaa gca gca aca aca gtg gct gta cct caa gac aaa tct gaa gaa gaa 163
Lys Ala Ala Thr Thr Val Ala Val Pro Gln Asp Lys Ser Glu Glu Glu
                        10                      15                      20

aaa gtt aaa gag cga ttg aca aag cgg gaa ctt acc tgt gaa gac ctt 211
Lys Val Lys Glu Arg Leu Thr Lys Arg Glu Leu Thr Cys Glu Asp Leu
                        25                      30                      35

aaa gat aac ggc tat act gtc aat ttt gaa gac att tct att tta gag 259
Lys Asp Asn Gly Tyr Thr Val Asn Phe Glu Asp Ile Ser Ile Leu Glu
                        40                      45                      50

ttg ttg cag ttc gta agt aaa att tct gga acg aac ttt gtc ttt gat 307
Leu Leu Gln Phe Val Ser Lys Ile Ser Gly Thr Asn Phe Val Phe Asp
                        55                      60                      65

agc aac gat ttg caa ttc aat gtc acg atc gtt tcc cac gat cct act 355
Ser Asn Asp Leu Gln Phe Asn Val Thr Ile Val Ser His Asp Pro Thr
                        70                      75                      80                      85

tct gta gat gat tta tct aca atc tta cta caa gtc tta aaa atg cat 403
Ser Val Asp Asp Leu Ser Thr Ile Leu Leu Gln Val Leu Lys Met His
                        90                      95                      100

gac ttg aag gtt gtt gaa caa ggc aat aac gtc ctt atc tat cgt aat 451
Asp Leu Lys Val Val Glu Gln Gly Asn Asn Val Leu Ile Tyr Arg Asn
                        105                      110                      115

cct cat ctt tct aag cta tcc aca gta gtc aca gac agc tcc tta aaa 499
Pro His Leu Ser Lys Leu Ser Thr Val Val Thr Asp Ser Ser Leu Lys
                        120                      125                      130

gaa acg tgt gaa gct gtt gtg gtt acc cga gtg ttc cgt ctt tac agg 547
Glu Thr Cys Glu Ala Val Val Val Thr Arg Val Phe Arg Leu Tyr Arg
                        135                      140                      145

cgt cag ccc tct gca gca gta aat att att caa cct tta ctt tcc cat 595
Arg Gln Pro Ser Ala Ala Val Asn Ile Ile Gln Pro Leu Leu Ser His
                        150                      155                      160                      165

gat gct atc gtt agt gct tca gaa gct act cgt cat gtt atc atc tcg 643
Asp Ala Ile Val Ser Ala Ser Glu Ala Thr Arg His Val Ile Ile Ser
                        170                      175                      180

gat att gct ggt aat gtc gat aaa gtc agt gat ttg cta gca gct cta 691
Asp Ile Ala Gly Asn Val Asp Lys Val Ser Asp Leu Leu Ala Ala Leu
                        185                      190                      195

```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 15 con't)

gat tgc cca ggc aca tct gtg gac atg act gaa tac gaa gtt aaa tat	739
Asp Cys Pro Gly Thr Ser Val Asp Met Thr Glu Tyr Glu Val Lys Tyr	
200 205 210	
gcc aat ccc gca gct ctt gtt agc tac tgc caa gat gtt ctt ggt act	787
Ala Asn Pro Ala Ala Leu Val Ser Tyr Cys Gln Asp Val Leu Gly Thr	
215 220 225	
ctg gcc gaa gat gat gct ttc caa atg ttc atc caa cct gga acg aac	835
Leu Ala Glu Asp Asp Ala Phe Gln Met Phe Ile Gln Pro Gly Thr Asn	
230 235 240 245	
aaa att ttc gtc gtc tct tca cca cgt ctt gca aat aag gca gag cag	883
Lys Ile Phe Val Val Ser Ser Pro Arg Leu Ala Asn Lys Ala Glu Gln	
250 255 260	
ctc ctg aag tcc tta gat gtc cca gaa atg gca cat acc cta gat gat	931
Leu Leu Lys Ser Leu Asp Val Pro Glu Met Ala His Thr Leu Asp Asp	
265 270 275	
cct gca agt act gcc ttg gct ttg gga gga aca gga acc acg agc cct	979
Pro Ala Ser Thr Ala Leu Ala Leu Gly Gly Thr Gly Thr Thr Ser Pro	
280 285 290	
aag agt ttg cgg ttc ttt atg tac aag ctg aag tat caa aat gga gaa	1027
Lys Ser Leu Arg Phe Phe Met Tyr Lys Leu Lys Tyr Gln Asn Gly Glu	
295 300 305	
gtg att gct aat gcc ctc caa gat atc ggt tac aat cta tat gta acc	1075
Val Ile Ala Asn Ala Leu Gln Asp Ile Gly Tyr Asn Leu Tyr Val Thr	
310 315 320 325	
aca gct atg gac gaa gat ttc att aac act ctc aat agt atc cag tgg	1123
Thr Ala Met Asp Glu Asp Phe Ile Asn Thr Leu Asn Ser Ile Gln Trp	
330 335 340	
tta gag gtc aat aac tcc ata gtt att atc gga aac caa ggg aat gtc	1171
Leu Glu Val Asn Asn Ser Ile Val Ile Ile Gly Asn Gln Gly Asn Val	
345 350 355	
gac aga gtt att ggc ctc tta aac ggt tta gat tta cct cct aaa cag	1219
Asp Arg Val Ile Gly Leu Leu Asn Gly Leu Asp Leu Pro Pro Lys Gln	
360 365 370	
gtt tac atc gaa gtt tta att cta gat acc agc tta gag aaa tcc tgg	1267
Val Tyr Ile Glu Val Leu Ile Leu Asp Thr Ser Leu Glu Lys Ser Trp	
375 380 385	
gac ttt gga gtg caa tgg gta gcc cta ggt gat gaa caa agt aaa gta	1315
Asp Phe Gly Val Gln Trp Val Ala Leu Gly Asp Glu Gln Ser Lys Val	
390 395 400 405	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

097830446

WO 00/24765

PCT/CA99/00992

Fig. 15 con't)

gct tat gct tct gga cta ttg aat aat act ggc ata gcc aca cct aca	1363
Ala Tyr Ala Ser Gly Leu Leu Asn Asn Thr Gly Ile Ala Thr Pro Thr	
410 415 420	
aaa gca act gtc cct ccc ggc acg cca aat cct ggt tgc atc cct ctt	1411
Lys Ala Thr Val Pro Pro Gly Thr Pro Asn Pro Gly Ser Ile Pro Leu	
425 430 435	
cct acg cca gga caa ttg aca ggg ttc tca gat atg ctg aac tct tgc	1459
Pro Thr Pro Gly Gln Leu Thr Phe Ser Asp Met Leu Asn Ser Ser	
440 445 450	
tca gca ttc ggt cta gga atc atc gga aat gtc cta agt cat aaa ggg	1507
Ser Ala Phe Gly Leu Gly Ile Ile Gly Asn Val Leu Ser His Lys Gly	
455 460 465	
aag tct ttc ctt act ttg gga ggc tta tta agt gcc tta gat caa gat	1555
Lys Ser Phe Leu Thr Leu Gly Gly Leu Leu Ser Ala Leu Asp Gln Asp	
470 475 480 485	
gga gat act gtc att gtc ttg aat cct aga atc atg gct cag gat acg	1603
Gly Asp Thr Val Ile Val Leu Asn Pro Arg Ile Met Ala Gln Asp Thr	
490 495 500	
caa caa gct tgc ttt ttt gta ggg caa acg gtc cct tac caa act atc	1651
Gln Gln Ala Ser Phe Phe Val Gly Gln Thr Val Pro Tyr Gln Thr Ile	
505 510 515	
aaa tac tat atc caa gaa aca gga act gta acg caa aat atc gat tat	1699
Lys Tyr Tyr Ile Gln Glu Thr Gly Thr Val Thr Gln Asn Ile Asp Tyr	
520 525 530	
gaa gat att gga gtg aac ctt gtc gtt acc tct aca gtt gct ccc aac	1747
Glu Asp Ile Gly Val Asn Leu Val Val Thr Ser Thr Val Ala Pro Asn	
535 540 545	
aat gta gtt aca cta caa atc gaa cag acg atc tca gaa tta cat tcc	1795
Asn Val Val Thr Leu Gln Ile Glu Gln Thr Ile Ser Glu Leu His Ser	
550 555 560 565	
gcg tct gga tca cta aca cct gtc aca gat aaa act tat gca gcc aca	1843
Ala Ser Gly Ser Leu Thr Pro Val Thr Asp Lys Thr Tyr Ala Ala Thr	
570 575 580	
cgc tta caa att ccc gac ggt tgt ttc tta gtt atg agt ggg cat atc	1891
Arg Leu Gln Ile Pro Asp Gly Cys Phe Leu Val Met Ser Gly His Ile	
585 590 595	
aga gat aaa act aca aaa gtg gtt tca gga gtg cct ttg cta aac tcc	1939
Arg Asp Lys Thr Thr Lys Val Val Ser Gly Val Pro Leu Leu Asn Ser	
600 605 610	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/28/94 446

PCT/CA99/00992

WO 00/24765

Fig. 15 con't)

ata cca tta att cgt ggt tta ttt agc cgt acc atc gac caa agg caa	1987
Ile Pro Leu Ile Arg Gly Leu Phe Ser Arg Thr Ile Asp Gln Arg Gln	
615 620 625	
aaa cgc aat atc atg atg ttt att aag cct aag gtg att agt agc ttt	2035
Lys Arg Asn Ile Met Met Phe Ile Lys Pro Lys Val Ile Ser Ser Phe	
630 635 640 645	
gaa gaa ggc act cgt gtt acc aat aag gaa gga tac aga tac aat tgg	2083
Glu Glu Gly Thr Arg Val Thr Asn Lys Glu Gly Tyr Arg Tyr Asn Trp	
650 655 660	
gaa gct gat gaa gga tcc atg caa gtg gcc cct cgc cat gct cct gaa	2131
Glu Ala Asp Glu Gly Ser Met Gln Val Ala Pro Arg His Ala Pro Glu	
665 670 675	
tgc caa gga cct cct tct tta cag gct gaa agt gac ttt aaa ata ata	2179
Cys Gln Gly Pro Pro Ser Leu Gln Ala Glu Ser Asp Phe Lys Ile Ile	
680 685 690	
gaa ata gaa gct cag tagtggtata taaaagagga agatgatatt ctccgccgtg	2234
Glu Ile Glu Ala Gln	
695	
gaatagcttc tgactctgtt gcattcaggg ggaaagccaa gaagatgtag agtcggccgt	2294
ataact	2300

Figure 16 (RY-41)

Restriction enzyme analysis of CPN100538




Fig. 16 (con't)




Fig. 16 (con't)




Fig. 16 (cont')





Fig. 16 (con't)




Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

Fig. 16 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

09/830446

Fig. 16 (con't)





Fig. 16 (cont)




Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

WO 00/24765

PCT/CA99/00992

Fig. 16 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

097830446

WO 00/24765

PCT/CA99/00992

Figure 17: CPN100557

tagcttgaaa tagcttcttc caattgtgat ttctgaagaa gtataggggg aaatgtcgaa	60
gagatagtct tgttttaaag gaggagggga aaacggttta atg agc aga aaa gac	115
	Met Ser Arg Lys Asp
	Arg Lys Asp
	1 5
aat gag gtt tcc tta gct cgt tca att ttt aat ata tta tcc gga act	163
Asn Glu Val Ser Leu Ala Arg Ser Ile Phe Asn Ile Leu Ser Gly Thr	
Asn Glu Val Ser Leu Ala Arg Ser Ile Phe Asn Ile Leu Ser Gly Thr	
	10 15 20
ttc tgt agt cgt att aca ggg ata ttt cga gaa att gca atg gca acc	211
Phe Cys Ser Arg Ile Thr Gly Ile Phe Arg Glu Ile Ala Met Ala Thr	
Phe Cys Ser Arg Ile Thr Gly Ile Phe Arg Glu Ile Ala Met Ala Thr	
	25 30 35
tat ttt gga gct gat cca att gta gct gct ttc tgg tta ggt ttc cgt	259
Tyr Phe Gly Ala Asp Pro Ile Val Ala Ala Phe Trp Leu Gly Phe Arg	
Tyr Phe Gly Ala Asp Pro Ile Val Ala Ala Phe Trp Leu Gly Phe Arg	
	40 45 50
act gtt ttt ttc tta aga aaa att tta gga ggg ctc att cta gaa caa	307
Thr Val Phe Phe Leu Arg Lys Ile Leu Gly Gly Leu Ile Leu Glu Gln	
Thr Val Phe Phe Leu Arg Lys Ile Leu Gly Gly Leu Ile Leu Glu Gln	
	55 60 65
gcc ttc atc cct cat ttt gaa ttt ctc cgt gct caa agt ctc gat cgt	355
Ala Phe Ile Pro His Phe Glu Phe Leu Arg Ala Gln Ser Leu Asp Arg	
Ala Phe Ile Pro His Phe Glu Phe Leu Arg Ala Gln Ser Leu Asp Arg	
	70 75 80 85
gcg gcg ttt ttt ttc cga cgc ttt tct aga ttg att aaa ggc agc act	403
Ala Ala Phe Phe Phe Arg Arg Phe Ser Arg Leu Ile Lys Gly Ser Thr	
Ala Ala Phe Phe Phe Arg Arg Phe Ser Arg Leu Ile Lys Gly Ser Thr	
	90 95 100
att ata ttc act ctg ctt att gaa gca gta ttg tgg gta ttc ttc aat	451
Ile Ile Phe Thr Leu Leu Ile Glu Ala Val Leu Trp Val Phe Phe Asn	
Ile Ile Phe Thr Leu Leu Ile Glu Ala Val Leu Trp Val Phe Phe Asn	
	105 110 115
aac gtt gaa gag ggg act tac gat atg att ctc ctt act atg ata ctc	499
Asn Val Glu Glu Gly Thr Tyr Asp Met Ile Leu Leu Thr Met Ile Leu	
Asn Val Glu Glu Gly Thr Tyr Asp Met Ile Leu Leu Thr Met Ile Leu	
	120 125 130
ttg ccc tgt ggc att ttc tta atg atg tac aat gta aac ggc gct ttg	547
Leu Pro Cys Gly Ile Phe Leu Met Met Tyr Asn Val Asn Gly Ala Leu	
Leu Pro Cys Gly Ile Phe Leu Met Met Tyr Asn Val Asn Gly Ala Leu	
	135 140 145
ctt cac tgt gga aat aag ttt ttc ggg gtg gga tta gct ccc gta gtt	595
Leu His Cys Gly Asn Lys Phe Phe Gly Val Gly Leu Ala Pro Val Val	
Leu His Cys Gly Asn Lys Phe Phe Gly Val Gly Leu Ala Pro Val Val	
	150 155 160 165
gta aat atc att tgg att ttc ttt gtt ata gcg gct cgt cat tca gat	643
Val Asn Ile Ile Trp Ile Phe Phe Val Ile Ala Ala Arg His Ser Asp	
Val Asn Ile Ile Trp Ile Phe Phe Val Ile Ala Ala Arg His Ser Asp	
	170 175 180

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

09/830446

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

Fig. 17 (con't)

cct aga gag cgt att atc ggt tta tcc gtg gct cta gtt atc ggg ttt	691
Pro Arg Glu Arg Ile Ile Gly Leu Ser Val Ala Leu Val Ile Gly Phe	
Pro Arg Glu Arg Ile Ile Gly Leu Ser Val Ala Leu Val Ile Gly Phe	
185 190 195	
ttc ttc gaa tgg tta atc acg gtt cct gga gta tgg aaa ttt cta tta	739
Phe Phe Glu Trp Leu Ile Thr Val Pro Gly Val Trp Lys Phe Leu Leu	
Phe Phe Glu Trp Leu Ile Thr Val Pro Gly Val Trp Lys Phe Leu Leu	
200 205 210	
gaa gcg aag agc cca cct caa gaa cac gat agt gtt cga gct tta tta	787
Glu Ala Lys Ser Pro Pro Gln Glu His Asp Ser Val Arg Ala Leu Leu	
Glu Ala Lys Ser Pro Pro Gln Glu His Asp Ser Val Arg Ala Leu Leu	
215 220 225	
gct ccc tta tct ttg ggt att tta act tca agc atc ttc cag ctg aac	835
Ala Pro Leu Ser Leu Gly Ile Leu Thr Ser Ser Ile Phe Gln Leu Asn	
Ala Pro Leu Ser Leu Gly Ile Leu Thr Ser Ser Ile Phe Gln Leu Asn	
230 235 240 245	
ctt ctt tct gat atc tgc ttg gct cgc tat gta cat gaa ata ggc cct	883
Leu Leu Ser Asp Ile Cys Leu Ala Arg Tyr Val His Glu Ile Gly Pro	
Leu Leu Ser Asp Ile Cys Leu Ala Arg Tyr Val His Glu Ile Gly Pro	
250 255 260	
cta tat ctt atg tac tcc tta aag att tat cag ctc ccc ata cat ctc	931
Leu Tyr Leu Met Tyr Ser Leu Lys Ile Tyr Gln Leu Pro Ile His Leu	
Leu Tyr Leu Met Tyr Ser Leu Lys Ile Tyr Gln Leu Pro Ile His Leu	
265 270 275	
ttt ggc ttt ggt gtg ttt acc gtt ctc ctc cca gca att tct cgt tgt	979
Phe Gly Phe Gly Val Phe Thr Val Leu Leu Pro Ala Ile Ser Arg Cys	
Phe Gly Phe Gly Val Phe Thr Val Leu Leu Pro Ala Ile Ser Arg Cys	
280 285 290	
gta cag cga gaa gat cat gag agg gga ttg aaa ctt atg aag ttc gtt	1027
Val Gln Arg Glu Asp His Glu Arg Gly Leu Lys Leu Met Lys Phe Val	
Val Gln Arg Glu Asp His Glu Arg Gly Leu Lys Leu Met Lys Phe Val	
295 300 305	
ctc acc cta acc atg tcc gta atg atc att atg aca gca ggg cta ttg	1075
Leu Thr Leu Thr Met Ser Val Met Ile Ile Met Thr Ala Gly Leu Leu	
Leu Thr Leu Thr Met Ser Val Met Ile Ile Met Thr Ala Gly Leu Leu	
310 315 320 325	
ctc tta gct tta cct gga gtc cgt gtc ctt tat gaa cac gga ctt ttc	1123
Leu Leu Ala Leu Pro Gly Val Arg Val Leu Tyr Glu His Gly Leu Phe	
Leu Leu Ala Leu Pro Gly Val Arg Val Leu Tyr Glu His Gly Leu Phe	
330 335 340	
cct cag agt gct gtc tac gct att gtt cgt gta ttg cga ggt tat ggt	1171
Pro Gln Ser Ala Val Tyr Ala Ile Val Arg Val Leu Arg Gly Tyr Gly	
Pro Gln Ser Ala Val Tyr Ala Ile Val Arg Val Leu Arg Gly Tyr Gly	
345 350 355	
gcc agt att atc cct atg gcc ttg gct cct tta gtc tct gtt ctt ttt	1219
Ala Ser Ile Ile Pro Met Ala Leu Ala Pro Leu Val Ser Val Leu Phe	
Ala Ser Ile Ile Pro Met Ala Leu Ala Pro Leu Val Ser Val Leu Phe	
360 365 370	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

09/830446

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

Fig. 17 (con't)

tat gca cag cgg cag tat gct gtt ccg ctc ttt ata gga atc ggt acg	1267
Tyr Ala Gln Arg Gln Tyr Ala Val Pro Leu Phe Ile Gly Ile Gly Thr	
Tyr Ala Gln Arg Gln Tyr Ala Val Pro Leu Phe Ile Gly Ile Gly Thr	
375 380 385	
gct ttg gcc aat att gtt tta agc ttg gtt cta ggt cgt tgg gtt tta	1315
Ala Leu Ala Asn Ile Val Leu Ser Leu Val Leu Gly Arg Trp Val Leu	
Ala Leu Ala Asn Ile Val Leu Ser Leu Val Leu Gly Arg Trp Val Leu	
390 395 400 405	
aaa gac gtc tcg ggc att tcc tat gct aca tcc ata act gct tgg gtg	1363
Lys Asp Val Ser Gly Ile Ser Tyr Ala Thr Ser Ile Thr Ala Trp Val	
Lys Asp Val Ser Gly Ile Ser Tyr Ala Thr Ser Ile Thr Ala Trp Val	
410 415 420	
cag tta tat ttc ctc tgg tat tat tct tcg aaa aga ctc cct atg tac	1411
Gln Leu Tyr Phe Leu Trp Tyr Tyr Ser Ser Lys Arg Leu Pro Met Tyr	
Gln Leu Tyr Phe Leu Trp Tyr Tyr Ser Ser Lys Arg Leu Pro Met Tyr	
425 430 435	
tct aag tta ctt tgg gag agc atc cgg cgt tcc ata aaa gtt atg gga	1459
Ser Lys Leu Leu Trp Glu Ser Ile Arg Arg Ser Ile Lys Val Met Gly	
Ser Lys Leu Leu Trp Glu Ser Ile Arg Arg Ser Ile Lys Val Met Gly	
440 445 450	
acc act atg ctt gct tgt atg att act cta ggc tta aat atc ctt acg	1507
Thr Thr Met Leu Ala Cys Met Ile Thr Leu Gly Leu Asn Ile Leu Thr	
Thr Thr Met Leu Ala Cys Met Ile Thr Leu Gly Leu Asn Ile Leu Thr	
455 460 465	
caa act aca tat gta att ttc tta aac ccc ctc aca cca ctt gct tgg	1555
Gln Thr Thr Tyr Val Ile Phe Leu Asn Pro Leu Thr Pro Leu Ala Trp	
Gln Thr Thr Tyr Val Ile Phe Leu Asn Pro Leu Thr Pro Leu Ala Trp	
470 475 480 485	
ccc tta tcc tcc ata acg gct caa gca att gct ttt tta tct gag agc	1603
Pro Leu Ser Ser Ile Thr Ala Gln Ala Ile Ala Phe Leu Ser Glu Ser	
Pro Leu Ser Ser Ile Thr Ala Gln Ala Ile Ala Phe Leu Ser Glu Ser	
490 495 500	
tgc att ttc ttg gct ttt ttg ttt ggt ttt gca aaa ctg ctt cga gta	1651
Cys Ile Phe Leu Ala Phe Leu Phe Gly Phe Ala Lys Leu Leu Arg Val	
Cys Ile Phe Leu Ala Phe Leu Phe Gly Phe Ala Lys Leu Leu Arg Val	
505 510 515	
gaa gat ctt att aat ttg gct tct ttt gaa tac tgg cgt ggg caa cgg	1699
Glu Asp Leu Ile Asn Leu Ala Ser Phe Glu Tyr Trp Arg Gly Gln Arg	
Glu Asp Leu Ile Asn Leu Ala Ser Phe Glu Tyr Trp Arg Gly Gln Arg	
520 525 530	
ggg ctt ttg caa aga caa cac gtg atg caa gac act caa aat	1741
Gly Leu Leu Gln Arg Gln His Val Met Gln Asp Thr Gln Asn	
Gly Leu Leu Gln	
535 540 545	
taatcatggt tggttcttgt agctcagtcg ctttctttta gctttaagtt ttgatagcct	1801
gcttggtctt ctgtttctac acttaatat gatactaagg atactatgaa aaaacaggta	1861
tatcaatggt tagcgagtgt gggtctttta gcgctgaca	1900

Figure 18 (RY-43)

Restriction enzyme analysis of CPN100557




Fig. 18 (cont')




Fig. 18 (con't)




Fig. 18 (con't)

Fig. 18 (con't)





Fig. 18 (con't)



WO 00/24765

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF
Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

PCT/CA99/00992

Fig. 18 (con't)

```

                SspI      DdeI
                MseI      BciVI
                |      |      |
1801  TGCTTGGTCTTCTGTTTCTACACTTAATATTGATACTAAGGATACTATGAAAAACAGGT
-----+-----+-----+-----+-----+-----+-----+-----+ 1860
      ACGAACCAGAAGACAAAGATGTGAATTATACTATGATTCCTATGATACTTTTTTGTCCA

                        HaeII
                        HhaI
                DrdII  Eco47III
                |      |      |
1861  ATATCAATGGTTAGCGAGTGTGGTTCTTTTAGCGCTGACA
-----+-----+-----+-----+-----+-----+ 1900
      TATAGTTACCAATCGCTCACACCAAGAAAATCGCGACTGT
```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

PCT/CA99/00992

WO 00/24765

Figure 19: CPN100622

```

tctcaagagt aaccttatcc ttagattatt cagctcaagt ctctctcgta actgtaggtc 60

aataccttaa agctgagagt cattgcacat tttaaccaca atg aaa aca tca agg 115
                                         Met Lys Thr Ser Arg
                                         1           5

aat aaa cag tgc aaa ata aca gat ccc tta agt aaa tct tcc ttc ttt 163
Asn Lys Gln Cys Lys Ile Thr Asp Pro Leu Ser Lys Ser Ser Phe Phe
                        10           15           20

gtt gga gcc tta att tta ggt aaa act aca ata ctc ctt aat gcg act 211
Val Gly Ala Leu Ile Leu Gly Lys Thr Thr Ile Leu Leu Asn Ala Thr
                        25           30           35

ccg ttg tct gac tat ttt gat aat caa gca aat caa ctc aca aca ctc 259
Pro Leu Ser Asp Tyr Phe Asp Asn Gln Ala Asn Gln Leu Thr Thr Leu
                        40           45           50

ttc cct cta att gat act ctt act aac atg act ccc tac tct cat aga 307
Phe Pro Leu Ile Asp Thr Leu Thr Asn Met Thr Pro Tyr Ser His Arg
                        55           60           65

gca aca ctt ttt gga gtt agg gat gac act aac caa gac att gtc ctc 355
Ala Thr Leu Phe Gly Val Arg Asp Asp Thr Asn Gln Asp Ile Val Leu
                        70           75           80           85

gat cac cag aat tcc ata gaa agc tgg ttc gaa aac ttc tct caa gac 403
Asp His Gln Asn Ser Ile Glu Ser Trp Phe Glu Asn Phe Ser Gln Asp
                        90           95           100

ggc ggt gct ctc tct tgc aaa tca ctt gcc ata acg aat aca aaa aac 451
Gly Gly Ala Leu Ser Cys Lys Ser Leu Ala Ile Thr Asn Thr Lys Asn
                        105           110           115

caa att ctt ttc cta aat agc ttt gct att aaa aga gct ggt gcg atg 499
Gln Ile Leu Phe Leu Asn Ser Phe Ala Ile Lys Arg Ala Gly Ala Met
                        120           125           130

tat gtt gat ggt aat ttc gat ctt tct gag aat cat ggt tcc atc att 547
Tyr Val Asp Gly Asn Phe Asp Leu Ser Glu Asn His Gly Ser Ile Ile
                        135           140           145

ttc tct ggg aat tta agc ttt cct aat gca agt aat ttc gct gat act 595
Phe Ser Gly Asn Leu Ser Phe Pro Asn Ala Ser Asn Phe Ala Asp Thr
                        150           155           160           165

tgt aca ggg gga gct gtt tta tgt tcg aaa aat gtt aca atc tca aaa 643
Cys Thr Gly Gly Ala Val Leu Cys Ser Lys Asn Val Thr Ile Ser Lys
      Thr Gly Gly Ala Val Leu Cys Ser Lys Asn Val Thr Ile Ser Lys
                        170           175           180

aat caa gga acc gca tac ttc att aac aac aag gca aaa tct tca gga 691
Asn Gln Gly Thr Ala Tyr Phe Ile Asn Asn Lys Ala Lys Ser Ser Gly
Asn Gln Gly Thr Ala Tyr Phe Ile Asn Asn Lys Ala Lys Ser Ser Gly
                        185           190           195

```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

097830446

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

Fig. 19 (con't)

gga gca atc caa gct gca atc ata aac att aag gac aac act ggc cct	739
Gly Ala Ile Gln Ala Ala Ile Ile Asn Ile Lys Asp Asn Thr Gly Pro	
Gly Ala Ile Gln Ala Ala Ile Ile Asn Ile Lys Asp Asn Thr Gly Pro	
200 205 210	
tgc ctg ttt ttt aat aat gct gca ggc gga aca gcg ggg ggc gcg ttg	787
Cys Leu Phe Phe Asn Asn Ala Ala Gly Gly Thr Ala Gly Gly Ala Leu	
Cys Leu Phe Phe Asn Asn Ala Ala Gly Gly Thr Ala Gly Gly Ala Leu	
215 220 225	
ttc gct aat gct tgt aga att gag aat aat tct cag cct atc tat ttt	835
Phe Ala Asn Ala Cys Arg Ile Glu Asn Asn Ser Gln Pro Ile Tyr Phe	
Phe Ala Asn Ala Cys Arg Ile Glu Asn Asn Ser Gln Pro Ile Tyr Phe	
230 235 240 245	
ttg aat aac caa tca ggt ctg ggt ggt gca ata aga gta cat caa gag	883
Leu Asn Asn Gln Ser Gly Leu Gly Gly Ala Ile Arg Val His Gln Glu	
Leu Asn Asn Gln Ser Gly Leu Gly Gly Ala Ile Arg Val His Gln Glu	
250 255 260	
tgc att ctt aca aag aat acc ggt tct gtg atc ttc aac aat aat ttt	931
Cys Ile Leu Thr Lys Asn Thr Gly Ser Val Ile Phe Asn Asn Asn Phe	
Cys Ile Leu Thr Lys Asn Thr Gly Ser Val Ile Phe Asn Asn Asn Phe	
265 270 275	
gcc atg gaa gcg gac atc tct gct aac cat tcc tct gga ggg gct atc	979
Ala Met Glu Ala Asp Ile Ser Ala Asn His Ser Ser Gly Gly Ala Ile	
Ala Met Glu Ala Asp Ile Ser Ala Asn His Ser Ser Gly Gly Ala Ile	
280 285 290	
tat tgc att agt tgt tct ata aaa gac aac cca gga att gca gcc ttc	1027
Tyr Cys Ile Ser Cys Ser Ile Lys Asp Asn Pro Gly Ile Ala Ala Phe	
Tyr Cys Ile Ser Cys Ser Ile Lys Asp Asn Pro Gly Ile Ala Ala Phe	
295 300 305	
gat aat aat act gca gca cga gat gga ggt gct atc tgt aca caa tct	1075
Asp Asn Asn Thr Ala Ala Arg Asp Gly Gly Ala Ile Cys Thr Gln Ser	
Asp Asn Asn Thr Ala Ala Arg Asp Gly Gly Ala Ile Cys Thr Gln Ser	
310 315 320 325	
cta act ata caa gac agt ggt ccc gtc tat ttc aca aac aat cag gga	1123
Leu Thr Ile Gln Asp Ser Gly Pro Val Tyr Phe Thr Asn Asn Gln Gly	
Leu Thr Ile Gln Asp Ser Gly Pro Val Tyr Phe Thr Asn Asn Gln Gly	
330 335 340	
act tgg ggc ggc gct atc atg ctc cgt caa gat ggt gca tgc act tta	1171
Thr Trp Gly Gly Ala Ile Met Leu Arg Gln Asp Gly Ala Cys Thr Leu	
Thr Trp Gly Gly Ala Ile Met Leu Arg Gln Asp Gly Ala Cys Thr Leu	
345 350 355	
ttt gct gat cag gga gat att att ttt tat aat aat aga cac ttc aaa	1219
Phe Ala Asp Gln Gly Asp Ile Ile Phe Tyr Asn Asn Arg His Phe Lys	
Phe Ala Asp Gln Gly Asp Ile Ile Phe Tyr Asn Asn Arg His Phe Lys	
360 365 370	
gat act ttc agc aat cat gtt tct gta aac tgc acg cgt aat gtc tca	1267
Asp Thr Phe Ser Asn His Val Ser Val Asn Cys Thr Arg Asn Val Ser	
Asp Thr Phe Ser Asn His Val Ser Val Asn Cys Thr Arg Asn Val Ser	
375 380 385	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

097830446

WO 00/24765

PCT/CA99/00992

Fig. 19 (con't)

tta	aca	gtt	gga	gca	agt	caa	ggt	cat	tct	gct	acc	ttc	tat	gat	ccc	1315
Leu	Thr	Val	Gly	Ala	Ser	Gln	Gly	His	Ser	Ala	Thr	Phe	Tyr	Asp	Pro	
Leu	Thr	Val	Gly	Ala	Ser	Gln	Gly	His	Ser	Ala	Thr	Phe	Tyr	Asp	Pro	
390					395					400					405	
ata	cta	caa	aga	tat	act	ata	caa	aac	tct	atc	caa	aaa	ttt	aat	cct	1363
Ile	Leu	Gln	Arg	Tyr	Thr	Ile	Gln	Asn	Ser	Ile	Gln	Lys	Phe	Asn	Pro	
Ile	Leu	Gln	Arg	Tyr	Thr	Ile	Gln	Asn	Ser	Ile	Gln	Lys	Phe	Asn	Pro	
			410						415					420		
aat	cca	gaa	cac	ctc	gga	act	atc	ttg	ttc	tcc	tca	aca	tat	att	cgg	1411
Asn	Pro	Glu	His	Leu	Gly	Thr	Ile	Leu	Phe	Ser	Ser	Thr	Tyr	Ile	Pro	
Asn	Pro	Glu	His	Leu	Gly	Thr	Ile	Leu	Phe	Ser	Ser	Thr	Tyr	Ile	Pro	
			425					430					435			
gat	aca	tcg	act	tct	cgt	gat	gac	ttc	att	tca	cat	ttc	aga	aac	cac	1459
Asp	Thr	Ser	Thr	Ser	Arg	Asp	Asp	Phe	Ile	Ser	His	Phe	Arg	Asn	His	
Asp	Thr	Ser	Thr	Ser	Arg	Asp	Asp	Phe	Ile	Ser	His	Phe	Arg	Asn	His	
			440					445					450			
att	gga	ctg	tac	aac	ggc	aca	ctc	gct	ctt	gaa	gat	cga	gca	gag	tgg	1507
Ile	Gly	Leu	Tyr	Asn	Gly	Thr	Leu	Ala	Leu	Glu	Asp	Arg	Ala	Glu	Trp	
Ile	Gly	Leu	Tyr	Asn	Gly	Thr	Leu	Ala	Leu	Glu	Asp	Arg	Ala	Glu	Trp	
	455					460					465					
aaa	gtc	tat	aaa	ttt	gat	caa	ttt	ggt	ggg	act	cta	cgg	tta	ggc	agt	1555
Lys	Val	Tyr	Lys	Phe	Asp	Gln	Phe	Gly	Gly	Thr	Leu	Arg	Leu	Gly	Ser	
Lys	Val	Tyr	Lys	Phe	Asp	Gln	Phe	Gly	Gly	Thr	Leu	Arg	Leu	Gly	Ser	
470					475					480					485	
aga	gct	gtg	ttt	tct	aca	aca	gac	gaa	gaa	caa	agt	agc	agt	agt	gtg	1603
Arg	Ala	Val	Phe	Ser	Thr	Thr	Asp	Glu	Glu	Gln	Ser	Ser	Ser	Ser	Val	
Arg	Ala	Val	Phe	Ser	Thr	Thr	Asp	Glu	Glu	Gln	Ser	Ser	Ser	Ser	Val	
				490					495						500	
ggt	tct	gta	att	aac	atc	aat	aat	ctt	gca	att	aac	ctt	ccc	tct	atc	1651
Gly	Ser	Val	Ile	Asn	Ile	Asn	Asn	Leu	Ala	Ile	Asn	Leu	Pro	Ser	Ile	
Gly	Ser	Val	Ile	Asn	Ile	Asn	Asn	Leu	Ala	Ile	Asn	Leu	Pro	Ser	Ile	
			505					510					515			
tta	ggc	aac	aga	gtt	gct	ccc	aag	cta	tgg	att	cgc	ccc	aca	ggt	tca	1699
Leu	Gly	Asn	Arg	Val	Ala	Pro	Lys	Leu	Trp	Ile	Arg	Pro	Thr	Gly	Ser	
Leu	Gly	Asn	Arg	Val	Ala	Pro	Lys	Leu	Trp	Ile	Arg	Pro	Thr	Gly	Ser	
			520					525				530				
tca	gca	ccc	tat	agc	gaa	gat	aat	aac	cct	ata	atc	aat	ctc	tca	gga	1747
Ser	Ala	Pro	Tyr	Ser	Glu	Asp	Asn	Asn	Pro	Ile	Ile	Asn	Leu	Ser	Gly	
Ser	Ala	Pro	Tyr	Ser	Glu	Asp	Asn	Asn	Pro	Ile	Ile	Asn	Leu	Ser	Gly	
	535					540					545					
cct	ttg	agc	cta	ctg	gat	gac	gag	aac	cta	gat	ccc	tat	gat	act	gca	1795
Pro	Leu	Ser	Leu	Leu	Asp	Asp	Glu	Asn	Leu	Asp	Pro	Tyr	Asp	Thr	Ala	
Pro	Leu	Ser	Leu	Leu	Asp	Asp	Glu	Asn	Leu	Asp	Pro	Tyr	Asp	Thr	Ala	
550					555					560					565	
gac	ctt	gcc	caa	cct	atc	gca	gaa	gtt	cct	ctt	ctg	tat	ctc	tta	gac	1843
Asp	Leu	Ala	Gln	Pro	Ile	Ala	Glu	Val	Pro	Leu	Leu	Tyr	Leu	Leu	Asp	
Asp	Leu	Ala	Gln	Pro	Ile	Ala	Glu	Val	Pro	Leu	Leu	Tyr	Leu	Leu	Asp	
				570					575						580	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

WO 00/24765

PCT/CA99/00992

Fig. 19 (con't)

tac agc aac cac cat atc aaa gca tct gga tat tct gga aaa ata caa	2467
Tyr Ser Asn His His Ile Lys Ala Ser Gly Tyr Ser Gly Lys Ile Gln	
Tyr Ser Asn His His Ile Lys Ala Ser Gly Tyr Ser Gly Lys Ile Gln	
775 780 785	
acg gaa ggc aaa tgt tat agt acg aca tta ggg gcg gct ctc tct tgc	2515
Thr Glu Gly Lys Cys Tyr Ser Thr Thr Leu Gly Ala Ala Leu Ser Cys	
Thr Glu Gly Lys Cys Tyr Ser Thr Thr Leu Gly Ala Ala Leu Ser Cys	
790 795 800 805	
tct cta tct cta caa tgg cga tca cga cct ctc cac ttc act cct ttt	2563
Ser Leu Ser Leu Gln Trp Arg Ser Arg Pro Leu His Phe Thr Pro Phe	
Ser Leu Ser Leu Gln Trp Arg Ser Arg Pro Leu His Phe Thr Pro Phe	
810 815 820	
atc caa gca att gcc gtt cgt tct aat caa act gcg ttt caa gaa agt	2611
Ile Gln Ala Ile Ala Val Arg Ser Asn Gln Thr Ala Phe Gln Glu Ser	
Ile Gln Ala Ile Ala Val Arg Ser Asn Gln Thr Ala Phe Gln Glu Ser	
825 830 835	
gga gat aaa gct aga aaa ttt tct gtt cat aaa ccc tta tat aac ctg	2659
Gly Asp Lys Ala Arg Lys Phe Ser Val His Lys Pro Leu Tyr Asn Leu	
Gly Asp Lys Ala Arg Lys Phe Ser Val His Lys Pro Leu Tyr Asn Leu	
840 845 850	
aca gtc cct ctg gga att cag agc gct tgg gaa tcc aag ttc cgt ctt	2707
Thr Val Pro Leu Gly Ile Gln Ser Ala Trp Glu Ser Lys Phe Arg Leu	
Thr Val Pro Leu Gly Ile Gln Ser Ala Trp Glu Ser Lys Phe Arg Leu	
855 860 865	
cct acc tat tgg aac ata gag ctt gct tat cag cct gtc ctc tac caa	2755
Pro Thr Tyr Trp Asn Ile Glu Leu Ala Tyr Gln Pro Val Leu Tyr Gln	
Pro Thr Tyr Trp Asn Ile Glu Leu Ala Tyr Gln Pro Val Leu Tyr Gln	
870 875 880 885	
caa aat cct gag atc aac gtg agt cta gaa tct agt gga tcg tca tgg	2803
Gln Asn Pro Glu Ile Asn Val Ser Leu Glu Ser Ser Gly Ser Ser Trp	
Gln Asn Pro Glu Ile Asn Val Ser Leu Glu Ser Ser Gly Ser Ser Trp	
890 895 900	
ctc cta tca gga acc acc ctt gct cgc aat gcc att gct ttt aaa gga	2851
Leu Leu Ser Gly Thr Thr Leu Ala Arg Asn Ala Ile Ala Phe Lys Gly	
Leu Leu Ser Gly Thr Thr Leu Ala Arg Asn Ala Ile Ala Phe Lys Gly	
905 910 915	
aga aac caa att ttt atc ttc cct aaa ctt tcg gtg ttc tta gac tat	2899
Arg Asn Gln Ile Phe Ile Phe Pro Lys Leu Ser Val Phe Leu Asp Tyr	
Arg Asn Gln Ile Phe Ile Phe Pro Lys Leu Ser Val Phe Leu Asp Tyr	
920 925 930	
caa ggc tcg gta tcc tca tca acg acg aca cat tac ctt cac gca gga	2947
Gln Gly Ser Val Ser Ser Ser Thr Thr Thr His Tyr Leu His Ala Gly	
Gln Gly Ser Val Ser Ser Ser Thr Thr Thr His Tyr Leu His Ala Gly	
935 940 945	
acg acc ttt aag ttt taaaagcatg ttatatagac aatgcaacct gtaaagacca	3002
Thr Thr Phe Lys Phe	
Thr Thr Phe Lys Phe	
950	
aatagagagt agtgaacact cctaccatc atgaatctta tgggagaagc taagggaat	3062
ccacagatac gtttccccc taaaaattaa gaaccggata catcctcact agagattcga	3122
aagaactact taaatcctaa gcattcga	3150

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

097830446

WO 00/24765


PCT/CA99/00992

Fig. 19 (con't)

gtc	aca	gct	aaa	cat	att	aat	acg	gat	aat	ttc	tac	cct	gag	ggt	cta	1891
Val	Thr	Ala	Lys	His	Ile	Asn	Thr	Asp	Asn	Phe	Tyr	Pro	Glu	Gly	Leu	
Val	Thr	Ala	Lys	His	Ile	Asn	Thr	Asp	Asn	Phe	Tyr	Pro	Glu	Gly	Leu	
			585												595	
aat	aca	act	caa	cac	tac	ggc	tac	caa	ggc	gtt	tgg	tcc	cct	tac	tgg	1939
Asn	Thr	Thr	Gln	His	Tyr	Gly	Tyr	Gln	Gly	Val	Trp	Ser	Pro	Tyr	Trp	
Asn	Thr	Thr	Gln	His	Tyr	Gly	Tyr	Gln	Gly	Val	Trp	Ser	Pro	Tyr	Trp	
			600												610	
atc	gaa	aca	atc	aca	act	tct	gat	acc	tct	tct	gaa	gat	act	gtg	aat	1987
Ile	Glu	Thr	Ile	Thr	Thr	Ser	Asp	Thr	Ser	Ser	Glu	Asp	Thr	Val	Asn	
Ile	Glu	Thr	Ile	Thr	Thr	Ser	Asp	Thr	Ser	Ser	Glu	Asp	Thr	Val	Asn	
			615												625	
act	tta	cat	cgc	cag	ctt	tat	ggt	gat	tgg	aca	cct	aca	gga	tat	aag	2035
Thr	Leu	His	Arg	Gln	Leu	Tyr	Gly	Asp	Trp	Thr	Pro	Thr	Gly	Tyr	Lys	
Thr	Leu	His	Arg	Gln	Leu	Tyr	Gly	Asp	Trp	Thr	Pro	Thr	Gly	Tyr	Lys	
															645	
															640	
gta	aac	cca	gaa	aac	aaa	gga	gac	att	gcc	cta	tct	gcc	ttc	tgg	caa	2083
Val	Asn	Pro	Glu	Asn	Lys	Gly	Asp	Ile	Ala	Leu	Ser	Ala	Phe	Trp	Gln	
Val	Asn	Pro	Glu	Asn	Lys	Gly	Asp	Ile	Ala	Leu	Ser	Ala	Phe	Trp	Gln	
															660	
															650	
tct	ttc	cat	aac	tta	ttt	gcg	aca	cta	cgt	tat	caa	aca	cag	caa	ggc	2131
Ser	Phe	His	Asn	Leu	Phe	Ala	Thr	Leu	Arg	Tyr	Gln	Thr	Gln	Gln	Gly	
Ser	Phe	His	Asn	Leu	Phe	Ala	Thr	Leu	Arg	Tyr	Gln	Thr	Gln	Gln	Gly	
															675	
															665	
caa	ata	gca	cct	aca	gct	tct	gga	gaa	gct	act	cga	ctc	ttc	gtg	cat	2179
Gln	Ile	Ala	Pro	Thr	Ala	Ser	Gly	Glu	Ala	Thr	Arg	Leu	Phe	Val	His	
Gln	Ile	Ala	Pro	Thr	Ala	Ser	Gly	Glu	Ala	Thr	Arg	Leu	Phe	Val	His	
															685	
															690	
caa	aat	agc	aac	aat	gat	gcg	aaa	gga	ttc	cat	atg	gaa	gct	acg	ggt	2227
Gln	Asn	Ser	Asn	Asn	Asp	Ala	Lys	Gly	Phe	His	Met	Glu	Ala	Thr	Gly	
Gln	Asn	Ser	Asn	Asn	Asp	Ala	Lys	Gly	Phe	His	Met	Glu	Ala	Thr	Gly	
															695	
															700	
tat	tct	ttg	gga	aca	acc	tca	aac	act	gct	tct	aat	cat	agc	ttt	ggt	2275
Tyr	Ser	Leu	Gly	Thr	Thr	Ser	Asn	Thr	Ala	Ser	Asn	His	Ser	Phe	Gly	
Tyr	Ser	Leu	Gly	Thr	Thr	Ser	Asn	Thr	Ala	Ser	Asn	His	Ser	Phe	Gly	
															710	
															715	
															720	
gta	aac	ttc	tcc	caa	ctt	ttc	agt	aat	ctc	tac	gag	agc	cac	tcc	gac	2323
Val	Asn	Phe	Ser	Gln	Leu	Phe	Ser	Asn	Leu	Tyr	Glu	Ser	His	Ser	Asp	
Val	Asn	Phe	Ser	Gln	Leu	Phe	Ser	Asn	Leu	Tyr	Glu	Ser	His	Ser	Asp	
															730	
															735	
															740	
aat	tcc	gtg	gct	tcg	cat	acg	aca	act	gta	gcg	ctc	cag	atc	aat	aat	2371
Asn	Ser	Val	Ala	Ser	His	Thr	Thr	Thr	Val	Ala	Leu	Gln	Ile	Asn	Asn	
Asn	Ser	Val	Ala	Ser	His	Thr	Thr	Thr	Val	Ala	Leu	Gln	Ile	Asn	Asn	
															745	
															750	
															755	
cct	tgg	ctg	caa	gag	aga	ttc	tct	aca	tct	gca	tct	cta	gcc	tac	agc	2419
Pro	Trp	Leu	Gln	Glu	Arg	Phe	Ser	Thr	Ser	Ala	Ser	Leu	Ala	Tyr	Ser	
Pro	Trp	Leu	Gln	Glu	Arg	Phe	Ser	Thr	Ser	Ala	Ser	Leu	Ala	Tyr	Ser	
															760	
															765	
															770	

Figure 20 (RY-44)

Restriction enzyme analysis of CPN100622



[illegible]

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF


Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

WO 00/24765

PCT/CA99/00992

09/830446

Fig. 20 (cont)



DpnI
 Sau3AI
 MboII
 MspI
 BsaWI
 BsrFI
 PinAI
 Tsp509I
 NlaIII
 MwoI
 BsaJI
 BstDSI
 NcoI
 StyI
 AcII
 CviJI
 Hin4I
 BslI
 Hpy178III
 BstXI
 MnlI
 BpmI
 CviRI
 Tsp509I
 ScrFI
 BsaJI
 EcoRII
 Fnu4HI
 CviRI
 TseI
 MnlI
 BssSI
 PstI
 Fnu4HI
 CviRI
 TseI
 TaqI
 CviJI
 BbvI
 SfcI
 BbvI
 BccI
 Hin4I
 BsrGI
 TatI
 BsmFI
 Sth132I
 BscGI
 NlaIV
 TspRI
 AvaII
 Sau96I
 PshAI
 TaaI
 HaeII
 Fnu4HI
 TauI
 Tth111III
 AcII
 HhaI

TACCGGTTCTGTGATCTTCAACAATAATTTTGCCATGGAAGCGGACATCTCTGCTAACCA
 ATGGCCAAGACACTAGAAGTTGTTATTAAAACGGTACCTTCGCCTGTAGAGACGATTGGT
 TTCCTCTGGAGGGCTATCTATTGCATTAGTTGTTCTATAAAAGACAACCCAGGAATTGC
 AAGGAGACCTCCCCGATAGATAACGTAATCAACAAGATATTTTCTGTTGGGTCCTTAACG
 AGCCTTCGATAATAATACTGCAGCACGAGATGGAGGTGCTATCTGTACACAATCTCTAAC
 TCGGAAGCTATTATTATGACGTCGTGCTCTACCTCCACGATAGACATGTGTTAGAGATTG
 TATACAAGACAGTGGTCCCGTCTATTTCAACAACATCAGGGAACCTTGGGGCGGCGCTAT
 ATATGTTCTGTCAACAGGGCAGATAAAGTGTTTGTTAGTCCCTTGAACCCCGCCGCGATA

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 20 (con't)




Fig. 20 (con't)





Fig. 20 (con't)



09/830446

Fig. 20 (cont)





Fig. 20 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 20 (con't)




Fig. 20 (con't)




Fig. 20 (con't)




Figure 21A: CPN100626 Coding Sequence

tectgaactc	cactcgaat	tactgattag	ccaaggtacg	tggacgacgc	agggcactcc	60
tgtgacctac	aatgctttag	ggatcaaagt	gaaaaatacc	atgcaggtgt	ttcctaaagt	120
cactctctcc	ttagattact	ctgcggatat	ttcttctctc	acgctgagtc	actacttaaa	180
cgtggcgagt	agaatgagat	ttttaacaat	aagtgcacaa	aacagaaaga	ttaaggaacc	240
tctagtgtca	aagactcctc	ctaagttttt	attctatctc	gggaatttca	cagcctgcac	300
gttcgggatg	actcctgcag	tgtatagttt	acaaacggac	tcccttgaaa	agtttgcttt	360
agagagggat	gaagagtttc	gtacgagctt	tccctcttta	gactctctct	ccactcttac	420
aggattttct	ccaataacta	cgtttggttg	aaatagacat	aattcctctc	aagacattgt	480
actttctaac	tacaagtcta	ttgataacat	ccttcttctt	tggacatcgg	ctgggggagc	540
tgtgtcctgt	aataatttct	tattatcaaa	tgttgaagac	catgccttct	tcagtaaaaa	600
tctcgcgatt	gggactggag	gcgcgattgc	ttgccaggga	gcctgcacaa	tcacgaagaa	660
tagaggaccc	cttatttttt	tcagcaatcg	aggtcttaac	aatgcgagta	caggaggaga	720
aactcgtggg	ggtgcgattg	cctgtaatgg	agacttcacg	atttctcaaa	atcaagggac	780
tttctacttt	gtcaacaatt	ccgtcaacaa	ctggggagga	gccctctcca	ccaatggaca	840
ctgccgctat	caaagcaaca	gggcacctct	actctttttt	aacaatacag	cccctagtgg	900
aggggggtgcg	cttcgtagtg	aaaatacaac	gatctctgat	aacacgcgtc	ctattttattt	960
taagaacaac	tgtgggaaca	atggcggggc	cattcaacaa	agcgttactg	ttgcgataaa	1020
aaataactcc	gggtcgggtg	ttttcaataa	caacacagcg	ttatctgggt	cgataaattc	1080
aggaaatggg	tcaggagggg	cgattttatac	aacaaacctt	tccatagacg	ataaccctgg	1140
aactattctt	ttcaataata	actactgcac	tcgcgatggc	ggagctatct	gtacacaatt	1200
tttgacaatc	aaaaatagtg	gccacgtata	tttcaccaac	aatcaaggaa	actggggagg	1260
tgtctttatg	ctcctacagg	acagcacctg	cctactcttc	gcggaacaag	gaaatatcgc	1320
atttcaaaat	aatgagggtt	tctcaccac	atttggtaga	tacaacgcca	tacattgtac	1380
accaaatagc	aacttacaac	ttggagctaa	taaggggtat	acgactgctt	tttttgatcc	1440
tatagaacac	caacatccaa	ctacaaatcc	tctaattctt	aatcccaatg	cgaaccatca	1500
gggaacgatc	ttattttctt	cagcctatat	cccagaagct	tctgactacg	aaaataattt	1560
cattagcagc	tcgaaaaata	cctctgaact	tcgcaatggg	gtcctctcta	tcgaggatcg	1620
tgcgggatgg	caattctata	agttcactca	aaaaggaggt	atccttaaat	tagggcatgc	1680
ggcgaggtat	gcaacaactg	ccaactctga	gactccatca	actagtgtag	gctcccaggt	1740
catcattaat	aaccttgcca	ttaacctccc	ctcgatctta	gcaaaaggaa	aagctcctac	1800
cttggtggatc	cgctcctctc	aatctagtgc	tcctttcaca	gaggacaata	accctacaat	1860
tactttatca	ggctcctctg	cactcttaaa	tgaggaaaac	cgcgatccct	acgacagtat	1920
agatctctct	gagcctttac	aaaacattca	tcttctttct	ttatcggatg	taacagcacg	1980
tcatatcaat	accgataact	ttcctcctga	aagcttaaat	gcgactgagc	attacgggta	2040
tcaaggcata	tggctcctct	attgggtaga	gacgataaca	acaacaaata	acgcttctat	2100
agagacggca	aacacctctc	acagagctct	gtatgccaat	tggactccct	taggatataa	2160
gggtcaatcct	gaataccaag	gagatcttgc	tacgactccc	ctatggcaat	cctttcatac	2220
tatgttctct	ctattaagaa	gttataatcg	aactgggtgat	tctgatatcg	agaggccttt	2280
cttagaaatt	caagggattg	ccgacggcct	ctttgttcat	caaaatagca	tccccggggc	2340
tccaggatcc	cgtatccaat	ctacagggta	ttccttacaa	gcctcctccg	aaacttcttt	2400
acatcagaaa	atctccttag	gttttgcaca	gttcttcacc	cgcactaaag	aaatcggatc	2460
aagcaacaac	gtctcggctc	acaatacagt	ctcttcactt	tatgttgagc	ttccgtgggt	2520
ccaagaggcc	tttgcaacat	cccacagttt	agcgtatggc	tatggggacc	atcacctcca	2580
cgcctacatc	cgtcacatca	agaacagggc	agaagggacg	tgttatagcc	atacattagc	2640
agcagctatc	ggctgttctt	tcccttgcca	acagaaatcc	tatcttcacc	tcagcccgtt	2700
cgttcaggca	attgcaatac	gttctcacca	aacagcgttc	gaagagattg	gtgacaatcc	2760
ccgaaagttt	gtctctcaaa	agcctttcta	taatctgacc	ttacctctag	gaatccaagg	2820
aaaatggcag	tcaaaattcc	acgtacctac	agaatggact	ctagaacttt	cttaccaccc	2880
gggtactctat	caacaaaatc	cccaaactcg	tgtcacgcta	cttgcgagcg	gaggttctctg	2940
ggatataccta	ggccataact	atgttcgcaa	tgttttaggg	tacaaaagtc	acaatacaac	3000
tgcgtctctc	catctctctg	atctattctt	ggattaccaa	ggatcgggtc	cctcctcgac	3060
atctacgcac	catctccaag	caggaagtac	cttaaaattc	taaaataaaa	gaacgataaa	3120
attgaaatct	ttagaattaa	czactatccg	atgagctacg	ttagcccaat	cggtagagga	3180
ctccctcaaa	atttaataaa					3200

Figure 21B: CPN100626 Deduced Amino Acid Sequence

Met	Gln	Val	Phe	Pro	Lys	Val	Thr	Leu	Ser	Leu	Asp	Tyr	Ser	Ala	Asp	1	5	10	15
Ile	Ser	Ser	Ser	Thr	Leu	Ser	His	Tyr	Leu	Asn	Val	Ala	Ser	Arg	Met	20	25	30	
Arg	Phe	Leu	Thr	Ile	Ser	Asp	Gln	Asn	Arg	Lys	Ile	Lys	Glu	Pro	Leu	35	40	45	
Val	Ser	Lys	Thr	Pro	Pro	Lys	Phe	Leu	Phe	Tyr	Leu	Gly	Asn	Phe	Thr	50	55	60	
Ala	Cys	Met	Phe	Gly	Met	Thr	Pro	Ala	Val	Tyr	Ser	Leu	Gln	Thr	Asp	65	70	75	80
Ser	Leu	Glu	Lys	Phe	Ala	Leu	Glu	Arg	Asp	Glu	Glu	Phe	Arg	Thr	Ser	85	90	95	
Phe	Pro	Leu	Leu	Asp	Ser	Leu	Ser	Thr	Leu	Thr	Gly	Phe	Ser	Pro	Ile	100	105	110	
Thr	Thr	Phe	Val	Gly	Asn	Arg	His	Asn	Ser	Ser	Gln	Asp	Ile	Val	Leu	115	120	125	
Ser	Asn	Tyr	Lys	Ser	Ile	Asp	Asn	Ile	Leu	Leu	Leu	Trp	Thr	Ser	Ala	130	135	140	
Gly	Gly	Ala	Val	Ser	Cys	Asn	Asn	Phe	Leu	Leu	Ser	Asn	Val	Glu	Asp	145	150	155	160
His	Ala	Phe	Phe	Ser	Lys	Asn	Leu	Ala	Ile	Gly	Thr	Gly	Gly	Ala	Ile	165	170	175	
Ala	Cys	Gln	Gly	Ala	Cys	Thr	Ile	Thr	Lys	Asn	Arg	Gly	Pro	Leu	Ile	180	185	190	
Phe	Phe	Ser	Asn	Arg	Gly	Leu	Asn	Asn	Ala	Ser	Thr	Gly	Gly	Glu	Thr	195	200	205	
Arg	Gly	Gly	Ala	Ile	Ala	Cys	Asn	Gly	Asp	Phe	Thr	Ile	Ser	Gln	Asn	210	215	220	
Gln	Gly	Thr	Phe	Tyr	Phe	Val	Asn	Asn	Ser	Val	Asn	Asn	Trp	Gly	Gly	225	230	235	240
Ala	Leu	Ser	Thr	Asn	Gly	His	Cys	Arg	Ile	Gln	Ser	Asn	Arg	Ala	Pro	245	250	255	
Leu	Leu	Phe	Phe	Asn	Asn	Thr	Ala	Pro	Ser	Gly	Gly	Gly	Ala	Leu	Arg	260	265	270	
Ser	Glu	Asn	Thr	Thr	Ile	Ser	Asp	Asn	Thr	Arg	Pro	Ile	Tyr	Phe	Lys	275	280	285	

Fig. 21B (con't)

Asn	Asn	Cys	Gly	Asn	Asn	Gly	Gly	Ala	Ile	Gln	Thr	Ser	Val	Thr	Val
290						295					300				
Ala	Ile	Lys	Asn	Asn	Ser	Gly	Ser	Val	Ile	Phe	Asn	Asn	Asn	Thr	Ala
305					310					315					320
Leu	Ser	Gly	Ser	Ile	Asn	Ser	Gly	Asn	Gly	Ser	Gly	Gly	Ala	Ile	Tyr
				325					330					335	
Thr	Thr	Asn	Leu	Ser	Ile	Asp	Asp	Asn	Pro	Gly	Thr	Ile	Leu	Phe	Asn
			340					345					350		
Asn	Asn	Tyr	Cys	Ile	Arg	Asp	Gly	Gly	Ala	Ile	Cys	Thr	Gln	Phe	Leu
		355					360				365				
Thr	Ile	Lys	Asn	Ser	Gly	His	Val	Tyr	Phe	Thr	Asn	Asn	Gln	Gly	Asn
	370					375					380				
Trp	Gly	Gly	Ala	Leu	Met	Leu	Leu	Gln	Asp	Ser	Thr	Cys	Leu	Leu	Phe
385					390					395					400
Ala	Glu	Gln	Gly	Asn	Ile	Ala	Phe	Gln	Asn	Asn	Glu	Val	Phe	Leu	Thr
				405					410					415	
Thr	Phe	Gly	Arg	Tyr	Asn	Ala	Ile	His	Cys	Thr	Pro	Asn	Ser	Asn	Leu
			420					425					430		
Gln	Leu	Gly	Ala	Asn	Lys	Gly	Tyr	Thr	Thr	Ala	Phe	Phe	Asp	Pro	Ile
		435					440					445			
Glu	His	Gln	His	Pro	Thr	Thr	Asn	Pro	Leu	Ile	Phe	Asn	Pro	Asn	Ala
	450					455					460				
Asn	His	Gln	Gly	Thr	Ile	Leu	Phe	Ser	Ser	Ala	Tyr	Ile	Pro	Glu	Ala
465					470					475					480
Ser	Asp	Tyr	Glu	Asn	Asn	Phe	Ile	Ser	Ser	Ser	Lys	Asn	Thr	Ser	Glu
				485					490					495	
Leu	Arg	Asn	Gly	Val	Leu	Ser	Ile	Glu	Asp	Arg	Ala	Gly	Trp	Gln	Phe
			500					505					510		
Tyr	Lys	Phe	Thr	Gln	Lys	Gly	Gly	Ile	Leu	Lys	Leu	Gly	His	Ala	Ala
		515					520					525			
Ser	Ile	Ala	Thr	Thr	Ala	Asn	Ser	Glu	Thr	Pro	Ser	Thr	Ser	Val	Gly
	530					535					540				
Ser	Gln	Val	Ile	Ile	Asn	Asn	Leu	Ala	Ile	Asn	Leu	Pro	Ser	Ile	Leu
545					550					555					560
Ala	Lys	Gly	Lys	Ala	Pro	Thr	Leu	Trp	Ile	Arg	Pro	Leu	Gln	Ser	Ser
				565					570					575	

Fig. 21B (con't)

Ala Pro Phe Thr Glu Asp Asn Asn Pro Thr Ile Thr Leu Ser Gly Pro
580 585 590

Leu Thr Leu Leu Asn Glu Glu Asn Arg Asp Pro Tyr Asp Ser Ile Asp
595 600 605

Leu Ser Glu Pro Leu Gln Asn Ile His Leu Leu Ser Leu Ser Asp Val
610 615 620

Thr Ala Arg His Ile Asn Thr Asp Asn Phe His Pro Glu Ser Leu Asn
625 630 635 640

Ala Thr Glu His Tyr Gly Tyr Gln Gly Ile Trp Ser Pro Tyr Trp Val
645 650 655

Glu Thr Ile Thr Thr Thr Asn Asn Ala Ser Ile Glu Thr Ala Asn Thr
660 665 670

Leu Tyr Arg Ala Leu Tyr Ala Asn Trp Thr Pro Leu Gly Tyr Lys Val
675 680 685

Asn Pro Glu Tyr Gln Gly Asp Leu Ala Thr Thr Pro Leu Trp Gln Ser
690 695 700

Phe His Thr Met Phe Ser Leu Leu Arg Ser Tyr Asn Arg Thr Gly Asp
705 710 715 720

Ser Asp Ile Glu Arg Pro Phe Leu Glu Ile Gln Gly Ile Ala Asp Gly
725 730 735

Leu Phe Val His Gln Asn Ser Ile Pro Gly Ala Pro Gly Phe Arg Ile
740 745 750

Gln Ser Thr Gly Tyr Ser Leu Gln Ala Ser Ser Glu Thr Ser Leu His
755 760 765

Gln Lys Ile Ser Leu Gly Phe Ala Gln Phe Phe Thr Arg Thr Lys Glu
770 775 780

Ile Gly Ser Ser Asn Asn Val Ser Ala His Asn Thr Val Ser Ser Leu
785 790 795 800

Tyr Val Glu Leu Pro Trp Phe Gln Glu Ala Phe Ala Thr Ser His Ser
805 810 815

Leu Ala Tyr Gly Tyr Gly Asp His His Leu His Ala Tyr Ile Arg His
820 825 830

Ile Lys Asn Arg Ala Glu Gly Thr Cys Tyr Ser His Thr Leu Ala Ala
835 840 845

Ala Ile Gly Cys Ser Phe Pro Trp Gln Gln Lys Ser Tyr Leu His Leu
850 855 860

50030409/830446
Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

Fig. 21B (con't)

Ser	Pro	Phe	Val	Gln	Ala	Ile	Ala	Ile	Arg	Ser	His	Gln	Thr	Ala	Phe	
865					870				875						880	
Glu	Glu	Ile	Gly	Asp	Asn	Pro	Arg	Lys	Phe	Val	Ser	Gln	Lys	Pro	Phe	
			885						890					895		
Tyr	Asn	Leu	Thr	Leu	Pro	Leu	Gly	Ile	Gln	Gly	Lys	Trp	Gln	Ser	Lys	
			900					905					910			
Phe	His	Val	Pro	Thr	Glu	Trp	Thr	Leu	Glu	Leu	Ser	Tyr	Gln	Pro	Val	
		915					920					925				
Leu	Tyr	Gln	Gln	Asn	Pro	Gln	Ile	Gly	Val	Thr	Leu	Leu	Ala	Ser	Gly	
	930					935					940					
Gly	Ser	Trp	Asp	Ile	Leu	Gly	His	Asn	Tyr	Val	Arg	Asn	Ala	Leu	Gly	
945					950				955						960	
Tyr	Lys	Val	His	Asn	Gln	Thr	Ala	Leu	Phe	Arg	Ser	Leu	Asp	Leu	Phe	
				965					970					975		
Leu	Asp	Tyr	Gln	Gly	Ser	Val	Ser	Ser	Ser	Thr	Ser	Thr	His	His	Leu	
		980					985						990			
Gln	Ala	Gly	Ser	Thr	Leu	Lys	Phe									
		995					1000									

Figure 22 (RY-45)

Restriction enzyme analysis of CPN100626






Fig. 22 (con't)



PCT/CA99/00992



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

Fig. 22 (con't)




Fig. 22 (con't)




Fig. 22 (con't)





Fig. 22 (con't)



100,000,000
WO 00/24765

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF
Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446
PCT/CA99/00992

Fig. 22 (con't)




Fig. 22 (con't)




Fig. 22 (con't)





Fig. 22 (con't)







Fig. 22 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

WO 00/24765

Figure 23:

```

tagacactat aaaacaaatt atagacaaaa aatctagcat tgattttattc agaatatatttc 60

tttctatttg tgaacgagta tgcgcttttt ttgcttcgga atg ttg ctt cct ttt 115
Met Leu Leu Pro Phe
1 5

act ttt gta ttg gct aat gaa ggt ctc caa ctt cct ttg gag acc tat 163
Thr Phe Val Leu Ala Asn Glu Gly Leu Gln Leu Pro Leu Glu Thr Tyr
10 15 20

att aca tta agt cct gaa tat caa gca gcc cct caa gta ggg ttt act 211
Ile Thr Leu Ser Pro Glu Tyr Gln Ala Ala Pro Gln Val Gly Phe Thr
25 30 35

cat aac caa aat caa gat ctc gca att gtc ggg aat cac aat gat ttc 259
His Asn Gln Asn Gln Asp Leu Ala Ile Val Gly Asn His Asn Asp Phe
40 45 50

atc ttg gac tat aag tac tat cgg tcg aat gga ggt gct ctt acc tgt 307
Ile Leu Asp Tyr Lys Tyr Tyr Arg Ser Asn Gly Gly Ala Leu Thr Cys
55 60 65

aag aat ctt ctg atc tct gaa aat ata ggg aat gtc ttc ttt gag aag 355
Lys Asn Leu Leu Ile Ser Glu Asn Ile Gly Asn Val Phe Phe Glu Lys
70 75 80 85

aat gtc tgt ccc aat tct ggc ggg gca att tat gct gct caa aat tgc 403
Asn Val Cys Pro Asn Ser Gly Gly Ala Ile Tyr Ala Ala Gln Asn Cys
90 95 100

acg atc tcc aag aat cag aac tat gca ttt act aca aac ttg gtc tct 451
Thr Ile Ser Lys Asn Gln Asn Tyr Ala Phe Thr Thr Asn Leu Val Ser
105 110 115

gac aat cct aca gcc act gcg gga tca cta ttg ggt gga gct ctc ttt 499
Asp Asn Pro Thr Ala Thr Ala Gly Ser Leu Leu Gly Gly Ala Leu Phe
120 125 130

gcc ata aat tgc tct att act aat aac cta gga cag gga act ttc gtt 547
Ala Ile Asn Cys Ser Ile Thr Asn Asn Leu Gly Gln Gly Thr Phe Val
135 140 145

gac aat ctc gct tta aat aag ggg ggt gcc ctc tat act gag acg aac 595
Asp Asn Leu Ala Leu Asn Lys Gly Gly Ala Leu Tyr Thr Glu Thr Asn
150 155 160 165

tta tct att aaa gac aat aaa ggc ccg atc ata atc aag cag aat cgg 643
Leu Ser Ile Lys Asp Asn Lys Gly Pro Ile Ile Ile Lys Gln Asn Arg
170 175 180

gca cta aat tcg gac agt tta gga gga ggg att tat agt ggg aac tct 691
Ala Leu Asn Ser Asp Ser Leu Gly Gly Gly Ile Tyr Ser Gly Asn Ser
185 190 195

```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

097830446

WO 00/24765

PCT/CA99/00992

Fig. 23 (con't)

cta aat ata gag gga aat tct gga gct ata cag atc aca agc aac tct	739
Leu Asn Ile Glu Gly Asn Ser Gly Ala Ile Gln Ile Thr Ser Asn Ser	
200 205 210	
tca gga tct ggg gga ggc ata ttt tct acc caa aca ctc acg atc tcc	787
Ser Gly Ser Gly Gly Gly Ile Phe Ser Thr Gln Thr Leu Thr Ile Ser	
215 220 225	
tcg aat aaa aaa ctc ata gaa atc agt gaa aat tcc gcg ttc gca aat	835
Ser Asn Lys Lys Leu Ile Glu Ile Ser Glu Asn Ser Ala Phe Ala Asn	
230 235 240 245	
aac tat gga tcg aac ttc aat cca gga gga gga ggt ctt act acc acc	883
Asn Tyr Gly Ser Asn Phe Asn Pro Gly Gly Gly Gly Leu Thr Thr Thr	
250 255 260	
ttt tgc acg ata ttg aac aac cga gaa ggg gta ctc ttt aac aat aac	931
Phe Cys Thr Ile Leu Asn Asn Arg Glu Gly Val Leu Phe Asn Asn Asn	
265 270 275	
caa agc cag agc aac ggt gga gcc att cat gcg aaa tct atc att atc	979
Gln Ser Gln Ser Asn Gly Gly Ala Ile His Ala Lys Ser Ile Ile Ile	
280 285 290	
aaa gaa aat ggt cct gta tac ttt tta aat aac act gca act cgg gga	1027
Lys Glu Asn Gly Pro Val Tyr Phe Leu Asn Asn Thr Ala Thr Arg Gly	
295 300 305	
ggg gct ctc ctc aac tta tca gca ggt tct gga aac gga agc ttc atc	1075
Gly Ala Leu Leu Asn Leu Ser Ala Gly Ser Gly Asn Gly Ser Phe Ile	
310 315 320 325	
tta tct gca gat aat gga gat att atc ttt aac aat aat acg gcc tcc	1123
Leu Ser Ala Asp Asn Gly Asp Ile Ile Phe Asn Asn Asn Thr Ala Ser	
330 335 340	
aag cat gcc ctc aat cct cca tac aga aac gcc att cac tcg act cct	1171
Lys His Ala Leu Asn Pro Pro Tyr Arg Asn Ala Ile His Ser Thr Pro	
345 350 355	
aat atg aat ctg caa ata gga gcc cgt ccc ggc tat cga gtg ctg ttc	1219
Asn Met Asn Leu Gln Ile Gly Ala Arg Pro Gly Tyr Arg Val Leu Phe	
360 365 370	
tat gat ccc ata gaa cat gag ctc cct tcc tcc ttc ccc ata ctc ttt	1267
Tyr Asp Pro Ile Glu His Glu Leu Pro Ser Ser Phe Pro Ile Leu Phe	
375 380 385	
aat ttc gaa acc ggt cat aca ggt aca gtt tta ttt tca ggg gaa cat	1315
Asn Phe Glu Thr Gly His Thr Gly Thr Val Leu Phe Ser Gly Glu His	
390 395 400 405	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 23 (con't)

gta cac cag aac ttt acc gat gaa atg aat ttc ttt tcc tat tta agg	1363
Val His Gln Asn Phe Thr Asp Glu Met Asn Phe Phe Ser Tyr Leu Arg	
410 415 420	
aac act tcg gaa cta cgt caa gga gtc ctt gct gtt gaa gat ggt gcg	1411
Asn Thr Ser Glu Leu Arg Gln Gly Val Leu Ala Val Glu Asp Gly Ala	
425 430 435	
ggg ctg gcc tgc tat aag ttc ttc caa cga gga ggc act cta ctt cta	1459
Gly Leu Ala Cys Tyr Lys Phe Phe Gln Arg Gly Gly Thr Leu Leu Leu	
440 445 450	
ggt caa ggt gcg gtg atc acg aca gca gga acg att ccc aca cca tcc	1507
Gly Gln Gly Ala Val Ile Thr Thr Ala Gly Thr Ile Pro Thr Pro Ser	
455 460 465	
tca aca cca acg aca gta gga agt act ata act tta aat cac att gcc	1555
Ser Thr Pro Thr Thr Val Gly Ser Thr Ile Thr Leu Asn His Ile Ala	
470 475 480 485	
att gac ctt cct tct att ctt tct ttt caa gct cag gct cca aaa att	1603
Ile Asp Leu Pro Ser Ile Leu Ser Phe Gln Ala Gln Ala Pro Lys Ile	
490 495 500	
tgg att tac ccc aca aaa aca gga tct acc tat act gaa gat tcc aac	1651
Trp Ile Tyr Pro Thr Lys Thr Gly Ser Thr Tyr Thr Glu Asp Ser Asn	
505 510 515	
ccg aca atc aca atc tca gga act ctc acc tta cgc aac agc aac aac	1699
Pro Thr Ile Thr Ile Ser Gly Thr Leu Thr Leu Arg Asn Ser Asn Asn	
520 525 530	
gaa gat ccc tac gat agt ctg gat ctc tcg cac tct ctt gag aaa gtt	1747
Glu Asp Pro Tyr Asp Ser Leu Asp Leu Ser His Ser Leu Glu Lys Val	
535 540 545	
ccc ctt ctt tat att gtc gat gtc gct gca caa aaa att aac tct tcg	1795
Pro Leu Leu Tyr Ile Val Asp Val Ala Ala Gln Lys Ile Asn Ser Ser	
550 555 560 565	
caa ctg gat cta tcc aca tta aat tct ggc gaa cac tat ggg tat caa	1843
Gln Leu Asp Leu Ser Thr Leu Asn Ser Gly Glu His Tyr Gly Tyr Gln	
570 575 580	
ggc atc tgg tcg acc tat tgg gta gaa act aca aca atc acg aac cct	1891
Gly Ile Trp Ser Thr Tyr Trp Val Glu Thr Thr Thr Ile Thr Asn Pro	
585 590 595	
aca tct cta cta ggc gcg aat aca aaa cac aag ctg ctc tat gca aac	1939
Thr Ser Leu Leu Gly Ala Asn Thr Lys His Lys Leu Leu Tyr Ala Asn	
600 605 610	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 23 (con't)

tgg tct cct cta ggc tac cgt cct cat ccc gaa cgt cga gga gaa ttc	1987
Trp Ser Pro Leu Gly Tyr Arg Pro His Pro Glu Arg Arg Gly Glu Phe	
615 620 625	
att acg aat gcc ttg tgg caa tcg gca tat acg gct ctt gca gga ctc	2035
Ile Thr Asn Ala Leu Trp Gln Ser Ala Tyr Thr Ala Leu Ala Gly Leu	
630 635 640 645	
cac tcc ctc tcc tcc tgg gat gaa gag aag ggt cat gca gct tcc cta	2083
His Ser Leu Ser Ser Trp Asp Glu Glu Lys Gly His Ala Ala Ser Leu	
650 655 660	
caa ggc att ggt ctt ctg gtt cat caa aaa gac aaa aac ggt ttt aag	2131
Gln Gly Ile Gly Leu Leu Val His Gln Lys Asp Lys Asn Gly Phe Lys	
665 670 675	
gga ttt cgt agt cat atg aca ggt tat agt gct acc acc gaa gca acc	2179
Gly Phe Arg Ser His Met Thr Gly Tyr Ser Ala Thr Thr Glu Ala Thr	
680 685 690	
tct tct caa agt ccg aat ttc tct tta gga ttt gct cag ttc ttc tcc	2227
Ser Ser Gln Ser Pro Asn Phe Ser Leu Gly Phe Ala Gln Phe Phe Ser	
695 700 705	
aaa gct aaa gaa cat gaa tct caa aat agc acg tcc tct cac cac tat	2275
Lys Ala Lys Glu His Glu Ser Gln Asn Ser Thr Ser Ser His His Tyr	
710 715 720 725	
ttc tct gga atg tgc ata gca aaa tac tct ctt caa aga gtg ata cgt	2323
Phe Ser Gly Met Cys Ile Ala Lys Tyr Ser Leu Gln Arg Val Ile Arg	
730 735 740	
cta tct gtg tct ctt gct tat atg ttt acc tcg gaa cat acc cat aca	2371
Leu Ser Val Ser Leu Ala Tyr Met Phe Thr Ser Glu His Thr His Thr	
745 750 755	
atg tat cag ggt ctc ctg gaa ggg aac tct cag gga tct ttc cac aac	2419
Met Tyr Gln Gly Leu Leu Glu Gly Asn Ser Gln Gly Ser Phe His Asn	
760 765 770	
cat acc tta gca ggg gct ctc tcc tgt gtt ttc tta cct caa cct cac	2467
His Thr Leu Ala Gly Ala Leu Ser Cys Val Phe Leu Pro Gln Pro His	
775 780 785	
ggc gag tcc ctg cag atc tat ccc ttt att act gcc tta gcc atc cga	2515
Gly Glu Ser Leu Gln Ile Tyr Pro Phe Ile Thr Ala Leu Ala Ile Arg	
790 795 800 805	
gga aat ctt gct gcg ttt caa gaa tct gga gac cat gct cgg gaa ttt	2563
Gly Asn Leu Ala Ala Phe Gln Glu Ser Gly Asp His Ala Arg Glu Phe	
810 815 820	

Fig. 23 (con't)

tcc cta cac cgc ccc cta acg gac gtc tcc ctc cct gta gga atc cgc	2611
Ser Leu His Arg Pro Leu Thr Asp Val Ser Leu Pro Val Gly Ile Arg	
825 830 835	
gct tct tgg aag aac cac cac cga gtt ccc cta gtc tgg ctc aca gaa	2659
Ala Ser Trp Lys Asn His His Arg Val Pro Leu Val Trp Leu Thr Glu	
840 845 850	
att tcc tat cgc tct act ctc tat agg caa gat cct gaa ctc cac tcg	2707
Ile Ser Tyr Arg Ser Thr Leu Tyr Arg Gln Asp Pro Glu Leu His Ser	
855 860 865	
aaa tta ctg att agc caa ggt acg tgg acg acg cag gcc act cct gtg	2755
Lys Leu Leu Ile Ser Gln Gly Thr Trp Thr Thr Gln Ala Thr Pro Val	
870 875 880 885	
acc tac aat gct tta ggg atc aaa gtg aaa aat acc atg cag gtg ttt	2803
Thr Tyr Asn Ala Leu Gly Ile Lys Val Lys Asn Thr Met Gln Val Phe	
890 895 900	
cct aaa gtc act ctc tcc tta gat tac tct gcg gat att tct tcc tcc	2851
Pro Lys Val Thr Leu Ser Leu Asp Tyr Ser Ala Asp Ile Ser Ser Ser	
905 910 915	
acg ctg agt cac tac tta aac gtg gcg agt aga atg aga ttt	2893
Thr Leu Ser His Tyr Leu Asn Val Ala Ser Arg Met Arg Phe	
920 925 930	
taacaataag tgacaaaaac agaaagatta aggaacctct agtgtcaaag actcctccta	2953
agttttttatt ctatctcggg aatttcacag cctgcatgtt cgggatg	3000

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

WO 00/24765

PCT/CA99/00992

09/830446

Figure 24 (RY-46)

Restriction enzyme analysis of CPN100628





Fig. 24 (con't)



—





Fig. 24 (con't)







Fig. 24 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

Fig. 24 (con't)




Fig. 24 (con't)





Fig. 24 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF


WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

09/830446

Fig. 24 (con't)



[illegible]

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

PCT/CA99/00992

WO 00/24765

Figure 25:

```

cactgtggat gtgatattcg cagaacctcc cgtcaaatat actctagata taggaagcaa 60
attacgattt taaaccttat ttaacgacag ggttgaggc atg cct ctt tct ttc 114
                                Met Pro Leu Ser Phe
                                1           5
aaa tct tca tct ttt tgt cta ctt gcc tgt tta tgt agt gca agt tgc 162
Lys Ser Ser Ser Phe Cys Leu Leu Ala Cys Leu Cys Ser Ala Ser Cys
                                10           15           20
gcg ttt gct gag act aga ctc gga ggg aac ttt gtt cct cca att acg 210
Ala Phe Ala Glu Thr Arg Leu Gly Gly Asn Phe Val Pro Pro Ile Thr
                                25           30           35
aat cag ggt gaa gag atc tta ctc act tca gat ttt gtt tgt tca aac 258
Asn Gln Gly Glu Glu Ile Leu Leu Thr Ser Asp Phe Val Cys Ser Asn
                                40           45           50
ttc ttg ggg gcg agt ttt tca agt tcc ttt atc aat agt tcc agc aat 306
Phe Leu Gly Ala Ser Phe Ser Ser Ser Phe Ile Asn Ser Ser Ser Asn
                                55           60           65
ctc tcc tta tta ggg aag gcc ctt tcc tta acg ttt acc tct tgt caa 354
Leu Ser Leu Leu Gly Lys Gly Leu Ser Leu Thr Phe Thr Ser Cys Gln
                                70           75           80           85
gct cct aca aat agt aac tat gcg cta ctt tct gcc gca gag act ctg 402
Ala Pro Thr Asn Ser Asn Tyr Ala Leu Leu Ser Ala Ala Glu Thr Leu
                                90           95           100
acc ttc aag aat ttt tct tct ata aac ttt aca ggg aac caa tcg aca 450
Thr Phe Lys Asn Phe Ser Ser Ile Asn Phe Thr Gly Asn Gln Ser Thr
                                105           110           115
gga ctt ggc ggc ctc atc tac gga aaa gat att gtt ttc caa tct atc 498
Gly Leu Gly Gly Leu Ile Tyr Gly Lys Asp Ile Val Phe Gln Ser Ile
                                120           125           130
aaa gat ttg atc ttc act acg aac cgt gtt gcc tat tct cca gca tct 546
Lys Asp Leu Ile Phe Thr Thr Asn Arg Val Ala Tyr Ser Pro Ala Ser
                                135           140           145
gta act acg tcg gca act ccc gca atc act aca gta act aca gga gcc 594
Val Thr Thr Ser Ala Thr Pro Ala Ile Thr Thr Val Thr Thr Gly Ala
                                150           155           160           165
tct gct ctc caa cct aca gac tca ctc act gtc gaa aac ata tcc caa 642
Ser Ala Leu Gln Pro Thr Asp Ser Leu Thr Val Glu Asn Ile Ser Gln
Ser Ala Leu Gln Pro Thr Asp Ser Leu Thr Val Glu Asn Ile Ser Gln
                                170           175           180
tcg atc aag ttt ttt ggg aac ctt gcc aac ttc ggc tct gca att agc 690
Ser Ile Lys Phe Phe Gly Asn Leu Ala Asn Phe Gly Ser Ala Ile Ser
Ser Ile Lys Phe Phe Gly Asn Leu Ala Asn Phe Gly Ser Ala Ile Ser
                                185           190           195

```

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 25 (con't)

agt tct ccc acg gca gtc gtt aaa ttc atc aat aac acc gct acc atg	738
Ser Ser Pro Thr Ala Val Val Lys Phe Ile Asn Asn Thr Ala Thr Met	
Ser Ser Pro Thr Ala Val Val Lys Phe Ile Asn Asn Thr Ala Thr Met	
200 205 210	
agc ttc tcc cat aac ttt act tcg tca gga ggc ggc gtg att tat gga	786
Ser Phe Ser His Asn Phe Thr Ser Ser Gly Gly Gly Val Ile Tyr Gly	
Ser Phe Ser His Asn Phe Thr Ser Ser Gly Gly Gly Val Ile Tyr Gly	
215 220 225	
gga agc tct ctc ctt ttt gaa aac aat tct gga tgc atc atc ttc acc	834
Gly Ser Ser Leu Leu Phe Glu Asn Asn Ser Gly Cys Ile Ile Phe Thr	
Gly Ser Ser Leu Leu Phe Glu Asn Asn Ser Gly Cys Ile Ile Phe Thr	
230 235 240 245	
gcc aac tcc tgt gtg aac agc tta aaa ggc gtc acc cct tca tca gga	882
Ala Asn Ser Cys Val Asn Ser Leu Lys Gly Val Thr Pro Ser Ser Gly	
Ala Asn Ser Cys Val Asn Ser Leu Lys Gly Val Thr Pro Ser Ser Gly	
250 255 260	
acc tat gct tta gga agt ggc gga gcc atc tgc atc cct acg gga act	930
Thr Tyr Ala Leu Gly Ser Gly Gly Ala Ile Cys Ile Pro Thr Gly Thr	
Thr Tyr Ala Leu Gly Ser Gly Gly Ala Ile Cys Ile Pro Thr Gly Thr	
265 270 275	
ttc gaa tta aaa aac aat cag ggg aag tgc acc ttc tct tat aat ggt	978
Phe Glu Leu Lys Asn Asn Gln Gly Lys Cys Thr Phe Ser Tyr Asn Gly	
Phe Glu Leu Lys Asn Asn Gln Gly Lys Cys Thr Phe Ser Tyr Asn Gly	
280 285 290	
aca cca aat gat gcg ggt gcg atc tac gcc gaa acc tgc aac atc gta	1026
Thr Pro Asn Asp Ala Gly Ala Ile Tyr Ala Glu Thr Cys Asn Ile Val	
Thr Pro Asn Asp Ala Gly Ala Ile Tyr Ala Glu Thr Cys Asn Ile Val	
295 300 305	
ggg aac cag ggt gcc ttg ctc cta gat agc aac act gca gcg aga aat	1074
Gly Asn Gln Gly Ala Leu Leu Leu Asp Ser Asn Thr Ala Ala Arg Asn	
Gly Asn Gln Gly Ala Leu Leu Leu Asp Ser Asn Thr Ala Ala Arg Asn	
310 315 320 325	
ggc gga gcc atc tgt gct aaa gtg ctc aat att caa gga cgc ggt cct	1122
Gly Gly Ala Ile Cys Ala Lys Val Leu Asn Ile Gln Gly Arg Gly Pro	
Gly Gly Ala Ile Cys Ala Lys Val Leu Asn Ile Gln Gly Arg Gly Pro	
330 335 340	
att gaa ttc tct aga aac cgc gcg gag aag ggt gga gct att ttc ata	1170
Ile Glu Phe Ser Arg Asn Arg Ala Glu Lys Gly Gly Ala Ile Phe Ile	
Ile Glu Phe Ser Arg Asn Arg Ala Glu Lys Gly Gly Ala Ile Phe Ile	
345 350 355	
ggc ccc tct gtt gga gac cct gcg aag caa aca tcg aca ctt acg att	1213
Gly Pro Ser Val Gly Asp Pro Ala Lys Gln Thr Ser Thr Leu Thr Ile	
Gly Pro Ser Val Gly Asp Pro Ala Lys Gln Thr Ser Thr Leu Thr Ile	
360 365 370	
ttg gct tcc gaa ggt gat att gcg ttc caa gga aac atg ctc aat aca	1266
Leu Ala Ser Glu Gly Asp Ile Ala Phe Gln Gly Asn Met Leu Asn Thr	
Leu Ala Ser Glu Gly Asp Ile Ala Phe Gln Gly Asn Met Leu Asn Thr	
375 380 385	

Fig. 25 (con't)

aaa cct gga atc cgc aat gcc atc act gta gaa gca ggg gga gag att	1314
Lys Pro Gly Ile Arg Asn Ala Ile Thr Val Glu Ala Gly Gly Glu Ile	
Lys Pro Gly Ile Arg Asn Ala Ile Thr Val Glu Ala Gly Gly Glu Ile	
390 395 400 405	
gtg tct cta tct gca caa gga ggc tca cgt ctt gta ttt tat gat ccc	1362
Val Ser Leu Ser Ala Gln Gly Gly Ser Arg Leu Val Phe Tyr Asp Pro	
Val Ser Leu Ser Ala Gln Gly Gly Ser Arg Leu Val Phe Tyr Asp Pro	
410 415 420	
att aca cat agc ctc cca acc aca agt cgg tct aat aaa gac att aca	1410
Ile Thr His Ser Leu Pro Thr Thr Ser Pro Ser Asn Lys Asp Ile Thr	
Ile Thr His Ser Leu Pro Thr Thr Ser Pro Ser Asn Lys Asp Ile Thr	
425 430 435	
atc aac gct aat ggc gct tca gga tct gta gtc ttt aca agt aag gga	1458
Ile Asn Ala Asn Gly Ala Ser Gly Ser Val Val Phe Thr Ser Lys Gly	
Ile Asn Ala Asn Gly Ala Ser Gly Ser Val Val Phe Thr Ser Lys Gly	
440 445 450	
ctc tcc tct aca gaa ctc ctg ttg cct gcc aac acg aca act ata ctt	1506
Leu Ser Ser Thr Glu Leu Leu Leu Pro Ala Asn Thr Thr Thr Ile Leu	
Leu Ser Ser Thr Glu Leu Leu Leu Pro Ala Asn Thr Thr Thr Ile Leu	
455 460 465	
cta gga aca gtc aag atc gct agt gga gaa ctg aag att act gac aat	1554
Leu Gly Thr Val Lys Ile Ala Ser Gly Glu Leu Lys Ile Thr Asp Asn	
Leu Gly Thr Val Lys Ile Ala Ser Gly Glu Leu Lys Ile Thr Asp Asn	
470 475 480 485	
gcg gtt gtc aat gtt gct ggc ttc gct act cag ggc tca ggt cag ctt	1602
Ala Val Val Asn Val Ala Gly Phe Ala Thr Gln Gly Ser Gly Gln Leu	
Ala Val Val Asn Val Ala Gly Phe Ala Thr Gln Gly Ser Gly Gln Leu	
490 495 500	
acc ctg ggc tct gga gga acc tta ggg ctg gca aca ccc acg gga gca	1650
Thr Leu Gly Ser Gly Gly Thr Leu Gly Leu Ala Thr Pro Thr Gly Ala	
Thr Leu Gly Ser Gly Gly Thr Leu Gly Leu Ala Thr Pro Thr Gly Ala	
505 510 515	
cct gcc gct gta gac ttt acg att gga aag tta gca ttc gat cct ttt	1698
Pro Ala Ala Val Asp Phe Thr Ile Gly Lys Leu Ala Phe Asp Pro Phe	
Pro Ala Ala Val Asp Phe Thr Ile Gly Lys Leu Ala Phe Asp Pro Phe	
520 525 530	
tcc ttc cta aaa aga gat ttt gtt tca gca tca gta aat gca ggc aca	1746
Ser Phe Leu Lys Arg Asp Phe Val Ser Ala Ser Val Asn Ala Gly Thr	
Ser Phe Leu Lys Arg Asp Phe Val Ser Ala Ser Val Asn Ala Gly Thr	
535 540 545	
aaa aac gtc act tta aca gga gct ctg gtt ctt gat gaa cat gac gtt	1794
Lys Asn Val Thr Leu Thr Gly Ala Leu Val Leu Asp Glu His Asp Val	
Lys Asn Val Thr Leu Thr Gly Ala Leu Val Leu Asp Glu His Asp Val	
550 555 560 565	
aca gat ctt tat gat atg gtg tca tta caa tct cca gta gca att cct	1842
Thr Asp Leu Tyr Asp Met Val Ser Leu Gln Ser Pro Val Ala Ile Pro	
Thr Asp Leu Tyr Asp Met Val Ser Leu Gln Ser Pro Val Ala Ile Pro	
570 575 580	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

09/830446

Fig. 25 (con't)

atc gct gtt ttc aaa gga gca acc gtt act aag aca gga ttt cct gat	1890
Ile Ala Val Phe Lys Gly Ala Thr Val Thr Lys Thr Gly Phe Pro Asp	
Ile Ala Val Phe Lys Gly Ala Thr Val Thr Lys Thr Gly Phe Pro Asp	
585 590 595	
ggg gag att gcg act cca agc cac tac ggc tac caa gga aag tgg tcc	1938
Gly Glu Ile Ala Thr Pro Ser His Tyr Gly Tyr Gln Gly Lys Trp Ser	
Gly Glu Ile Ala Thr Pro Ser His Tyr Gly Tyr Gln Gly Lys Trp Ser	
600 605 610	
tac aca tgg tcc cgt ccc ctg tta att cca gct cct gat gga gga ttt	1986
Tyr Thr Trp Ser Arg Pro Leu Leu Ile Pro Ala Pro Asp Gly Gly Phe	
Tyr Thr Trp Ser Arg Pro Leu Leu Ile Pro Ala Pro Asp Gly Gly Phe	
615 620 625	
cct gga ggt ccc tct cct agc gca aat act ctc tat gct gta tgg aat	2034
Pro Gly Gly Pro Ser Pro Ser Ala Asn Thr Leu Tyr Ala Val Trp Asn	
Pro Gly Gly Pro Ser Pro Ser Ala Asn Thr Leu Tyr Ala Val Trp Asn	
630 635 640 645	
tca gac act ctc gtg cgt tct acc tat atc tta gat ccc gag cgt tac	2082
Ser Asp Thr Leu Val Arg Ser Thr Tyr Ile Leu Asp Pro Glu Arg Tyr	
Ser Asp Thr Leu Val Arg Ser Thr Tyr Ile Leu Asp Pro Glu Arg Tyr	
650 655 660	
gga gaa att gtc agc aac agc tta tgg att tcc ttc tta gga aat cag	2130
Gly Glu Ile Val Ser Asn Ser Leu Trp Ile Ser Phe Leu Gly Asn Gln	
Gly Glu Ile Val Ser Asn Ser Leu Trp Ile Ser Phe Leu Gly Asn Gln	
665 670 675	
gca ttc tct gat att ctc caa gat gtt ctt ttg ata gat cat ccc ggg	2178
Ala Phe Ser Asp Ile Leu Gln Asp Val Leu Leu Ile Asp His Pro Gly	
Ala Phe Ser Asp Ile Leu Gln Asp Val Leu Leu Ile Asp His Pro Gly	
680 685 690	
ttg tcc ata acc gcg aaa gct tta gga gcc tat gtc gaa cac aca cca	2226
Leu Ser Ile Thr Ala Lys Ala Leu Gly Ala Tyr Val Glu His Thr Pro	
Leu Ser Ile Thr Ala Lys Ala Leu Gly Ala Tyr Val Glu His Thr Pro	
695 700 705	
aga caa gga cat gag ggc ttt tca ggt cgc tat gga ggc tac caa gct	2274
Arg Gln Gly His Glu Gly Phe Ser Gly Arg Tyr Gly Gly Tyr Gln Ala	
Arg Gln Gly His Glu Gly Phe Ser Gly Arg Tyr Gly Gly Tyr Gln Ala	
710 715 720 725	
gcg cta tct atg aac tac acg gac cac act acg tta gga ctt tct ttc	2322
Ala Leu Ser Met Asn Tyr Thr Asp His Thr Thr Leu Gly Leu Ser Phe	
Ala Leu Ser Met Asn Tyr Thr Asp His Thr Thr Leu Gly Leu Ser Phe	
730 735 740	
ggg cag ctt tat gga aaa act aac gcc aac ccc tac gat tca cgt tgc	2370
Gly Gln Leu Tyr Gly Lys Thr Asn Ala Asn Pro Tyr Asp Ser Arg Cys	
Gly Gln Leu Tyr Gly Lys Thr Asn Ala Asn Pro Tyr Asp Ser Arg Cys	
745 750 755	
tca gaa caa atg tat tta ctc tgc ttc ttt ggt caa ttc cct atc gtg	2418
Ser Glu Gln Met Tyr Leu Leu Ser Phe Phe Gly Gln Phe Pro Ile Val	
Ser Glu Gln Met Tyr Leu Leu Ser Phe Phe Gly Gln Phe Pro Ile Val	
760 765 770	

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

09/830446

WO 00/24765

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

Fig. 25 (con't)

act	caa	aag	agc	gag	gcc	tta	att	tcc	tgg	aaa	gca	gct	tat	ggg	tat	2466
Thr	Gln	Lys	Ser	Glu	Ala	Leu	Ile	Ser	Trp	Lys	Ala	Ala	Tyr	Gly	Tyr	
Thr	Gln	Lys	Ser	Glu	Ala	Leu	Ile	Ser	Trp	Lys	Ala	Ala	Tyr	Gly	Tyr	
775						780					785					
tcc	aaa	aat	cac	cta	aat	acc	acc	tac	ctc	aga	cct	gac	aaa	gct	cca	2514
Ser	Lys	Asn	His	Leu	Asn	Thr	Thr	Tyr	Leu	Arg	Pro	Asp	Lys	Ala	Pro	
Ser	Lys	Asn	His	Leu	Asn	Thr	Thr	Tyr	Leu	Arg	Pro	Asp	Lys	Ala	Pro	
790					795					800					805	
aaa	tct	caa	ggg	caa	tgg	cat	aac	aat	agt	tac	tat	gtt	ctt	att	tct	2562
Lys	Ser	Gln	Gly	Gln	Trp	His	Asn	Asn	Ser	Tyr	Tyr	Val	Leu	Ile	Ser	
Lys	Ser	Gln	Gly	Gln	Trp	His	Asn	Asn	Ser	Tyr	Tyr	Val	Leu	Ile	Ser	
				810					815					820		
gca	gaa	cat	cct	ttc	cta	aac	tgg	tgt	ctt	ctt	aca	aga	cct	ctg	gct	2610
Ala	Glu	His	Pro	Phe	Leu	Asn	Trp	Cys	Leu	Leu	Thr	Arg	Pro	Leu	Ala	
Ala	Glu	His	Pro	Phe	Leu	Asn	Trp	Cys	Leu	Leu	Thr	Arg	Pro	Leu	Ala	
				825					830					835		
caa	gct	tgg	gat	ctt	tca	ggg	ttt	att	tcc	gca	gaa	ttc	cta	ggg	ggg	2658
Gln	Ala	Trp	Asp	Leu	Ser	Gly	Phe	Ile	Ser	Ala	Glu	Phe	Leu	Gly	Gly	
Gln	Ala	Trp	Asp	Leu	Ser	Gly	Phe	Ile	Ser	Ala	Glu	Phe	Leu	Gly	Gly	
				840					845					850		
tgg	caa	agt	aag	ttc	aca	gaa	act	gga	gat	ctg	caa	cgt	agc	ttt	agt	2706
Trp	Gln	Ser	Lys	Phe	Thr	Glu	Thr	Gly	Asp	Leu	Gln	Arg	Ser	Phe	Ser	
Trp	Gln	Ser	Lys	Phe	Thr	Glu	Thr	Gly	Asp	Leu	Gln	Arg	Ser	Phe	Ser	
				855			860					865				
aga	ggg	aaa	ggg	tac	aat	gtt	tcc	cta	ccg	ata	gga	tgt	tct	tct	caa	2754
Arg	Gly	Lys	Gly	Tyr	Asn	Val	Ser	Leu	Pro	Ile	Gly	Cys	Ser	Ser	Gln	
Arg	Gly	Lys	Gly	Tyr	Asn	Val	Ser	Leu	Pro	Ile	Gly	Cys	Ser	Ser	Gln	
870					875					880					885	
tgg	ttc	aca	cca	ttt	aag	aag	gct	cct	tct	aca	ctg	acc	atc	aaa	ctt	2802
Trp	Phe	Thr	Pro	Phe	Lys	Lys	Ala	Pro	Ser	Thr	Leu	Thr	Ile	Lys	Leu	
Trp	Phe	Thr	Pro	Phe	Lys	Lys	Ala	Pro	Ser	Thr	Leu	Thr	Ile	Lys	Leu	
				890					895						900	
gcc	tac	aag	cct	gat	atc	tat	cgt	gtc	aac	cct	cac	aat	att	gtg	act	2850
Ala	Tyr	Lys	Pro	Asp	Ile	Tyr	Arg	Val	Asn	Pro	His	Asn	Ile	Val	Thr	
Ala	Tyr	Lys	Pro	Asp	Ile	Tyr	Arg	Val	Asn	Pro	His	Asn	Ile	Val	Thr	
				905				910						915		
gtc	gtc	tca	aac	caa	gag	agc	act	tgc	atc	tca	gga	gca	aat	cta	cgc	2898
Val	Val	Ser	Asn	Gln	Glu	Ser	Thr	Ser	Ile	Ser	Gly	Ala	Asn	Leu	Arg	
Val	Val	Ser	Asn	Gln	Glu	Ser	Thr	Ser	Ile	Ser	Gly	Ala	Asn	Leu	Arg	
				920				925				930				
cgc	cac	ggg	ttg	ttt	gta	caa	atc	cat	gat	gta	gta	gat	ctc	acc	gag	2946
Arg	His	Gly	Leu	Phe	Val	Gln	Ile	His	Asp	Val	Val	Asp	Leu	Thr	Glu	
Arg	His	Gly	Leu	Phe	Val	Gln	Ile	His	Asp	Val	Val	Asp	Leu	Thr	Glu	
935						940						945				

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 25 (con't)

```
gac act cag gcc ttt cta aac tat acc ttt gac ggg aaa aat gga ttt 2994
Asp Thr Gln Ala Phe Leu Asn Tyr Thr Phe Asp Gly Lys Asn Gly Phe
Asp Thr Gln Ala Phe Leu Asn Tyr Thr Phe Asp Gly Lys Asn Gly Phe
950                      955                      960                      965

aca aac cac cga gtg tct aca gga cta aaa tcc aca ttt taaaactcta 3043
Thr Asn His Arg Val Ser Thr Gly Leu Lys Ser Thr Phe
Thr Asn His Arg Val Ser Thr Gly Leu Lys Ser Thr Phe
970                      975

agctctgctt agagttttct gtagcccccgg tcgtcttaga atcctctatc catcatcgaa 3103
gaacttagca atgaaggcca agattctcac tctatgagaa ccccccc 3150
```

Figure 26 (RY-47)

Restriction enzyme analysis of CPN100630




Fig. 26 (con't)

CviJI
 HaeIII
 EcoO109I
 BslI
 Sau96I
 AclI
 MaeII
 MseI
 AluI
 CviJI
 MnlI

301 AGCAATCTCTCCTTATTAGGGAAGGGCCTTTCTTAACGTTTACCTCTTGTCAGCTCCT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 360
 TCGTTAGAGAGGAATAATCCCTTCCCGGAAAGGAATTGCAAATGGAGAACAGTTCGAGGA

PleI
 AciI
 Fnu4HI
 TauI
 BsmAI
 HinfI
 Hpy188IX
 Hpy178III
 ApoI
 Tsp509I
 MboII

MaeIII
 HhaI

361 ACAAATAGTAACTATGCGCTACTTTCTGCCGCAGAGACTCTGACCTTCAAGAATTTTTCT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 420
 TGTTTATCATTGATACGCGATGAAAGACGGCGTCTCTGAGACTGGAAGTTCCTTAAAAAGA

DrdII
 NlaIV
 Bsp24I
 CjeI
 CjePI
 TaqI
 CviJI
 HaeIII
 Fnu4HI
 TauI
 AciI
 CjeI
 MnlI
 CjePI
 Bsp24I

421 TCTATAAACTTTACAGGGAACCAATCGACAGGACTTGGCGGCCTCATCTACGGAAAAGAT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 480
 AGATATTTGAAATGTCCCTTGCTTAGCTGTCTCTGAACCGCCGGAGTAGATGCCTTTTCTA

CjeI
 BsbI
 TaaI
 BpmI
 Pfl1108I
 DpnI
 Sau3AI
 MboII

481 ATTGTTTTCCAATCTATCAAAGATTTGATCTTCACTACGAACCGTGTTGCCTATTCTCCA
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 540
 TAACAAAAGGTTAGATAGTTTCTAACTAGAAGTGATGCTTGGCACAACGGATAAGAGGT

MaeIII
 SfcI
 FauI
 Sth132I
 AciI
 MwoI
 CjeI
 MaeII
 SfaNI
 MaeIII
 AlwNI
 CviJI
 NlaIV

541 GCATCTGTAACTACGTCGGCAACTCCCGCAATCACTACAGTAACCTACAGGAGCCTCTGCT
 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 600
 CGTAGACATTGATGCAGCCGTTGAGGGCGTTAGTGATGTTCATTGATGTCTCTCGGAGACGA

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 26 (con't)




Fig. 26 (con't)




Fig. 26 (con't)

[illegible]

HaeIV
 Hin4I
 SfcI
 AlwNI
 DpnI
 BstYI
 Sau3AI
 Hpy178III
 HaeII
 HhaI
 MnlI
 Eco57I
 MwoI
 1381
 ACCACAAGTCCGTCTAATAAAGACATTACAATCAACGCTAATGGCGCTTCAGGATCTGTA
 -----+-----+-----+-----+-----+-----+-----+-----+ 1440
 TGGTGTTCAGGCAGATTATTTCTGTAATGTTAGTTGCGATTACCGCGAAGTCCTAGACAT
 BseRI
 PleI
 HinfI
 BsmFI
 SfcI
 MnlI
 Cac8I
 BsbI
 1441
 GTCTTTACAAGTAAGGGACTCTCCTCTACAGAACTCCTGTTGCCTGCCAACACGACAAC
 -----+-----+-----+-----+-----+-----+-----+-----+ 1500
 CAGAAATGTTTCATTCCCTGAGAGGAGATGTCTTGAGGACAACGGACGGTTGTGCTGTTGA
 DpnI
 Sau3AI
 Hpy178III
 TaaI
 CjePI
 BfaI
 BfaI
 CjePI
 MboII
 Eco57I
 AciI
 1501
 ATACTTCTAGGAACAGTCAAGATCGCTAGTGGAGAACTGAAGATTACTGACAATGCGGTT
 -----+-----+-----+-----+-----+-----+-----+-----+ 1560
 TATGAAGATCCTTGTTCAGTTCTAGCGATCACCTCTTGACTTCTAATGACTGTTACGCCAA
 Hpy178III
 BanII
 Bsp1286I
 CviJI
 MnlI
 ScrFI
 BsaJI
 BsaJI
 BseMII
 EcoRII
 BanII
 Bsp1286I
 Bpu10I
 DdeI
 CviJI
 MwoI
 CviJI
 Cac8I
 DdeI
 CviJI
 BseMII
 NlaIV
 1561
 GTCAATGTTGCTGGCTTCGCTACTCAGGGCTCAGGTCAGCTTACCCTGGGCTCTGGAGGA
 -----+-----+-----+-----+-----+-----+-----+-----+ 1620
 CAGTTACAACGACCGAAGCGATGAGTCCCAGTCCAGTCGAATGGGACCCGAGACCTCT

WO 00/24765

PCT/CA99/00992

Fig. 26 (con't)




Fig. 26 (con't)





Fig. 26 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF


Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 26 (con't)



BfaI
 AvrII
 BsaJI
 ApoI
 EcoRI
 Tsp509I
 StyI
 CjeI
 AlwNI
 DpnI
 BglII
 BsrI
 BstYI
 Sau3AI
 CviRI
 MaeII
 AluI
 CviJI
 CjeI
 GCAGAATTCCTAGGTGGTTGGCAAAGTAAGTTCACAGAAACTGGAGATCTGCAACGTAGC
 2641 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2700
 CGTCTTAAGGATCCACCAACCGTTTCATTCAAGTGTCTTTGACCTCTAGACGTTGCATCG
 BpmI
 MnlI
 RsaI
 MboII
 FokI
 DrdII
 TTTAGTAGAGGTAAAGGGTACAATGTTTCCCTACCGATAGGATGTTCTTCTCAATGGTTC
 2701 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2760
 AAATCATCTCCATTCCCATGTTACAAAGGGATGGCTATCCTACAAGAAGAGTTACCAAG
 NlaIV
 BccI
 BsaBI
 MseI
 CviJI
 TspRI
 CviJI
 EcoRV
 ACACCATTTAAGAAGGCTCCTTCTACACTGACCATCAAACCTTGCCCTACAAGCCTGATATC
 2761 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2820
 TGTGGTAAATTCTTCCGAGGAAGATGTGACTGGTAGTTTGAACGGATGTTCCGACTATAG
 DdeI
 DpnI
 Sau3AI
 MaeIII
 Tsp45I
 MnlI
 PshAI
 BsmAI
 BsiHKA
 HincII
 SspI
 TaaI
 BsmBI
 Bsp1286I
 TATCGTGTCAACCCCTACAATATTGTGACTGTCTGCTCTCAAACCAAGAGAGCACTTCGATC
 2821 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2880
 ATAGCACAGTTGGGAGTGTTATAACACTGACAGCAGAGTTTGTTCTCTCGTGAAGCTAG
 BsaJI
 BstDSI
 Tth111II
 AciI
 Fnu4HI
 BseMII
 CjeI
 TauI
 TaaI
 RsaI
 BsrGI
 TatI
 NlaIII
 HphI
 MnlI
 DpnI
 BglII
 BstYI
 Sau3AI
 Hpy178III
 TCAGGAGCAAATCTACGCCGCCACGGTTTGTGTTGTACAAATCCATGATGTAGTAGATCTC
 2881 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2940
 AGTCCTCGTTTTAGATGCGGCGGTGCCAAACAAACATGTTTGGTACTACATCATCTAGAG

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF


Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Fig. 26 (con't)



Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

WO 00/24765

Figure 27: CPN100397

1	MKIPLRFLLI	SLVPTLSMSN	LLGAATTEEL	SASNSFDGTT	STTSFSSKTS
51	SATDGTINYVF	KDSVVIENVP	KTGETQSTSC	FKNDAAAGDL	NFLGGGFSFT
101	FSNIDATTAS	GAAIGSEAAN	KTVTLSGFSA	LSFLKSPAST	VTNGLGAINV
151	KGNLSLLDND	KVLIQDNFST	GDGGAINCAG	SLKIANNKSL	SFIGNSSSTR
201	GGAIHTKNLT	LSSGGETLFQ	GNTAPTAAGK	GGAIAIADSG	TLISIGDSGD
251	IIFEGNTIGA	TGTVSHSAID	LGTSAKITAL	RAAQGHTIYF	YDPITVTGST
301	SVADALNINS	PDTGDNKEYT	GTIVFSGEKL	TEAEAKDEKN	RTSKLLQNVA
351	FKNGTVVLKG	DVVL SANGFS	QDANSKLIMD	LGTSLVANTE	SIELTNLEIN
401	IDSLRNGKKI	KLSAATAQKD	IRIDRPVVLA	ISDESFYQNG	FLNEDHSYDG
451	ILELDAGKDI	VISADSRSID	AVQSPYGYQG	KWTINWSTDD	KKATVSWAKQ
501	SFNPTAEQEA	PLVPNLLWGS	FIDVRSFQNF	IELGTEGAPY	EKRFWVAGIS
551	NVLHRSGREN	QRKFRHVSGG	AVVGASTRMP	GGDTLSLGFA	QLFARDKDYF
601	MNTNFAKTYA	GSLRLQHDAS	LYSVVSILLG	EGGLREILLP	YVSKTLPCSF
651	YGQLSYGHTD	HRMKTESLPP	PPPTLSTDHT	SWG GYVWAGE	LGTRVAVENT
701	SGRGFFQEYT	PFVKVQAVYA	RQDSFVELGA	ISRDFS DSHL	YNLAIP LGIK
751	LEKRFAEQYY	HVVAMYS PDV	CRSNPKCTTT	LLSNQGSWKT	KGSNLARQAG
801	IVQASGFRSL	GAAAE LFGNF	GFEWRGSSRS	YNVDAGSKIK	F

Possible T cell epitope:

516 LLWGSFIDV

Possible B cell epitope:

554 HRSGRENQRKFRHV

WO 00/24765

Figure 28: CPN100421

1 MPPLNADDVL PRDHLSGDSF SDTYPDITTQ AIILIFLALS PFLVMLLTSY
51 LKIIITLVLL RNALGVQQTP PSQVLNGIAL ILSIYVMFPT GVAMYKDARK
101 EIEANTIPQS LFTAEGAETV FVALNKSKEP LRSFLIRNTP KAQIQSFYKI
151 SQKTFPSEIR AHLTASDFVI IIPAFIMGQI KNAFEIGVLI YLPFFVIDLV
201 TANVLVAMQM MMLSPLSISL PLKLLLVIMV DGWTLLLOGL MISFK

Possible T cell epitope:

188 VLIYLPFFV

Possible B cell epitope:

125 NKSKEPLR

Figure 29: CPN100422

1 MKFFSLIFKD DDVSPNKKVL SPEAFSAFLD AKELLEKTKA DSEAYVAETE
51 QKCAQIROEA KDQGFKEGSE SWSKQIAFLE EETKNLRIRV REALVPLAIA
101 SVRKIIIGKEL ELHPETIVSI ISQALKELTQ NKHIIISVNP KDLPLVEKSR
151 PELKNIVEYA DSLILTAKPD VTPGGCIET EAGIINAQLD VQLDALEKAF
201 STILKAKNPV DEPSETSSST DSSSLSDNQD KKE

Possible T cell epitope:

163 LILTAKPDV

Possible B cell epitope:

226 SNDQDKKE

Figure 30: CPN100424

1 MTLLCCTSCN SRSLIVHGLP GREANEIVVL LVSKGVAAQK LPQAAAATAG
51 AATEQMWDIA VPSAQITEAL AILNQAGLPR MKGTSLLDLF AKQGLVPSEL
101 QEKIRYQEGL SEQMASTIRK MDGVVDASVQ ISFTTENEDN LPLTASVYIK
151 HRGVLDNPNS IMVSKIKRLI ASAVPGLVPE NVSVVSDRAA YSDITINGPW
201 GLTEEIDYVS VWGIILAKSS LTKFRLIFYV LILILFVISC GLLWVIWKTH
251 TLIMTMGGTK GFFNPTPYTK NALEAKKAEG AAADKEKKED ADSQGESKNA
301 ETSDDSDSK DAPEGSNEIE GA

Possible T cell epitope:

201 GLTEEIDYV

Possible B cell epitope:

284 DKEKKEDADSQGESKNAETSDKSDSKDAPEGSNEIE

WO 00/24765

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF
Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

PCT/CA99/00992

Figure 31: CPN100426

1 MTIRVRNLAY SVNKKKILDG VTFSLERGHI TLFVGKSGSG KTMILRALAG
51 LVQPTQGGDIW IEGEAPALVF QOPELFSHMT VLGNCTHPQI HIKGRSTEEA
101 REKAFELLHL LDIEEVAKNY PDQLSGGQKQ RVAIVRSLCM DKHTLLFDEP
151 TSALDPFATA SFRHLETLR DQELTVGLTT HDMQFVHSLC DRIYLIDQGT
201 VAGVYDKRDG ELDSGHPLSK YIHSAQ

Possible T cell epitope:

145 LLFDEPTSA

Possible B cell epitope:

205 YDKRDGE

Figure 32: CPN100508

```
1 MKRPFFTYLC IIFYGSCASL SLHAGLSFPE VRGATAAVVH ADSGKVIFYDK
51 DIDAVIYPAS MTKIATALFI LKHYPTVLDL LIKVKQDAIA SITPOAKKQS
101 GYRSPPHWLE TDGSTIQLHL REELLGWDLF HALLVCSAND AANVLAMACC
151 GSVEKFMDKL NFFLKEEIGC THTHFNNPHG LHHPNHYTTT RDLISIMRCA
201 LKEPPFRGVI STTSYKIGAT NLHGERILSP TNKLLLPGST YHYPPALGGK
251 TGTTKTAGKN LIMAAEKNNR LLVTIATGYS GPVSDLYQDV IALCETVFNE
301 PLLRKELVPP SDCLQLEIAN LGKLSCPLPE GLYYDFYASE DREPLSVSFI
351 AHADAFPIEQ GDLLGHVVFY DDEGKKISSQ PFYAPCRFER TIKPWKLYMK
401 RVFTSYRTYM SITMLLMYFR IRKHKRYKNL KHYSKI
```

Possible T cell epitope:

156 FMDKLNFFL

Possible B cell epitope:

422 RKHKRYKN

WO 00/24765

PCT/CA99/00992

Figure 33: CPN100515.

```
1  MASNPILOIE DLSITLAKQR QQYPIVQSLS FTINEGQTLA IIGESGSGKS
51 VSAHAILRLL PCPPFSVSGQ VNFQGHNLLT ASRSIQKKII GTEISMIFQN
101 PQASLNPVFT IEQQFREIIH THLALTAEVA KEKMLYALEE TGFHDPRLCL
151 NLYPHQLSGG MLQRICIAM A LLCSPKLLIA DEPTTALDVS VQYQILQLLK
201 TLQKKTGMSL LIITHNMGVV AETADDVLVL YAGRMVECAP AVQMFHNPSH
251 PYTRDLLASR PSLQPQQLGS FNPIPGQPPH YTAFPSGCRY HPRCSKILNR
301 CSAEAPETIYP VREGHKVRVG CMTTNFPQPL IQATSLTKHY YKRSFWFQ GK
351 TIASRPVDDV SFSLYSRAV GLIGESGSGK STLALALAGL LPLTSGFLT F
401 NGTPIKLHSK HGRHQLRSQV RLVFQNPQAS LNPRKTILDS LGHSLLYHKL
451 VPKEKVLATV REYLELVGLS EEYFYRYPHQ LSGGQQQRVS IARALLGV PQ
501 LIICDEIVSA LDLSIQAQIL NMLAELQKKL SLTYLFISHD LAVVRSFCTE
551 VFIMYKGQIV EKGNTKRIFS DPQHPYTRML LNAQLPETPD QRQSKPIFQE
601 YHKDSEESCS TGCYFYNRCP QKQEACKSEI IPNQGDHHT YRCIH
```

Possible T cell epitope:

59 LLPCPPFSV

Possible B cell epitopes:

18 KORQQY
587 ETPDQRQSK

WO 00/24765

Figure 34: CPN100538

```
1  MPGIEKAATT VAVPQDKSEE EKVKERLTRK ELTCEDLKDN GYTVNFEDIS
51 ILELLQFVSK ISGTNFVFDN NDLQFNVTIV SHDPTSVDL STILLOVLKM
101 HDLKVVEQGN NVLIYRNPHL SKLSTVVTDS SLKETCEAVV VTRVFRLYRR
151 QPSAAVNIIQ PLLSHDAIVS ASEATRHVII SDIAGNVDKV SDLLAALDCP
201 GTSVDMTEYE VKYANPAALV SYCQDVLGTL AEDDAFQMFQ QPGTNKIFVV
251 SSPRLANKAE QLLKSLDVPE MAHTLDDPAS TALALGGTGT TSPKSLRFFM
301 YKLKYQNGEV IANALQDIGY NLYVTTAMDE DFINTLNSIQ WLEVNNNSIVI
351 IGNQGNVDRV IGLNLGLDLP PKQVYIEVLI LDTSLEKSWD FGVQWVALGD
401 EQSKVAYASG LLNNTGIATP TKATVPPGTP NPGSIPLPTP GQLTGFSDML
451 NSSSAFGLGI IGNVLSHKGK SFLTGLGGLS ALDQDGDVTI VLNPRIMAQD
501 TQQASFFVGQ TVPYQTIKYY IQETGTVTON IDYEDIGVNL VVTSTVAPNN
551 VVTLQIEQTI SELHSASGSL TPVTDKTYAA TRLQIPDGCF LVMSGHIRDK
601 TTKVVSGVPL LNSIPLIRGL FSRTIDQRQK RNIMMFIKPK VISSFEEGTR
651 VTNKEGYRYN WEADEGSMQV APRHAPECQG PPSLQAESDF KIIEIEAQ
```

Possible T cell epitope:

50 SILELLQFV

Possible B cell epitopes:

15 QDKSEEEK

626 DQRQKRN

WO 00/24765

PCT/CA99/00992

Figure 35: CPN100557

```
1  MSRKDNEVSL ARSIFNILSG TFCSRITGIF REIAMATYFG ADPIVAAFWL
51 GFRTVFFLRK ILGGLILEQA FIPHFEFLRA QSLDRAAFFF RRFSRLIKGS
101 TIIFTLLIEA VLWVFFNNVE EGTYDMILLT MILLPCGIFL MMYNVNGALL
151 HCGNKFFGVG LAPVVVNIW IFFVIAARHS DPRERIIGLS VALVIGFFFE
201 WLITVPGVWK FLLEAKSPPO EHDSVRALLA PLSLGILTSS IFQLNLLSDI
251 CLARYVHEIG PLYLMYSLKI YQLPIHLFGF GVFTVLLPAI SRCVQREDHE
301 RGLKLMKFVL TLTMSVMIIM TAGLLLLLALP GVRVLYEHGL FPQSAVYAIV
351 RVLRGYGASI IPMALAPLVS VLFYAQRQYA VPLFIGICTA LANIVLSLVL
401 GRWVLKDVSG ISYATSITAW VQLYFLWYYS SKRLPMYSKL LWESIRRSIK
451 VMGTTMLACM ITLGLNILTQ TTYVIFLNPL TPLAWPLSSI TAQAIAPLSE
501 SCIFLAFLFG FAKLLRVEDL INLASFEYWR GQRGLLQRQH VMQDTQN
```

Possible T cell epitope:

111 VLWVFFNNV

Possible B cell epitopes:

1 MSRKDNE
295 QREDHERG

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/830446

WO 00/24765

PCT/CA99/00992

Figure 36: CPN100622

1	MKTSRNKQCK	ITDPLSKSSF	FVGALILGKT	TILLNATPLS	DYFDNQANQL
51	TTLFPLIDTL	TNMTPLYSHRA	TLFGVRDDTN	QDIVLDHQNS	IESWFENFSQ
101	DGGALSCKSL	AITNTKNQIL	FLNSFAIKRA	GAMYVDGNFD	LESENHGSIIF
151	SGNLSFPNAS	NFADTCTGGA	VLCSKNVTIS	KNQGTAYFIN	NKAKSSGGAI
201	QAAIINIKDN	TGPCLFFNNA	AGGTAGGALF	ANACRIENNS	QPIYFLNNQS
251	GLGGAIRVHQ	ECILTKNTGS	VIFNNNFAME	ADISANHSSG	GAIYCISCSI
301	KDNPGIAAFD	NNTAARDGGA	ICTQSLTIQD	SGPVYFTNNQ	GTWGGAIMLR
351	QDGACTLFAD	QGDIIFYNNR	HFKDTFSNHV	SVNCTRVSL	TVGASQGHSA
401	TFYDPILQRY	TIQNSIQKFN	PNPEHLGTIL	FSSTYIPDTS	TSRDDFISHF
451	RNHIGLYNGT	LALEDRAEWK	VYKFDQFGGT	LRLGSRVFS	TTDEEQSSSS
501	VGSVININNL	AINLPSILGN	RVAPKLWIRP	TGSSAPYSED	NNPIINLSGP
551	LSLLDDENLD	PYDTADLAQP	IAEVPLLYLL	DVTAKHINTD	NFYPEGLNTT
601	QHYGYQGVWS	PYWIETITTS	DTSSSEDTVNT	LHRQLYGDWT	PTGYKVNPNEN
651	KGDIALSAFW	QSFHNLFATL	RYQTQQGQIA	PTASGEATRL	FVHQNSNNDNA
701	KGFHMEATGY	SLGTTSNTAS	NHSFGVNFSQ	LFSNLYESHS	DNSVASHTTT
751	VALQINNPNWL	QERFSTSASL	AYSYSNHHIK	ASGYSGKIQT	EGKCYSTTLG
801	AALSCSLSLQ	WRSRPLHFTP	FIQAIIVRSN	QTAFQESGDK	ARKFSVHKPL
851	YNLTVPLGIQ	SAWESKFRLP	TYWNIELAYQ	PVLYQQNPEI	NVSLESSGSS
901	WLLSGTTLAR	NAIAFKGRNQ	IFIFPKLSVF	LDYQGSVSSS	TTTHYLHAGT
951	TFKF				

Possible T cell epitope:

119 ILFLNSFAI

Possible B cell epitopes:

2 KTSRNKQ
647 NPENKG
694 QNSNNDK

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

09/2830446

PCT/CA99/00992

WO 00/24765

Figure 37: CPN100626

```
1  MQVFPKVTLS LDYSADISSS TLSHYLNVAS RMRFLTISDQ NRKIKEPLVS
51  KTPPKFLFYI GNFTACMFGM TPAVYSLQTD SLEKFALERD EEFRTSFPLL
101 DSLSTLTGFS PITTFVGNRH NSSQDIVLSN YKSIDNILL WTSAGGAVSC
151 NNFLLSNVED HAFFSKNLAI GTGGAIACQG ACTITKNRGP LIFFSNRGLN
201 NASTGETRG GAIACNGDFT ISQNQGTIFY VNNSVNNWGG ALSTNGHCRI
251 QSNRAPLLFF NNTAPSGGGA LRSENTTISD NTRPIYFKNN CGNNGGAIQT
301 SVTVAIKNNS GSVIFNMNTA LSGSINSNGG SGGAIYTTNL SIDDNPGTIL
351 FNNNYCIRDG GAICTQFLT I KNSGHVYFTN NQGNWGGALM LLQDSTCLLF
401 AEQGNIAFQN NEVFLTTFGR YNAIHCTPNS NLQLGANKGY TTAFFDPIEH
451 QHPTTNPLIF NPNANHOGTI LFSSAYIPEA SDYENNFISS SKNTSELNRG
501 VLSIEDRAGW QFYKFTQKGG ILKLGHAA SI ATTANSETPS TSVGSQVIIN
551 NLAINLPSIL AKGKAPTLWI RPLQSSAPFT EDNNPTITLS GPLTLLNEEN
601 RDPYDSIDLS EPLQNIHLLS LSDVTARHIN TDNFHPESLN ATEHYGYQGI
651 WSPYWVETIT TTNNASIETA NTLYRALYAN WTPLYGKVPN EYQGDLATTP
701 LWQSFHTMFS LLRSYNRTGD SDIERPFLEI QGIADGLFVH QNSIPGAPGF
751 RIQSTGYSLQ ASSETSILHQK ISLGFAQFFT RTKEIGSSNN VSAHNTVSSL
801 YVELPWFQEA FATSHSLAYG YGDHHLHAYI RHIKNRAEGT CYSHTLAAAI
851 GCSFPWQOKS YLHLSPPVQA IAIKSHQTAF EEIGDNPRKF VSQKPFYNLT
901 LPLGIQKQWQ SKFHVPTWT LELSYQPVLY QQNPQIGVTL LASGGSWDIL
951 GHNYVRNALG YKVHNQTALF RSLDLFLDYQ GSVSSSTSTH HLQAGSTLKF
```

Possible T cell epitope:

56 FLYLGNFT

Possible B cell epitopes:

39 DQNRKIK
597 NEENRDPYD

WO 00/24765

Figure 38: CPN100628

```
1  MLLPFTFVLA  NEGLQLPLET  YITLSPEYQA  APQVGFTTHQ  NQDLAIVGNH
51  NDFILDYKYY  RSNNGALTCK  NLLISENIGN  VFPEKNVCPN  SGGAIYAAQN
101 CTISKQNQYA  FTTNLVSDNP  TATAGSLLGG  ALFAINCST  NNLGQGTFFVD
151 NLALNKGKGA  YTETNLSIKD  NKGPIIIKQN  RALNSDSLGG  GIYSGNSLNI
201 EGN SGAIQIT  SNSSGSGGGI  FSTQTLTISS  NKKLIEISEN  SAFANNYGSN
251 FNPGGGGLTT  TFCTILNNRE  GVLFNNNQSQ  SNGGAIHAKS  I I I KENGPVY
301 FLNNTATRGG  ALLNLSAGSG  NGSFILSADN  GDII FNMNTA  SKHALNPPYR
351 NAIHSTPNMN  LQIGARPGYR  VLFYDPIEHE  LPSSFPILFN  FETGHTGTVL
401 FSGEHVHQN  TDEMNFYSYL  RNTSELRQGV  LAVEDGAGLA  CYKFFQRRGT
451 LLLGQGAVIT  TAGTIPTPSS  TPTTVGSTIT  LNHIAIDLPS  ILSFQAQAPK
501 IWIYPTKTGS  TYTEDSNPTI  TISGTLTLRN  SNNEDPYDSL  DLSHSLEKVP
551 LLYIVDVAAQ  KINSSQLDLS  TLNSGEHYGY  QGIWSTYWVE  TTTITNPTSL
601 LGANTKHKL  L  YANWSPLGYR  PHPERRGEFI  TNALWQSAYT  ALAGLHSLSS
651 WDEEKGHAAS  LQIGLLVHQ  KDKNGFKGFR  SHMTGYSATT  EATSSQSPNF
701 SLGFAQFFSK  AKEHESQNST  SSHHYFSGMC  IAKYSLQ RVI  RLSVSLAYMF
751 TSEHTHTMYQ  GLLEGNSQGS  FHNHTLAGAL  SCVFLPQPHG  ESLQIYPFIT
801 ALAIRGNLAA  FQESGDHARE  FSLHRPLTDV  SLPVGIRASW  KNHHRVPLVW
851 L TEISYRSTL  YRQDPELH  SK  LLISQGTWTT  QATPVTYNAL  GIKVKNTMQV
901 FPKVTLSLDY  SADISSSTLS  HYLNVASMR  F
```

Possible T cell epitope:

1 MLLPFTFVL

Possible B cell epitopes:

38 HNQNQ
619 YRPHPERRG
669 HQKDKNG

Title: CHLAMYDIA ANTIGENS AND
CORRESPONDING DNA FRAGMENTS
AND USES THEREOF

Inventor(s): Andrew D. MURDIN et al
DOCKET NO.: 032931/0251

PCT/CA99/00992

WO 00/24765

Figure 39: CPN100630

```
1  MPLSPKSSSF  CLLACLCSAS  CAFAETRLGG  NFVPPITNQG  EEILLTSDFV
51  CSNFLGASFS  SSFINSSSNL  SLLGKGLSLT  FTSCQAPTNS  NYALLSAAET
101 LTFKNFSSIN  FTGNQSTGLG  GLIYGKDIVF  QSIKDLIFTT  NRVAYSPASV
151 TTSATPAITT  VTTGASALQP  TDSLTVENIS  QSIKFFGNLA  NFGSAISSSP
201 TAVVKFINNT  ATMSFSHNFT  SSGGGVIYGG  SLLFENNNG  CIIFTANSCV
251 NSLKGVTSS  GTYALGSGGA  ICIPTGTFEL  KNNQKCTFS  YNGTPNDAGA
301 IYAETCNIVG  NQGALLLDSN  TAARNGGAIC  AKVLNIQGRG  PIEFSRNRAE
351 KGGAIFIGPS  VGDPKQTST  LTLASEGDI  AFQGNMLNTK  PGIRNAITVE
401 AGGEIVSLSA  QGGSRLVFD  PITHSLPTTS  PSNKDITINA  NGASGSVVFT
451 SKGLSSTELL  LPANTTILL  GTVKIASGEL  KITDNAVNV  AGFATQSGSQ
501 LTLGSGGTLG  LATPTGAPAA  VDFTIGKLAF  DPFSFLKRD  VSASVNAGTK
551 NVTLTGALVL  DEHDVTDLYD  MVSLOSPVAI  PIAVFKGATV  TKTGFDPGEI
601 ATPSHYGYQG  KWSYTWSRPL  LIPAPDGGFP  GGPPSANTL  YAVWNSDTLV
651 RSTYILDPER  YGEIVSNSLW  ISFLGNQAFS  DILQDVLLID  HPGLSITAKA
701 LGAYVEHTPR  QGHEGFSGRY  GGYQAALSMN  YTDHTTLGLS  FGQLYGKTNA
751 NPYDSRCSEQ  MYLLSFFGQF  PIVTQKSEAL  ISWKAAYGYS  KNHLNTTYLR
801 PDKAPKSQGG  WHNNSYYVLI  SAEHPFLNWC  LLTRPLAQAW  DLSGFISAEF
851 LGGWQSKFTE  TGDLORSFSR  GKGYNVSLPI  GCSSQWFTPF  KKAPSTLTIK
901 LAYKPDYRV  NPHNIVTVVS  NQESTSISGA  NLRRHGLFVQ  IHDVVDLTED
951 TQAFNLNYTFD  GKNGFTNHRV  STGLKSTF
```

Possible T cell epitope:

936 GLFVQIHDV

Possible B cell epitopes:

281 KNNQK
345 SRNRAEK
707 HTPRQGHE

MAY 30 2002

TECH CENTER 1000/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

the specification of which

- ☐ is attached hereto.
- ☒ was filed on April 27, 2001
- as U.S. Application Serial No. 09/830,446
- ☒ was filed on October 28, 1999
- as PCT International Application No. PCT/CA99/00992

and (if applicable) was amended on February 8, 2001

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §§1.56(a) and (b), which state:

- "(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
- (1) prior art cited in search reports of a foreign patent office in a counterpart application,
 - (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability."

I hereby claim foreign priority benefits under 35 United States Code, §119 and/or §365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing of this application:

PRIOR FOREIGN APPLICATION(S)

<u>Number</u>	<u>Country</u>	<u>Filing Date</u> <u>(Day/Month/Year)</u>	<u>Date First</u> <u>Laid-open or</u> <u>Published</u>	<u>Date Patented</u> <u>or Granted</u>	<u>Priority</u> <u>Claimed?</u>
---------------	----------------	---	--	---	------------------------------------

I hereby claim the benefit under 35 United States Code, §119(e) of any United States provisional application(s) listed below:

<u>Application Number</u>	<u>Filing Date</u>
60/106,034	October 28, 1998
60/106,044	October 28, 1998
60/106,039	October 28, 1998
60/106,042	October 28, 1998
60/106,087	October 29, 1998
60/106,072	October 29, 1998
60/106,073	October 29, 1998
60/106,074	October 29, 1998
60/106,589	November 2, 1998
60/107,034	November 2, 1998
60/107,035	November 2, 1998
60/106,587	November 2, 1998
60/106,588	November 2, 1998

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

PRIOR U.S. OR PCT APPLICATION(S)

<u>Application No.</u>	<u>Filing Date</u> (day/month/year)	<u>Status</u> (pending, abandoned, granted)
------------------------	--	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following patent agents with full power of substitution, association and revocation to prosecute this application and/or international application and to transact all business in the Patent and Trademark Office connected therewith:


HUGH O'GORMAN (Reg. No. 26140)	ALAN R. CAMPBELL (Reg. No. 26129)
A. DAVID MORROW (Reg. No. 28816)	ROBERT D. GOULD (Reg. No. 27523)
JAMES MCGRAW (Reg. No. 28168)	THOMAS R. KELLY (Reg. No. 29244)
JOHN BOCHNOVIC (Reg. No. 29229)	MICHAEL E. WHEELER (Reg. No. 29246)
JOY D. MORROW (Reg. No. 30911)	R. ALLAN BRETT (Reg. No. 40476)
TOKUO HIRAMA (Reg. No. 32551)	PHILIP D. LAPIN (Reg. No. 44443)
KOHI SUZUKI (Reg. No. 44467)	R. JOHN HALEY (Reg. No. 29502)
CHRISTINE N. GENGE (Reg. No. 45405)	THUY HUONG NGUYEN (Reg. No. 47336)
DENNIS S.K. LEUNG (Reg. No. 47325)	KEVIN K. GRAHAM (Reg. No. P-47,365)
MATTHEW M. ROY (Reg. No. 48,074)	DAVID E. SCHWARTZ (Reg. No. 48,211)
ELLIOTT S. SIMCOE (Reg. No. 50,010)	STEVEN B. GARLAND (Reg. No. 50,003)
DAVID E. SCHWARTZ (Reg. No. 48,211)	ELLIOTT S. SIMCOE (Reg. No. P-50,010)
STEPHEN A. BENT (Reg. No. 29,768)	DAVID A. BLUMENTHAL (Reg. No. 26,257)
BETH BURROUS (Reg. No. 35,087)	ALAN I. CANTOR (Reg. No. 28,163)
WILLIAM T. ELLIS (Reg. No. 26,874)	JOHN J. FELDHAUS (Reg. No. 28,822)
MICHAEL D. KAMINSKI (Reg. No. 32,904)	LYLE K. KIMMS (Reg. No. 34,079)
KENNETH E. KROSIN (Reg. No. 25,735)	JOHNNY A. KUMAR (Reg. No. 34,649)
JACK LAHR (Reg. No. 19,621)	GLENN LAW (Reg. No. 34,371)
PETER G. MACK (Reg. No. 26,001)	STEPHEN B. MAEBIUS (35,264)
BRIAN J. MCNAMARA (Reg. No. 32,789)	SYBIL MELOY (Reg. No. 22,749)
RICHARD C. PEET (Reg. No. 35,792)	GEORGE E. QUILLIN (Reg. No. 32,792)
ANDREW E. RAWLINS (Reg. No. 34,702)	BERNHARD D. SAXE (Reg. No. 28,665)
CHARLES F. SCHILL (Reg. No. 27,590)	RICHARD L. SCHWABB (Reg. No. 25,479)
MICHELE M. SIMKIN (Reg. No. 34,717)	HAROLD C. WEGNER (Reg. No. 25,258)

PLEASE SEND CORRESPONDENCE TO: BERNHARD D. SAXE
FOLEY & LARDNER
3000 K Street N.W.
Suite 500
Washington, D.C. 20007-5109
U.S.A.
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

416 667 2459

- 4 -

1 - 00 1) INVENTOR'S SIGNATURE:



Date: 22nd May 2002

Inventor's Name: ANDREW
(First)

D.
(Middle)

MURDIN
(Family Name)

Country of Citizenship: GREAT BRITAIN

Residence: Richmond Hill, Ontario, Canada CAX
(City, Province, Country)

Post Office Address: 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, Canada

2 - 00 2) INVENTOR'S SIGNATURE:



Date: 22nd May 2002

Inventor's Name: RAYMOND
(First)

P.
(Middle)


OOMEN
(Family Name)

Country of Citizenship: CANADA

Residence: Aurora, Ontario, Canada CAX
(City, Province, Country)

Post Office Address: 29 Kennedy St. W., Aurora, Ontario L0G 1T0, Canada

3 - 00 3) INVENTOR'S SIGNATURE:



Date: 22nd May 2002

Inventor's Name: JOE
(First)

(Middle)

WANG
(Family Name)

Country of Citizenship: CANADA

Residence: Toronto, Ontario, Canada CAX
(City, Province, Country)

Post Office Address: 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, Canada

5/83

```

cgc atg aag acc gag tct cta ccc ccc ccc ccc ccg acg ctc tcg acg 2131
Arg Met Lys Thr Glu Ser Leu Pro Pro Pro Pro Pro Thr Leu Ser Thr
        665                      670                      675

gat cat act tct tgg gga gga tat gtc tgg gct gga gag ctg gga act 2179
Asp His Thr Ser Trp Gly Gly Tyr Val Trp Ala Gly Glu Leu Gly Thr
        680                      685                      690

10  cga gtt gct gtt gaa aat acc agc ggc aga gga ttt ttc caa gag tac 2227
Arg Val Ala Val Glu Asn Thr Ser Gly Arg Gly Phe Phe Gln Glu Tyr
        695                      700                      705

act cca ttt gta aaa gtc caa gct gtt tac gct cgc caa gat agc ttt 2275
Thr Pro Phe Val Lys Val Gln Ala Val Tyr Ala Arg Gln Asp Ser Phe
        710                      715                      720                      725

20  gta gaa cta gga gct atc agt cgt gat ttt agt gat tcg cat ctt tat 2323
Val Glu Leu Gly Ala Ile Ser Arg Asp Phe Ser Asp Ser His Leu Tyr
        730                      735

aac ctt gcg att cct ctt gga atc aag tta gag aaa cgg ttt gca gag 2371
Asn Leu Ala Ile Pro Leu Gly Ile Lys Leu Glu Lys Arg Phe Ala Glu
        745                      750                      755

caa tat tat cat gtt gta gcg atg tat tct cca gat gtt tgt cgt agt 2419
Gln Tyr Tyr His Val Val Ala Met Tyr Ser Pro Asp Val Cys Arg Ser
        760                      765                      770

30  aac ccc aaa tgt acg act acc cta ctt tcc aac caa ggg agt tgg aag 2467
Asn Pro Lys Cys Thr Thr Thr Leu Leu Ser Asn Gln Gly Ser Trp Lys
        775                      780                      785

acc aaa ggt tcg aac tta gca aga cag gct ggt att gtt cag gcc tca 2515
Thr Lys Gly Ser Asn Leu Ala Arg Gln Ala Gly Ile Val Gln Ala Ser
        790                      795                      800                      805

40  ggt ttt cga tct ttg gga gct gca gca gag ctt ttc ggg aac ttt ggc 2563
Gly Phe Arg Ser Leu Gly Ala Ala Ala Glu Leu Phe Gly Asn Phe Gly
        810                      815                      820

ttt gaa tgg cgg gga tct tct cgt agc tat aat gta gat gcg ggt agc 2611
Phe Glu Trp Arg Gly Ser Ser Arg Ser Tyr Asn Val Asp Ala Gly Ser
        825                      830                      835

aaa atc aaa ttt tagcgatttc tctttcgatg ctatttttcc atggctatatt 2663
Lys Ile Lys Phe
        840

50  ttaaaatgat agccatgggt atagatacgt agtccttatt tcaaagaaga cactgttgca 2723
ttagatacgc tctctgatcc ctcaaaa 2750

<210> 2
<211> 2523
<212> DNA
<213> Chlamydia pneumoniae

60  <220>
    <221> CDS

```

6/83

<400> 2

atg	aag	att	cca	ctc	15
Met	Lys	Ile	Pro	Leu	
1				5	

cgc ttt tta ttg ata tca tta gta cct acg ctt tot atg tcg aat tta 63
Arg Phe Leu Leu Ile Ser Leu Val Pro Thr Leu Ser Met Ser Asn Leu

10 10 15 20

tta	gga	gct	gct	act	acc	gaa	gag	tta	tcg	gct	agc	aat	agc	ttc	gat	111
Leu	Gly	Ala	Ala	Thr	Thr	Glu	Glu	Leu	Ser	Ala	Ser	Asn	Ser	Phe	Asp	
			25					30					35			

gga act aca tca aca aca agc ttt tct agt aaa aca tca tcg gct aca 159
Gly Thr Thr Ser Thr Thr Ser Phe Ser Ser Lys Thr Ser Ser Ala Thr
40 45 50

20 gat ggc acc aat tat gtt ttt aaa gat tct gta gtt ata gaa aat gta 207
Asp Gly Thr Asn Tyr Val Phe Lys Asp Ser Val Val Ile Glu Asn Val

55 60 65

ccc aaa aca ggg gaa act cag tct act agt tgt ttt aaa aat gac gct 255
Pro Lys Thr Gly Glu Thr Gln Ser Thr Ser Cys Phe Lys Asn Asp Ala
70 75 80 85

gca gct gga gat ctaaat ttc tta gga ggg gga ttt tct ttcaca ttt 303
Ala Ala Gly Asp Leu Asn Phe Leu Gly Gly Gly Phe Ser Phe Thr Phe

30 90 95 100

agc aat atc gat gca acc acg gct tct gga gct gct att gga agt gaa 351
 Ser Asn Ile Asp Ala Thr Thr Ala Ser Gly Ala Ala Ile Gly Ser Glu
 105 110 115

gca gct aat aag aca gtc acg tta tca gga ttt tcg gca ctt tct ttt 399
Ala Ala Asn Lys Thr Val Thr Leu Ser Gly Phe Ser Ala Leu Ser Phe
120 125 130

40 ctt aaa tcc cca gca agt aca gtg act aat gga ttg gga gct atc aat 447
 Leu Lys Ser Pro Ala Ser Thr Val Thr Asn Gly Leu Gly Ala Ile Asn

 135 140 145

ggt aaa ggg aat tta agc cta ttg gat aat gat aag gta ttg att cag 495
Val Lys Gly Asn Leu Ser Leu Leu Asp Asn Asp Lys Val Leu Ile Gln
150 155 160 165

gac aat ttc tca aca gga gat ggc gga gca att aat tgt gca ggc tcc 543
Asp Asn Phe Ser Thr Gly Asp Gly Gly Ala Ile Asn Cys Ala Gly Ser

50 170 175 180

ttg aag atc gca aac aat aag tcc ctt tct ttt att gga aat agt tct 591
Leu Lys Ile Ala Asn Asn Lys Ser Leu Ser Phe Ile Gly Asn Ser Ser
185 190 195

tca aca cgt ggc gga gcg att cat acc aaa aac ctc aca cta tct tct 639
Ser Thr Arg Gly Gly Ala Ile His Thr Lys Asn Leu Thr Leu Ser Ser
200 205 210

60

8/83

	tta gat gct ggg aaa gac atc gtg att tct gca gat tct cgc agt ata	1407
	Leu Asp Ala Gly Lys Asp Ile Val Ile Ser Ala Asp Ser Arg Ser Ile	
	455 460 465	
	gat gct gta caa tct ccg tat ggc tat cag gga aag tgg acg atc aat	1455
	Asp Ala Val Gln Ser Pro Tyr Gly Tyr Gln Gly Lys Trp Thr Ile Asn	
	470 475 480 485	
10	tgg tct act gat gat aag aaa gct acg gtt tct tgg gcg aag cag agt	1503
	Trp Ser Thr Asp Asp Lys Lys Ala Thr Val Ser Trp Ala Lys Gln Ser	
	490 495 500	
	ttt aat ccc act gct gag cag gag gct ccg tta gtt cct aat ctt ctt	1551
	Phe Asn Pro Thr Ala Glu Gln Glu Ala Pro Leu Val Pro Asn Leu Leu	
	505 510 515	
20	tgg ggt tct ttt ata gat gtt cgt tcc ttc cag aat ttt ata gag cta	1599
	Trp Gly Ser Phe Ile Asp Val Arg Ser Phe Gln Asn Phe Ile Glu Leu	
	520 525 530	
	ggt act gaa ggt gct cct tac gaa aag aga ttt tgg gtt gca ggc att	1647
	Gly Thr Glu Gly Ala Pro Tyr Glu Lys Arg Phe Trp Val Ala Gly Ile	
	535 540 545	
	tcc aat gtt ttg cat agg agc ggt cgt gaa aat caa agg aaa ttc cgt	1695
	Ser Asn Val Leu His Arg Ser Gly Arg Glu Asn Gln Arg Lys Phe Arg	
	550 555 560 565	
30	cat gtg agt gga ggt gct gta gta ggt gct agc acg agg atg ccg ggt	1743
	His Val Ser Gly Gly Ala Val Val Gly Ala Ser Thr Arg Met Pro Gly	
	570 575 580	
	ggt gat acc ttg tct ctg ggt ttt gct cag ctc ttt gcg cgt gac aaa	1791
	Gly Asp Thr Leu Ser Leu Gly Phe Ala Gln Leu Phe Ala Arg Asp Lys	
	585 590 595	
40	gac tac ttt atg aat acc aat ttc gca aag acc tac gca gga tct tta	1839
	Asp Tyr Phe Met Asn Thr Asn Phe Ala Lys Thr Tyr Ala Gly Ser Leu	
	600 605 610	
	cgt ttg cag cac gat gct tcc cta tac tct gtg gtg agt atc ctt tta	1887
	Arg Leu Gln His Asp Ala Ser Leu Tyr Ser Val Val Ser Ile Leu Leu	
	615 620 625	
	gga gag gga gga ctc cgc gag atc ctg ttg cct tat gtt tcc aag act	1935
	Gly Glu Gly Gly Leu Arg Glu Ile Leu Leu Pro Tyr Val Ser Lys Thr	
	630 635 640 645	
50	ctg ccg tgc tct ttc tat ggg cag ctt agc tac ggc cat acg gat cat	1983
	Leu Pro Cys Ser Phe Tyr Gly Gln Leu Ser Tyr Gly His Thr Asp His	
	650 655 660	
	cgc atg aag acc gag tct cta ccc ccc ccc ccc ccg acg ctc tcg acg	2031
	Arg Met Lys Thr Glu Ser Leu Pro Pro Pro Pro Pro Thr Leu Ser Thr	
	665 670 675	
60	gat cat act tct tgg gga gga tat gtc tgg gct gga gag ctg gga act	2079
	Asp His Thr Ser Trp Gly Gly Tyr Val Trp Ala Gly Glu Leu Gly Thr	
	680 685 690	

11/83

taaggacacg tgccgtgtta gcatttttcg caactagttt caaatctggt ctttttgagt 895
 actcctacca atcattatta cttattttga ttgtttcggc acctcccatc atcttagctt 955
 ccatagtcgg gattatggtt gcgatcttcc aagccgcaac acaaa 1000

<210> 4

<211> 9

10 <212> PRT

<213> Chlamydia pneumoniae

<220>

<221> SITE

<222> (188)..(197)

<400> 4

Val Leu Ile Tyr Leu Pro Phe Phe Val

1

5

20

<210> 5

<211> 900

<212> DNA

<213> Chlamydia pneumoniae

<220>

<221> CDS

<222> (101)..(799)

30

<400> 5

tagctttata caaagtatag aaaaataaca cgacaataaa aggagcgggtg ttttctcttc 60

tgaggtaa at cagcctcaaa gatactacgc catagtaaag atg aag ttt ttt agc 115

Met Lys Phe Phe Ser

1

5

tta att ttt aaa gat gat gat gtc tcc cca aat aag aag gtt tta tct 163

Leu Ile Phe Lys Asp Asp Asp Val Ser Pro Asn Lys Lys Val Leu Ser

10

15

20

40

cct gaa gct ttc tct gct ttc ctt gat gcc aaa gag ctg tta gaa aaa 211

Pro Glu Ala Phe Ser Ala Phe Leu Asp Ala Lys Glu Leu Leu Glu Lys

25

30

35

aca aaa gcc gat agc gaa gcc tat gtt gca gag aca gaa caa aag tgt 259

Thr Lys Ala Asp Ser Glu Ala Tyr Val Ala Glu Thr Glu Gln Lys Cys

40

45

50

50 gca caa att cgt caa gaa gct aaa gat caa gga ttt aaa gag gga tct 307

Ala Gln Ile Arg Gln Glu Ala Lys Asp Gln Gly Phe Lys Glu Gly Ser

55

60

65

gaa tcc tgg agc aag caa att gct ttc tta gaa gaa gaa act aaa aat 355

Glu Ser Trp Ser Lys Gln Ile Ala Phe Leu Glu Glu Glu Thr Lys Asn

70

75

80

85

cta cgc ata aga gta cgc gag gcc ttg gtt cct ctg gca att gcg agt 403

Leu Arg Ile Arg Val Arg Glu Ala Leu Val Pro Leu Ala Ile Ala Ser

90

95

100

60

13/83

<220>
<221> CDS
<222> (101)..(1066)

<400> 7

tgttcgcgat tggcactaat cccccctttt gttatggtga ataaaaaggt atgcgtggat 60

10	tatggttcgt cgatctatatt ctttttgctt gttcttttcta	atg aca ttg ctg tgc	115
		Met Thr Leu Leu Cys	
		1 5	
	tgt aca agc tgt aac agc agg tct cta att gtg cac ggt ctt cct ggc	163	
	Cys Thr Ser Cys Asn Ser Arg Ser Leu Ile Val His Gly Leu Pro Gly		
	10 15 20		
	aga gaa gcg aat gag att gtg gtg ctt ttg gta agc aaa ggg gtg gct	211	
20	Arg Glu Ala Asn Glu Ile Val Val Leu Leu Val Ser Lys Gly Val Ala		
	25 30 35		
	gca caa aaa ttg cct caa gct gca gcg gct aca gcc gga gca gct act	259	
	Ala Gln Lys Leu Pro Gln Ala Ala Ala Thr Ala Gly Ala Ala Thr		
	40 45 50		
	gag caa atg tgg gat atc gcg gtt ccg tca gca caa atc aca gag gcc	307	
	Glu Gln Met Trp Asp Ile Ala Val Pro Ser Ala Gln Ile Thr Glu Ala		
	55 60 65		
30	ctt gcc att cta aat caa gcg ggt ctt cca cgt atg aaa ggg aca agc	355	
	Leu Ala Ile Leu Asn Gln Ala Gly Leu Pro Arg Met Lys Gly Thr Ser		
	70 75 80 85		
	ctg tta gat ctt ttt gca aaa caa ggt ctt gtt cct tcc gag ctt cag	403	
	Leu Leu Asp Leu Phe Ala Lys Gln Gly Leu Val Pro Ser Glu Leu Gln		
	90 95 100		
	gaa aaa atc cgt tat caa gaa ggc tta tca gaa cag atg gcc tct acg	451	
40	Glu Lys Ile Arg Tyr Gln Glu Gly Leu Ser Glu Gln Met Ala Ser Thr		
	105 110 115		
	att aga aaa atg gat ggc gtt gtc gat gcc tca gta cag att tcc ttc	499	
	Ile Arg Lys Met Asp Gly Val Val Asp Ala Ser Val Gln Ile Ser Phe		
	120 125 130		
	act aca gaa aat gaa gat aat ctt cct tta aca gcc tct gtg tat att	547	
	Thr Thr Glu Asn Glu Asp Asn Leu Pro Leu Thr Ala Ser Val Tyr Ile		
	135 140 145		
50	aag cat cga ggg gtt ttg gac aat ccg aac agc att atg gtt tcc aaa	595	
	Lys His Arg Gly Val Leu Asp Asn Pro Asn Ser Ile Met Val Ser Lys		
	150 155 160 165		
	att aag cgc ctt att gca agt gct gtt cca gga ctt gtg cca gag aac	643	
	Ile Lys Arg Leu Ile Ala Ser Ala Val Pro Gly Leu Val Pro Glu Asn		
	170 175 180		
	gtc tct gta gtg agc gat cgc gca gct tat agt gat att aca att aat	691	
60	Val Ser Val Val Ser Asp Arg Ala Ala Tyr Ser Asp Ile Thr Ile Asn		
	185 190 195		

14/83

```

      ggt cct tgg gga tta aca gaa gaa atc gat tat gtt tct gtt tgg ggt 739
      Gly Pro Trp Gly Leu Thr Glu Glu Ile Asp Tyr Val Ser Val Trp Gly
                200                      205                      210

      att att ctt gcg aag tct tcg ctc acc aaa ttc cgt ctc att ttt tat 787
      Ile Ile Leu Ala Lys Ser Ser Leu Thr Lys Phe Arg Leu Ile Phe Tyr
                215                      220                      225

10    gtc ttg att ctc att tta ttt gtt att tct tgt ggt ctc ctt tgg gtc 835
      Val Leu Ile Leu Ile Leu Phe Val Ile Ser Cys Gly Leu Leu Trp Val
      230                      235                      240                      245

      att tgg aaa act cat act ctc att atg act atg gga ggt aca aaa ggg 883
      Ile Trp Lys Thr His Thr Leu Ile Met Thr Met Gly Gly Thr Lys Gly
                250                      255                      260

20    ttc ttc aac cct aca cca tat aca aag aat gcc ttg gaa gcc aag aaa 931
      Phe Phe Asn Pro Thr Pro Tyr Thr Lys Asn Ala Leu Glu Ala Lys Lys
                265                      270                      275

      gcc gag gga gca gct gct gac aaa gag aaa aaa gaa gat gca gat tca 979
      Ala Glu Gly Ala Ala Ala Asp Lys Glu Lys Lys Glu Asp Ala Asp Ser
                280                      285                      290

      cag ggg gaa agc aaa aat gcg gaa acc agt gat aaa gac tct agt gat 1027
      Gln Gly Glu Ser Lys Asn Ala Glu Thr Ser Asp Lys Asp Ser Ser Asp
                295                      300                      305

30    aaa gat gct cca gaa gga agc aat gaa att gag ggt gct tagtgactgc 1076
      Lys Asp Ala Pro Glu Gly Ser Asn Glu Ile Glu Gly Ala
      310                      315                      320

      caacactttt ggaactctag acatcttgat gaagcactcc aaggaagatg acctctccag 1136
      gtttcttcct aaaaatcttc ttgttgaatc tcctcatccc gaagaaatcc ctttaaaatc 1196
      tttta                                           1200

40    <210> 8
      <211> 9
      <212> PRT
      <213> Chlamydia pneumoniae

      <220>
      <221> SITE
      <222> (201)..(209)

      <400> 8
50    Gly Leu Thr Glu Glu Ile Asp Tyr Val
      1                      5

      <210> 9
      <211> 850
      <212> DNA
      <213> Chlamydia pneumoniae

      <220>
60    <221> CDS
      <222> (101)..(778)

```


21/83

	tct gag gag tat ttt tat cgt tat cct cac cag ctt tct gga gga caa	1555
	Ser Glu Glu Tyr Phe Tyr Arg Tyr Pro His Gln Leu Ser Gly Gly Gln	
	470 475 480 485	
	caa caa cga gtc tct ata gcg aga gcc cta tta gga gtc cct cag tta	1603
	Gln Gln Arg Val Ser Ile Ala Arg Ala Leu Leu Gly Val Pro Gln Leu	
	490 495 500	
10	att att tgt gac gaa att gtt tct gct cta gat tta tct att caa gca	1651
	Ile Ile Cys Asp Glu Ile Val Ser Ala Leu Asp Leu Ser Ile Gln Ala	
	505 510 515	
	caa att ctg aat atg ctt gcc gag ctg caa aaa aaa ctc agc ctc aca	1699
	Gln Ile Leu Asn Met Leu Ala Glu Leu Gln Lys Lys Leu Ser Leu Thr	
	520 525 530	
20	tat ctc ttc att tcg cat gat ctt gcc gtt gta cgc tcg ttc tgc aca	1747
	Tyr Leu Phe Ile Ser His Asp Leu Ala Val Val Arg Ser Phe Cys Thr	
	535 540 545	
	gag gta ttc att atg tat aag ggg caa att gta gaa aaa gga aat aca	1795
	Glu Val Phe Ile Met Tyr Lys Gly Gln Ile Val Glu Lys Gly Asn Thr	
	550 555 560 565	
	aaa cgc att ttt tct gat cca caa cat cct tat acg cgc atg ttg tta	1843
	Lys Arg Ile Phe Ser Asp Pro Gln His Pro Tyr Thr Arg Met Leu Leu	
	570 575 580	
30	aat gcc caa ctt cca gag act cct gat caa agg caa tct aaa cct ata	1891
	Asn Ala Gln Leu Pro Glu Thr Pro Asp Gln Arg Gln Ser Lys Pro Ile	
	585 590 595	
	ttc caa gaa tat cac aaa gat tct gaa gaa tct tgc tct aca gga tgc	1939
	Phe Gln Glu Tyr His Lys Asp Ser Glu Glu Ser Cys Ser Thr Gly Cys	
	600 605 610	
40	tac ttt tac aat cgt tgt cca caa aaa caa gaa gct tgc aag tca gag	1987
	Tyr Phe Tyr Asn Arg Cys Pro Gln Lys Gln Glu Ala Cys Lys Ser Glu	
	615 620 625	
	atc atc cca aat caa gga gac gcg cac cat aca tac cgt tgt atc cat	2035
	Ile Ile Pro Asn Gln Gly Asp Ala His His Thr Tyr Arg Cys Ile His	
	630 635 640 645	
	tgattcgtcc tctacgtat tcttaagcta ccattaagga atcccaaggg agaggtctgc	2095
	tctat	2100
50		
	<210> 14	
	<211> 9	
	<212> PRT	
	<213> Chlamydia pneumoniae	
	<220>	
	<221> SITE	
	<222> (59)..(67)	

27/83

	cta	tat	ctt	atg	tac	tcc	tta	aag	att	tat	cag	ctc	ccc	ata	cat	ctc	931
	Leu	Tyr	Leu	Met	Tyr	Ser	Leu	Lys	Ile	Tyr	Gln	Leu	Pro	Ile	His	Leu	
				265					270					275			
	ttt	ggc	ttt	ggt	gtg	ttt	acc	gtt	ctc	ctc	cca	gca	att	tct	cgt	tgt	979
	Phe	Gly	Phe	Gly	Val	Phe	Thr	Val	Leu	Leu	Pro	Ala	Ile	Ser	Arg	Cys	
			280					285					290				
10	gta	cag	cga	gaa	gat	cat	gag	agg	gga	ttg	aaa	ctt	atg	aag	ttc	gtt	1027
	Val	Gln	Arg	Glu	Asp	His	Glu	Arg	Gly	Leu	Lys	Leu	Met	Lys	Phe	Val	
		295					300					305					
	ctc	acc	cta	acc	atg	tcc	gta	atg	atc	att	atg	aca	gca	ggg	cta	ttg	1075
	Leu	Thr	Leu	Thr	Met	Ser	Val	Met	Ile	Ile	Met	Thr	Ala	Gly	Leu	Leu	
	310					315					320					325	
20	ctc	tta	gct	tta	cct	gga	gtc	cgt	gtc	ctt	tat	gaa	cac	gga	ctt	ttc	1123
	Leu	Leu	Ala	Leu	Pro	Gly	Val	Arg	Val	Leu	Tyr	Glu	His	Gly	Leu	Phe	
					330					335					340		
	cct	cag	agt	gct	gtc	tac	gct	att	gtt	cgt	gta	ttg	cga	ggg	tat	ggg	1171
	Pro	Gln	Ser	Ala	Val	Tyr	Ala	Ile	Val	Arg	Val	Leu	Arg	Gly	Tyr	Gly	
				345					350					355			
30	gcc	agt	att	atc	cct	atg	gcc	ttg	gct	cct	tta	gtc	tct	gtt	ctt	ttt	1219
	Ala	Ser	Ile	Ile	Pro	Met	Ala	Leu	Ala	Pro	Leu	Val	Ser	Val	Leu	Phe	
			360					365					370				
	tat	gca	cag	cgg	cag	tat	gct	gtt	ccg	ctc	ttt	ata	gga	atc	ggg	acg	1267
	Tyr	Ala	Gln	Arg	Gln	Tyr	Ala	Val	Pro	Leu	Phe	Ile	Gly	Ile	Gly	Thr	
		375					380					385					
	gct	ttg	gcc	aat	att	gtt	tta	agc	ttg	gtt	cta	ggg	cgt	tgg	gtt	tta	1315
	Ala	Leu	Ala	Asn	Ile	Val	Leu	Ser	Leu	Val	Leu	Gly	Arg	Trp	Val	Leu	
	390					395					400					405	
40	aaa	gac	gtc	tcg	ggc	att	tcc	tat	gct	aca	tcc	ata	act	gct	tgg	gtg	1363
	Lys	Asp	Val	Ser	Gly	Ile	Ser	Tyr	Ala	Thr	Ser	Ile	Thr	Ala	Trp	Val	
					410					415					420		
	cag	tta	tat	ttc	ctc	tgg	tat	tat	tct	tcg	aaa	aga	ctc	cct	atg	tac	1411
	Gln	Leu	Tyr	Phe	Leu	Trp	Tyr	Tyr	Ser	Ser	Lys	Arg	Leu	Pro	Met	Tyr	
				425					430					435			
	tct	aag	tta	ctt	tgg	gag	agc	atc	cgg	cgt	tcc	ata	aaa	gtt	atg	gga	1459
	Ser	Lys	Leu	Leu	Trp	Glu	Ser	Ile	Arg	Arg	Ser	Ile	Lys	Val	Met	Gly	
			440					445					450				
50	acc	act	atg	ctt	gct	tgt	atg	att	act	cta	ggc	tta	aat	atc	ctt	acg	1507
	Thr	Thr	Met	Leu	Ala	Cys	Met	Ile	Thr	Leu	Gly	Leu	Asn	Ile	Leu	Thr	
			455				460					465					
	caa	act	aca	tat	gta	att	ttc	tta	aac	ccc	ctc	aca	cca	ctt	gct	tgg	1555
	Gln	Thr	Thr	Tyr	Val	Ile	Phe	Leu	Asn	Pro	Leu	Thr	Pro	Leu	Ala	Trp	
	470					475					480					485	
60	ccc	tta	tcc	tcc	ata	acg	gct	caa	gca	att	gct	ttt	tta	tct	gag	agc	1603
	Pro	Leu	Ser	Ser	Ile	Thr	Ala	Gln	Ala	Ile	Ala	Phe	Leu	Ser	Glu	Ser	
					490					495					500		

32/83

	tac agc aac cac cat atc aaa gca tct gga tat tct gga aaa ata caa	2467
	Tyr Ser Asn His His Ile Lys Ala Ser Gly Tyr Ser Gly Lys Ile Gln	
	775 780 785	
	acg gaa ggc aaa tgt tat agt acg aca tta ggg gcg gct ctc tct tgc	2515
	Thr Glu Gly Lys Cys Tyr Ser Thr Thr Leu Gly Ala Ala Leu Ser Cys	
	790 795 800 805	
10	tct cta tct cta caa tgg cga tca cga cct ctc cac ttc act cct ttt	2563
	Ser Leu Ser Leu Gln Trp Arg Ser Arg Pro Leu His Phe Thr Pro Phe	
	810 815 820	
	atc caa gca att gcc gtt cgt tct aat caa act gcg ttt caa gaa agt	2611
	Ile Gln Ala Ile Ala Val Arg Ser Asn Gln Thr Ala Phe Gln Glu Ser	
	825 830 835	
20	gga gat aaa gct aga aaa ttt tct gtt cat aaa ccc tta tat aac ctg	2659
	Gly Asp Lys Ala Arg Lys Phe Ser Val His Lys Pro Leu Tyr Asn Leu	
	840 845 850	
	aca gtc cct ctg gga att cag agc gct tgg gaa tcc aag ttc cgt ctt	2707
	Thr Val Pro Leu Gly Ile Gln Ser Ala Trp Glu Ser Lys Phe Arg Leu	
	855 860 865	
	cct acc tat tgg aac ata gag ctt gct tat cag cct gtc ctc tac caa	2755
	Pro Thr Tyr Trp Asn Ile Glu Leu Ala Tyr Gln Pro Val Leu Tyr Gln	
	870 875 880 885	
30	caa aat cct gag atc aac gtg agt cta gaa tct agt gga tgc tca tgg	2803
	Gln Asn Pro Glu Ile Asn Val Ser Leu Glu Ser Ser Gly Ser Ser Trp	
	890 895 900	
	ctc cta tca gga acc acc ctt gct cgc aat gcc att gct ttt aaa gga	2851
	Leu Leu Ser Gly Thr Thr Leu Ala Arg Asn Ala Ile Ala Phe Lys Gly	
	905 910 915	
40	aga aac caa att ttt atc ttc cct aaa ctt tgc gtg ttc tta gac tat	2899
	Arg Asn Gln Ile Phe Ile Phe Pro Lys Leu Ser Val Phe Leu Asp Tyr	
	920 925 930	
	caa ggc tgc gta tcc tca tca acg acg aca cat tac ctt cac gca gga	2947
	Gln Gly Ser Val Ser Ser Ser Thr Thr Thr His Tyr Leu His Ala Gly	
	935 940 945	
	acg acc ttt aag ttt taaaagcatg ttatatagac aatgcaacct gtaaagacca	3002
	Thr Thr Phe Lys Phe	
	950	
50	aatagagagt agtgaacact ctctaccatc atgaatctta tgggagaagc taagggaat	3062
	ccacagatac gtttccccca taaaaattaa gaaccgata catcctcact agagattcga	3122
	aagaactact taaatcctaa gcattcga	3150
	<210> 20	
	<211> 9	
	<212> PRT	
	<213> Chlamydia pneumoniae	
60	<220>	

33/83

<221> SITE
 <222> (119)..(127)

<400> 20
 Ile Leu Phe Leu Asn Ser Phe Ala Ile
 1 5

10

<210> 21
 <211> 3200
 <212> DNA
 <213> Chlamydia pneumoniae

 <220>
 <221> CDS
 <222> (101)..(3100)

20

<400> 21
 tcctgaactc cactcgaaat tactgattag ccaaggtacg tggacgacgc aggccactcc 60
 tgtgacctac aatgctttag ggatcaaagt gaaaaatacc atgcaggtgt ttcctaaagt 120
 cactctctcc ttagattact ctgcggatat ttcttctctc acgctgagtc actacttaaa 180
 cgtggcgagt agaatgagat ttttaacaat aagtgaccaa aacagaaaga ttaaggaacc 240
 tctagtgtca aagactcctc ctaagttttt attctatctc gggaatttca cagcctgcat 300
 gttcgggatg actcctgcag tgtatagttt acaaacggac tcccttgaaa agtttgcttt 360
 agagagggat gaagagtttc gtacgagctt tctctcttta gactctctct ccactcttac 420
 aggattttct ccaataacta cgtttgttgg aaatagacat aattcctctc aagacattgt 480
 acttttctaac tacaagtcta ttgataacat ccttcttctt tggacatcgg ctgggggagc 540
 30 tgtgtcctgt aataatttct tattatcaaa tgttgaagac catgccttct tcagtaaaaa 600
 tctcgcgatt gggactggag gcgcgattgc ttgccaggga gcctgcacaa tcacgaagaa 660
 tagaggaccc cttatttttt tcagcaatcg aggtcttaac aatgcgagta caggaggaga 720
 aactcgtggg ggtgcgattg cctgtaatgg agacttcacg atttctcaaa atcaagggac 780
 tttctacttt gtcaacaatt ccgtcaacaa ctggggagga gccctctcca ccaatggaca 840
 ctgccgcatc caaagcaaca gggcacctct actctttttt aacaatacag ccctagtgg 900
 aggggggtgc cttcgtagtg aaaatacaac gatctctgat aacacgcgtc ctattttatt 960
 taagaacaac tgtgggaaca atggcggggc cattcaaaac agcgttactg ttgcgataaa 1020
 aaataactcc gggtcggtga ttttcaataa caacacagcg ttatctgggt cgataaattc 1080
 aggaaatggg tcaggagggg cgattttata aacaaacctt tccatagacg ataaccctgg 1140
 40 aactattctt ttcaataata actactgcat tcgcgatggc ggagctatct gtacacaatt 1200
 tttgacaatc aaaaatagtg gccacgtata tttcaccaac aatcaaggaa actggggagg 1260
 tgctcttatg tctctacagg acagcacctg cctactcttc gcggaacaag gaaatctcgc 1320
 atttcaaaat aatgagggtt tctcaccac atttggtaga tacaacgcca tacattgtac 1380
 accaaatagc aacttacaac ttggagctaa taaggggtat acgactgctt tttttgatcc 1440
 tatagaacac caacatccaa ctacaaatcc tctaattctt aatcccaatg cgaaccatca 1500
 gggaaacgat ttattttctt cagcctatat ccagaagct tctgactacg aaaataattt 1560
 cattagcagc tcgaaaaata cctctgaact tcgcaatggg gtctctctct tcgaggatcg 1620
 tgcgggatgg caattctata agttcactca aaaaggaggt atcctttaat tagggcatgc 1680
 ggcgagtatt gcaacaactg ccaactctga gactccatca actagtgtag gctcccaggt 1740
 50 catcattaat aaccttgcca ttaacctccc ctcgactctt gcaaaaggaa aagctcctac 1800
 cttgtggatc cgtcctctac aatctagtgc tcctttcaca gaggacaata accctacaat 1860
 tactttatca ggtcctctga cactcttaaa tgaggaaaac cgcgatccct acgacagtat 1920
 agatctctct gagcctttac aaaacattca tcttctttct ttatcggatg taacagcacg 1980
 tcatatcaat accgataact ttcacacctg aagcttaaat gcgactgagc attacgggta 2040
 tcaaggcatc tgggtctcct attgggtaga gacgataaca acaacaaata acgcttctat 2100
 agagacggca aacacctctc acagagctct gtagccaat tggactccct taggatataa 2160
 ggtcaactct gaataccaag gagatcttgc tacgactccc ctatggcaat cctttcatac 2220
 tatgttctct ctattaagaa gttataatcg aactgggtgat tctgatatcg agaggccttt 2280
 cttagaaatt caagggattg ccgacggcct ctttgttcat caaaatagca tccccggggc 2340
 60 tccaggattc cgtatccaat ctacagggtt ttccttaca gcactctccg aaacttcttt 2400
 acatcagaaa atctccttag gttttgcaca gttcttcacc cgcactaaag aaatcggatc 2460

36/83

	aaa gaa aat ggt cct gta tac ttt tta aat aac act gca act cgg gga	1027
	Lys Glu Asn Gly Pro Val Tyr Phe Leu Asn Asn Thr Ala Thr Arg Gly	
	295 300 305	
	ggg gct ctc ctc aac tta tca gca ggt tct gga aac gga agc ttc atc	1075
	Gly Ala Leu Leu Asn Leu Ser Ala Gly Ser Gly Asn Gly Ser Phe Ile	
	310 315 320 325	
10	tta tct gca gat aat gga gat att atc ttt aac aat aat acg gcc tcc	1123
	Leu Ser Ala Asp Asn Gly Asp Ile Ile Phe Asn Asn Asn Thr Ala Ser	
	330 335 340	
	aag cat gcc ctc aat cct cca tac aga aac gcc att cac tcg act cct	1171
	Lys His Ala Leu Asn Pro Pro Tyr Arg Asn Ala Ile His Ser Thr Pro	
	345 350 355	
20	aat atg aat ctg caa ata gga gcc cgt ccc ggc tat cga gtg ctg ttc	1219
	Asn Met Asn Leu Gln Ile Gly Ala Arg Pro Gly Tyr Arg Val Leu Phe	
	360 365 370	
	tat gat ccc ata gaa cat gag ctc cct tcc tcc ttc ccc ata ctc ttt	1267
	Tyr Asp Pro Ile Glu His Glu Leu Pro Ser Ser Phe Pro Ile Leu Phe	
	375 380 385	
	aat ttc gaa acc ggt cat aca ggt aca gtt tta ttt tca ggg gaa cat	1315
	Asn Phe Glu Thr Gly His Thr Gly Thr Val Leu Phe Ser Gly Glu His	
	390 395 400 405	
30	gta cac cag aac ttt acc gat gaa atg aat ttc ttt tcc tat tta agg	1363
	Val His Gln Asn Phe Thr Asp Glu Met Asn Phe Phe Ser Tyr Leu Arg	
	410 415 420	
	aac act tcg gaa cta cgt caa gga gtc ctt gct gtt gaa gat ggt gcg	1411
	Asn Thr Ser Glu Leu Arg Gln Gly Val Leu Ala Val Glu Asp Gly Ala	
	425 430 435	
40	ggg ctg gcc tgc tat aag ttc ttc caa cga gga ggc act cta ctt cta	1459
	Gly Leu Ala Cys Tyr Lys Phe Phe Gln Arg Gly Gly Thr Leu Leu Leu	
	440 445 450	
	ggt caa ggt gcg gtg atc acg aca gca gga acg att ccc aca cca tcc	1507
	Gly Gln Gly Ala Val Ile Thr Thr Ala Gly Thr Ile Pro Thr Pro Ser	
	455 460 465	
	tca aca cca acg aca gta gga agt act ata act tta aat cac att gcc	1555
	Ser Thr Pro Thr Thr Val Gly Ser Thr Ile Thr Leu Asn His Ile Ala	
	470 475 480 485	
50	att gac ctt cct tct att ctt tct ttt caa gct cag gct cca aaa att	1603
	Ile Asp Leu Pro Ser Ile Leu Ser Phe Gln Ala Gln Ala Pro Lys Ile	
	490 495 500	
	tgg att tac ccc aca aaa aca gga tct acc tat act gaa gat tcc aac	1651
	Trp Ile Tyr Pro Thr Lys Thr Gly Ser Thr Tyr Thr Glu Asp Ser Asn	
	505 510 515	
60	ccg aca atc aca atc tca gga act ctc acc tta cgc aac agc aac aac	1699
	Pro Thr Ile Thr Ile Ser Gly Thr Leu Thr Leu Arg Asn Ser Asn Asn	
	520 525 530	

37/83

		gaa	gat	ccc	tac	gat	agt	ctg	gat	ctc	tcg	cac	tct	ctt	gag	aaa	gtt	1747
		Glu	Asp	Pro	Tyr	Asp	Ser	Leu	Asp	Leu	Ser	His	Ser	Leu	Glu	Lys	Val	
		535						540					545					
		ccc	ctt	ctt	tat	att	gtc	gat	gtc	gct	gca	caa	aaa	att	aac	tct	tcg	1795
		Pro	Leu	Leu	Tyr	Ile	Val	Asp	Val	Ala	Ala	Gln	Lys	Ile	Asn	Ser	Ser	
		550					555					560					565	
10		caa	ctg	gat	cta	tcc	aca	tta	aat	tct	ggc	gaa	cac	tat	ggg	tat	caa	1843
		Gln	Leu	Asp	Leu	Ser	Thr	Leu	Asn	Ser	Gly	Glu	His	Tyr	Gly	Tyr	Gln	
						570					575					580		
		ggc	atc	tgg	tcg	acc	tat	tgg	gta	gaa	act	aca	aca	atc	acg	aac	cct	1891
		Gly	Ile	Trp	Ser	Thr	Tyr	Trp	Val	Glu	Thr	Thr	Thr	Ile	Thr	Asn	Pro	
						585				590					595			
20		aca	tct	cta	cta	ggc	gcg	aat	aca	aaa	cac	aag	ctg	ctc	tat	gca	aac	1939
		Thr	Ser	Leu	Leu	Gly	Ala	Asn	Thr	Lys	His	Lys	Leu	Leu	Tyr	Ala	Asn	
				600					605					610				
		tgg	tct	cct	cta	ggc	tac	cgt	cct	cat	ccc	gaa	cgt	cga	gga	gaa	ttc	1987
		Trp	Ser	Pro	Leu	Gly	Tyr	Arg	Pro	His	Pro	Glu	Arg	Arg	Gly	Glu	Phe	
				615				620					625					
		att	acg	aat	gcc	ttg	tgg	caa	tcg	gca	tat	acg	gct	ctt	gca	gga	ctc	2035
		Ile	Thr	Asn	Ala	Leu	Trp	Gln	Ser	Ala	Tyr	Thr	Ala	Leu	Ala	Gly	Leu	
		630					635					640					645	
30		cac	tcc	ctc	tcc	tcc	tgg	gat	gaa	gag	aag	ggg	cat	gca	gct	tcc	cta	2083
		His	Ser	Leu	Ser	Ser	Trp	Asp	Glu	Glu	Lys	Gly	His	Ala	Ala	Ser	Leu	
						650					655					660		
		caa	ggc	att	ggg	ctt	ctg	gtt	cat	caa	aaa	gac	aaa	aac	ggg	ttt	aag	2131
		Gln	Gly	Ile	Gly	Leu	Leu	Val	His	Gln	Lys	Asp	Lys	Asn	Gly	Phe	Lys	
					665					670					675			
40		gga	ttt	cgt	agt	cat	atg	aca	ggg	tat	agt	gct	acc	acc	gaa	gca	acc	2179
		Gly	Phe	Arg	Ser	His	Met	Thr	Gly	Tyr	Ser	Ala	Thr	Thr	Glu	Ala	Thr	
				680					685					690				
		tct	tct	caa	agt	ccg	aat	ttc	tct	tta	gga	ttt	gct	cag	ttc	ttc	tcc	2227
		Ser	Ser	Gln	Ser	Pro	Asn	Phe	Ser	Leu	Gly	Phe	Ala	Gln	Phe	Phe	Ser	
				695				700					705					
		aaa	gct	aaa	gaa	cat	gaa	tct	caa	aat	agc	acg	tcc	tct	cac	cac	tat	2275
		Lys	Ala	Lys	Glu	His	Glu	Ser	Gln	Asn	Ser	Thr	Ser	Ser	His	His	Tyr	
		710					715					720					725	
50		ttc	tct	gga	atg	tgc	ata	gca	aaa	tac	tct	ctt	caa	aga	gtg	ata	cgt	2323
		Phe	Ser	Gly	Met	Cys	Ile	Ala	Lys	Tyr	Ser	Leu	Gln	Arg	Val	Ile	Arg	
						730					735					740		
		cta	tct	gtg	tct	ctt	gct	tat	atg	ttt	acc	tcg	gaa	cat	acc	cat	aca	2371
		Leu	Ser	Val	Ser	Leu	Ala	Tyr	Met	Phe	Thr	Ser	Glu	His	Thr	His	Thr	
						745				750					755			
60		atg	tat	cag	ggg	ctc	ctg	gaa	ggg	aac	tct	cag	gga	tct	ttc	cac	aac	2419
		Met	Tyr	Gln	Gly	Leu	Leu	Glu	Gly	Asn	Ser	Gln	Gly	Ser	Phe	His	Asn	
				760					765						770			

38/83

cat acc tta gca ggg gct ctc tcc tgt gtt ttc tta cct caa cct cac 2467
 His Thr Leu Ala Gly Ala Leu Ser Cys Val Phe Leu Pro Gln Pro His
 775 780 785

ggc gag tcc ctg cag atc tat ccc ttt att act gcc tta gcc atc cga 2515
 Gly Glu Ser Leu Gln Ile Tyr Pro Phe Ile Thr Ala Leu Ala Ile Arg
 790 795 800 805

10 gga aat ctt gct gcg ttt caa gaa tct gga gac cat gct cgg gaa ttt 2563
 Gly Asn Leu Ala Ala Phe Gln Glu Ser Gly Asp His Ala Arg Glu Phe
 810 815 820

tcc cta cac cgc ccc cta acg gac gtc tcc ctc cct gta gga atc cgc 2611
 Ser Leu His Arg Pro Leu Thr Asp Val Ser Leu Pro Val Gly Ile Arg
 825 830 835

20 gct tct tgg aag aac cac cac cga gtt ccc cta gtc tgg ctc aca gaa 2659
 Ala Ser Trp Lys Asn His His Arg Val Pro Leu Val Trp Leu Thr Glu
 840 845 850

att tcc tat cgc tct act ctc tat agg caa gat cct gaa ctc cac tcg 2707
 Ile Ser Tyr Arg Ser Thr Leu Tyr Arg Gln Asp Pro Glu Leu His Ser
 855 860 865

aaa tta ctg att agc caa ggt acg tgg acg acg cag gcc act cct gtg 2755
 Lys Leu Leu Ile Ser Gln Gly Thr Trp Thr Thr Gln Ala Thr Pro Val
 870 875 880 885

30 acc tac aat gct tta ggg atc aaa gtg aaa aat acc atg cag gtg ttt 2803
 Thr Tyr Asn Ala Leu Gly Ile Lys Val Lys Asn Thr Met Gln Val Phe
 890 895 900

cct aaa gtc act ctc tcc tta gat tac tct gcg gat att tct tcc tcc 2851
 Pro Lys Val Thr Leu Ser Leu Asp Tyr Ser Ala Asp Ile Ser Ser Ser
 905 910 915

acg ctg agt cac tac tta aac gtg gcg agt aga atg aga ttt 2893
 40 Thr Leu Ser His Tyr Leu Asn Val Ala Ser Arg Met Arg Phe
 920 925 930

taacaataag tgaccaaacc agaaagatta aggaacctct agtgtcaaag actcctccta 2953
 agtttttatt ctatctcggg aatttcacag cctgcatgtt cgggatg 3000

<210> 24
 <211> 9
 <212> PRT
 50 <213> Chlamydia pneumoniae

<220>
 <221> SITE
 <222> (1)..(9)

<400> 24
 Met Leu Leu Pro Phe Thr Phe Val Leu
 1 5

40/83

	tcg atc aag ttt ttt ggg aac ctt gcc aac ttc ggc tct gca att agc	690
	Ser Ile Lys Phe Phe Gly Asn Leu Ala Asn Phe Gly Ser Ala Ile Ser	
	185 190 195	
	agt tct ccc acg gca gtc gtt aaa ttc atc aat aac acc gct acc atg	738
	Ser Ser Pro Thr Ala Val Val Lys Phe Ile Asn Asn Thr Ala Thr Met	
	200 205 210	
10	agc ttc tcc cat aac ttt act tcg tca gga ggc ggc gtg att tat gga	786
	Ser Phe Ser His Asn Phe Thr Ser Ser Gly Gly Gly Val Ile Tyr Gly	
	215 220 225	
	gga agc tct ctc ctt ttt gaa aac aat tct gga tgc atc atc ttc acc	834
	Gly Ser Ser Leu Leu Phe Glu Asn Asn Ser Gly Cys Ile Ile Phe Thr	
	230 235 240 245	
20	gcc aac tcc tgt gtg aac agc tta aaa ggc gtc acc cct tca tca gga	882
	Ala Asn Ser Cys Val Asn Ser Leu Lys Gly Val Thr Pro Ser Ser Gly	
	250 255 260	
	acc tat gct tta gga agt ggc gga gcc atc tgc atc cct acg gga act	930
	Thr Tyr Ala Leu Gly Ser Gly Gly Ala Ile Cys Ile Pro Thr Gly Thr	
	265 270 275	
	ttc gaa tta aaa aac aat cag ggg aag tgc acc ttc tct tat aat ggt	978
	Phe Glu Leu Lys Asn Asn Gln Gly Lys Cys Thr Phe Ser Tyr Asn Gly	
	280 285 290	
30	aca cca aat gat gcg ggt gcg atc tac gcc gaa acc tgc aac atc gta	1026
	Thr Pro Asn Asp Ala Gly Ala Ile Tyr Ala Glu Thr Cys Asn Ile Val	
	295 300 305	
	ggg aac cag ggt gcc ttg ctc cta gat agc aac act gca gcg aga aat	1074
	Gly Asn Gln Gly Ala Leu Leu Leu Asp Ser Asn Thr Ala Ala Arg Asn	
	310 315 320 325	
40	ggc gga gcc atc tgt gct aaa gtg ctc aat att caa gga cgc ggt cct	1122
	Gly Gly Ala Ile Cys Ala Lys Val Leu Asn Ile Gln Gly Arg Gly Pro	
	330 335 340	
	att gaa ttc tct aga aac cgc gcg gag aag ggt gga gct att ttc ata	1170
	Ile Glu Phe Ser Arg Asn Arg Ala Glu Lys Gly Gly Ala Ile Phe Ile	
	345 350 355	
	ggc ccc tct gtt gga gac cct gcg aag caa aca tcg aca ctt acg att	1218
	Gly Pro Ser Val Gly Asp Pro Ala Lys Gln Thr Ser Thr Leu Thr Ile	
	360 365 370	
50	ttg gct tcc gaa ggt gat att gcg ttc caa gga aac atg ctc aat aca	1266
	Leu Ala Ser Glu Gly Asp Ile Ala Phe Gln Gly Asn Met Leu Asn Thr	
	375 380 385	
	aaa cct gga atc cgc aat gcc atc act gta gaa gca ggg gga gag att	1314
	Lys Pro Gly Ile Arg Asn Ala Ile Thr Val Glu Ala Gly Gly Glu Ile	
	390 395 400 405	
60	gtg tct cta tct gca caa gga ggc tca cgt ctt gta ttt tat gat ccc	1362
	Val Ser Leu Ser Ala Gln Gly Gly Ser Arg Leu Val Phe Tyr Asp Pro	
	410 415 420	

41/83

10		att Ile	aca Thr	cat His	agc Ser 425	ctc Leu	cca Pro	acc Thr	aca Thr	agt Ser 430	ccg Pro	tct Ser	aat Asn	aaa Lys	gac Asp 435	att Ile	aca Thr	1410
		atc Ile	aac Asn	gct Ala 440	aat Asn	ggc Gly	gct Ala	tca Ser	gga Gly 445	tct Ser	gta Val	gtc Val	ttt Phe	aca Thr 450	agt Ser	aag Lys	gga Gly	1458
		ctc Leu	tcc Ser	tct Ser	aca Thr	gaa Glu	ctc Leu	ctg Leu	ttg Leu	cct Pro	gcc Ala	aac Asn	acg Thr 465	aca Thr	act Thr	ata Ile	ctt Leu	1506
		cta Leu 470	gga Gly	aca Thr	gtc Val	aag Lys	atc Ile 475	gct Ala	agt Ser	gga Gly	gaa Glu	ctg Leu 480	aag Lys	att Ile	act Thr	gac Asp	aat Asn 485	1554
20		gcg Ala	gtt Val	gtc Val	aat Asn 490	gtt Val	gct Ala	ggc Gly	ttc Phe	gct Ala	act Thr 495	cag Gln	ggc Gly	tca Ser	ggg Gly	cag Gln 500	ctt Leu	1602
		acc Thr	ctg Leu	ggc Gly	tct Ser 505	gga Gly	gga Gly	acc Thr	tta Leu	ggg Gly 510	ctg Leu	gca Ala	aca Thr	ccc Pro	acg Thr 515	gga Gly	gca Ala	1650
30		cct Pro	gcc Ala	gct Ala	gta Val 520	gac Asp	ttt Phe	acg Thr	att Ile 525	gga Gly	aag Lys	tta Leu	gca Ala	ttc Phe 530	gat Asp	cct Pro	ttt Phe	1698
		tcc Ser	ttc Phe 535	cta Leu	aaa Lys	aga Arg	gat Asp	ttt Phe 540	gtt Val	tca Ser	gca Ala	tca Ser	gta Val 545	aat Asn	gca Ala	ggc Gly	aca Thr	1746
		aaa Lys 550	aac Asn	gtc Val	act Thr	tta Leu	aca Thr 555	gga Gly	gct Ala	ctg Leu	gtt Val	ctt Leu 560	gat Asp	gaa Glu	cat His	gac Asp	gtt Val 565	1794
40		aca Thr	gat Asp	ctt Leu	tat Tyr 570	gat Asp	atg Met	gtg Val	tca Ser	tta Leu	caa Gln 575	tct Ser	cca Pro	gta Val	gca Ala	att Ile 580	cct Pro	1842
		atc Ile	gct Ala	gtt Val	ttc Phe 585	aaa Lys	gga Gly	gca Ala	acc Thr	gtt Val 590	act Thr	aag Lys	aca Thr	gga Gly	ttt Phe 595	cct Pro	gat Asp	1890
50		ggg Gly	gag Glu	att Ile 600	gcg Ala	act Thr	cca Pro	agc Ser	cac His 605	tac Tyr	ggc Gly	tac Tyr	caa Gln 610	gga Gly	aag Lys	tgg Trp	tcc Ser	1938
		tac Tyr	aca Thr 615	tgg Trp	tcc Ser	cgt Arg	ccc Pro	ctg Leu	tta Leu 620	att Ile	cca Pro	gct Ala	cct Pro 625	gat Asp	gga Gly	gga Gly	ttt Phe	1986
		cct Pro 630	gga Gly	ggg Gly	ccc Pro	tct Ser	cct Pro 635	agc Ser	gca Ala	aat Asn	act Thr	ctc Leu 640	tat Tyr	gct Ala	gta Val	tgg Trp	aat Asn 645	2034
60		tca Ser	gac Asp	act Thr	ctc Leu	gtg Val 650	cgt Arg	tct Ser	acc Thr	tat Tyr	atc Ile 655	tta Leu	gat Asp	ccc Pro	gag Glu	cgt Arg 660	tac Tyr	2082

42/83

10		gga Gly	gaa Glu	att Ile	gtc Val 665	agc Ser	aac Asn	agc Ser	tta Leu	tgg Trp 670	att Ile	tcc Ser	ttc Phe	tta Leu	gga Gly 675	aat Asn	cag Gln	2130
		gca Ala	ttc Phe	tct Ser 680	gat Asp	att Ile	ctc Leu	caa Gln	gat Asp 685	gtt Val	ctt Leu	ttg Leu	ata Ile	gat Asp 690	cat His	ccc Pro	ggg Gly	2178
		ttg Leu	tcc Ser 695	ata Ile	acc Thr	gcg Ala	aaa Lys	gct Ala 700	tta Leu	gga Gly	gcc Ala	tat Tyr	gtc Val 705	gaa Glu	cac His	aca Thr	cca Pro	2226
20		aga Arg 710	caa Gln	gga Gly	cat His	gag Glu	ggc Gly 715	ttt Phe	tca Ser	ggg Gly	cgc Arg	tat Tyr 720	gga Gly	ggc Gly	tac Tyr	caa Gln	gct Ala 725	2274
		gcg Ala	cta Leu	tct Ser	atg Met	aac Asn 730	tac Tyr	acg Thr	gac Asp	cac His	act Thr 735	acg Thr	tta Leu	gga Gly	ctt Leu	tct Ser 740	ttc Phe	2322
		ggg Gly	cag Gln	ctt Leu	tat Tyr 745	gga Gly	aaa Lys	act Thr	aac Asn	gcc Ala 750	aac Asn	ccc Pro	tac Tyr	gat Asp	tca Ser 755	cgt Arg	tgc Cys	2370
30		tca Ser	gaa Glu	caa Gln 760	atg Met	tat Tyr	tta Leu	ctc Leu	tcg Ser 765	ttc Phe	ttt Phe	ggg Gly	caa Gln	ttc Phe 770	cct Pro	atc Ile	gtg Val	2418
		act Thr	caa Gln 775	aag Lys	agc Ser	gag Glu	gcc Ala	tta Leu 780	att Ile	tcc Ser	tgg Trp	aaa Lys 785	gca Ala	gct Ala	tat Tyr	ggg Gly	tat Tyr	2466
		tcc Ser 790	aaa Lys	aat Asn	cac His	cta Leu	aat Asn 795	acc Thr	acc Thr	tac Tyr	ctc Leu	aga Arg 800	cct Pro	gac Asp	aaa Lys	gct Ala	cca Pro 805	2514
40		aaa Lys	tct Ser	caa Gln	ggg Gly 810	caa Gln	tgg Trp	cat His	aac Asn	aat Asn	agt Ser 815	tac Tyr	tat Tyr	gtt Val	ctt Leu	att Ile 820	tct Ser	2562
		gca Ala	gaa Glu	cat His	cct Pro 825	ttc Phe	cta Leu	aac Asn	tgg Trp	tgt Cys 830	ctt Leu	ctt Leu	aca Thr	aga Arg	cct Pro 835	ctg Leu	gct Ala	2610
		caa Gln	gct Ala	tgg Trp 840	gat Asp	ctt Leu	tca Ser	ggg Gly	ttt Phe 845	att Ile	tcc Ser	gca Ala	gaa Glu	ttc Phe 850	cta Leu	ggg Gly	ggg Gly	2658
50		tgg Trp	caa Gln 855	agt Ser	aag Lys	ttc Phe	aca Thr	gaa Glu 860	act Thr	gga Gly	gat Asp	ctg Leu	caa Gln 865	cgt Arg	agc Ser	ttt Phe	agt Ser	2706
		aga Arg 870	ggg Gly	aaa Lys	ggg Gly	tac Tyr	aat Asn 875	gtt Val	tcc Ser	cta Leu	ccg Pro	ata Ile 880	gga Gly	tgt Cys	tct Ser	tct Ser	caa Gln 885	2754
		tgg Trp	ttc Phe	aca Thr	cca Pro	ttt Phe 890	aag Lys	aag Lys	gct Ala	cct Pro	tct Ser 895	aca Thr	ctg Leu	acc Thr	atc Ile	aaa Lys 900	ctt Leu	2802

43 / 83

	gcc	tac	aag	cct	gat	atc	tat	cgt	gtc	aac	cct	cac	aat	att	gtg	act	2850
	Ala	Tyr	Lys	Pro	Asp	Ile	Tyr	Arg	Val	Asn	Pro	His	Asn	Ile	Val	Thr	
				905					910					915			
	gtc	gtc	tca	aac	caa	gag	agc	act	tcg	atc	tca	gga	gca	aat	cta	cgc	2898
	Val	Val	Ser	Asn	Gln	Glu	Ser	Thr	Ser	Ile	Ser	Gly	Ala	Asn	Leu	Arg	
			920					925					930				
10	cgc	cac	ggt	ttg	ttt	gta	caa	atc	cat	gat	gta	gta	gat	ctc	acc	gag	2946
	Arg	His	Gly	Leu	Phe	Val	Gln	Ile	His	Asp	Val	Val	Asp	Leu	Thr	Glu	
		935					940					945					
	gac	act	cag	gcc	ttt	cta	aac	tat	acc	ttt	gac	ggg	aaa	aat	gga	ttt	2994
	Asp	Thr	Gln	Ala	Phe	Leu	Asn	Tyr	Thr	Phe	Asp	Gly	Lys	Asn	Gly	Phe	
	950					955					960					965	
	aca	aac	cac	cga	gtg	tct	aca	gga	cta	aaa	tcc	aca	ttt	taaaactcta			3043
20	Thr	Asn	His	Arg	Val	Ser	Thr	Gly	Leu	Lys	Ser	Thr	Phe				
					970					975							
	agctctgctt	agagtttttct	gtagcccccg	tcgtcttaga	atcctctatc	catcatcgaa	3103										
	gaacttagca	atgaaggcca	agattctcac	tctatgagaa	cccccc		3150										
	<210>	26															
	<211>	9															
	<212>	PRT															
30	<213>	Chlamydia pneumoniae															
	<220>																
	<221>	SITE															
	<222>	(936)..(944)															
	<400>	26															
	Gly	Leu	Phe	Val	Gln	Ile	His	Asp	Val								
	1				5												
40	<210>	27															
	<211>	841															
	<212>	PRT															
	<213>	Chlamydia pneumoniae															
	<400>	27															
	Met	Lys	Ile	Pro	Leu	Arg	Phe	Leu	Leu	Ile	Ser	Leu	Val	Pro	Thr	Leu	
	1				5					10					15		
50	Ser	Met	Ser	Asn	Leu	Leu	Gly	Ala	Ala	Thr	Thr	Glu	Glu	Leu	Ser	Ala	
				20					25					30			
	Ser	Asn	Ser	Phe	Asp	Gly	Thr	Thr	Ser	Thr	Thr	Ser	Phe	Ser	Ser	Lys	
			35					40					45				
	Thr	Ser	Ser	Ala	Thr	Asp	Gly	Thr	Asn	Tyr	Val	Phe	Lys	Asp	Ser	Val	
		50					55					60					
60	Val	Ile	Glu	Asn	Val	Pro	Lys	Thr	Gly	Glu	Thr	Gln	Ser				

44 / 83

	Phe	Lys	Asn	Asp	Ala	Ala	Gly	Asp	Leu	Asn	Phe	Leu	Gly	Gly	Gly	
					85				90					95		
	Phe	Ser	Phe	Thr	Phe	Ser	Asn	Ile	Asp	Ala	Thr	Thr	Ala	Ser	Gly	Ala
				100					105					110		
	Ala	Ile	Gly	Ser	Glu	Ala	Ala	Asn	Lys	Thr	Val	Thr	Leu	Ser	Gly	Phe
			115					120					125			
10	Ser	Ala	Leu	Ser	Phe	Leu	Lys	Ser	Pro	Ala	Ser	Thr	Val	Thr	Asn	Gly
		130					135					140				
	Leu	Gly	Ala	Ile	Asn	Val	Lys	Gly	Asn	Leu	Ser	Leu	Leu	Asp	Asn	Asp
	145					150					155					160
	Lys	Val	Leu	Ile	Gln	Asp	Asn	Phe	Ser	Thr	Gly	Asp	Gly	Gly	Ala	Ile
					165					170					175	
20	Asn	Cys	Ala	Gly	Ser	Leu	Lys	Ile	Ala	Asn	Asn	Lys	Ser	Leu	Ser	Phe
				180					185					190		
	Ile	Gly	Asn	Ser	Ser	Ser	Thr	Arg	Gly	Gly	Ala	Ile	His	Thr	Lys	Asn
			195					200					205			
	Leu	Thr	Leu	Ser	Ser	Gly	Gly	Glu	Thr	Leu	Phe	Gln	Gly	Asn	Thr	Ala
		210					215					220				
30	Pro	Thr	Ala	Ala	Gly	Lys	Gly	Gly	Ala	Ile	Ala	Ile	Ala	Asp	Ser	Gly
	225					230					235					240
	Thr	Leu	Ser	Ile	Ser	Gly	Asp	Ser	Gly	Asp	Ile	Ile	Phe	Glu	Gly	Asn
					245					250					255	
	Thr	Ile	Gly	Ala	Thr	Gly	Thr	Val	Ser	His	Ser	Ala	Ile	Asp	Leu	Gly
				260					265					270		
	Thr	Ser	Ala	Lys	Ile	Thr	Ala	Leu	Arg	Ala	Ala	Gln	Gly	His	Thr	Ile
			275					280					285			
40	Tyr	Phe	Tyr	Asp	Pro	Ile	Thr	Val	Thr	Gly	Ser	Thr	Ser	Val	Ala	Asp
		290					295					300				
	Ala	Leu	Asn	Ile	Asn	Ser	Pro	Asp	Thr	Gly	Asp	Asn	Lys	Glu	Tyr	Thr
	305					310					315					320
	Gly	Thr	Ile	Val	Phe	Ser	Gly	Glu	Lys	Leu	Thr	Glu	Ala	Glu	Ala	Lys
					325					330					335	
50	Asp	Glu	Lys	Asn	Arg	Thr	Ser	Lys	Leu	Leu	Gln	Asn	Val	Ala	Phe	Lys
				340					345					350		
	Asn	Gly	Thr	Val	Val	Leu	Lys	Gly	Asp	Val	Val	Leu	Ser	Ala	Asn	Gly
			355					360					365			
	Phe	Ser	Gln	Asp	Ala	Asn	Ser	Lys	Leu	Ile	Met	Asp	Leu	Gly	Thr	Ser
		370					375					380				
60	Leu	Val	Ala	Asn	Thr	Glu	Ser	Ile	Glu	Leu	Thr	Asn	Leu	Glu	Ile	Asn
	385					390					395					400

45 / 83

10	Ile	Asp	Ser	Leu	Arg	Asn	Gly	Lys	Lys	Ile	Lys	Leu	Ser	Ala	Ala	Thr	
					405					410					415		
	Ala	Gln	Lys	Asp	Ile	Arg	Ile	Asp	Arg	Pro	Val	Val	Leu	Ala	Ile	Ser	
					420					425					430		
	Asp	Glu	Ser	Phe	Tyr	Gln	Asn	Gly	Phe	Leu	Asn	Glu	Asp	His	Ser	Tyr	
				435					440					445			
20	Asp	Gly	Ile	Leu	Glu	Leu	Asp	Ala	Gly	Lys	Asp	Ile	Val	Ile	Ser	Ala	
					450					455					460		
	Asp	Ser	Arg	Ser	Ile	Asp	Ala	Val	Gln	Ser	Pro	Tyr	Gly	Tyr	Gln	Gly	
					465					470					475		
	Lys	Trp	Thr	Ile	Asn	Trp	Ser	Thr	Asp	Asp	Lys	Lys	Ala	Thr	Val	Ser	
				485					490					495			
30	Trp	Ala	Lys	Gln	Ser	Phe	Asn	Pro	Thr	Ala	Glu	Gln	Glu	Ala	Pro	Leu	
					500					505					510		
	Val	Pro	Asn	Leu	Leu	Trp	Gly	Ser	Phe	Ile	Asp	Val	Arg	Ser	Phe	Gln	
					515					520					525		
	Asn	Phe	Ile	Glu	Leu	Gly	Thr	Glu	Gly	Ala	Pro	Tyr	Glu	Lys	Arg	Phe	
				530					535					540			
40	Trp	Val	Ala	Gly	Ile	Ser	Asn	Val	Leu	His	Arg	Ser	Gly	Arg	Glu	Asn	
					545					550					555		
	Gln	Arg	Lys	Phe	Arg	His	Val	Ser	Gly	Gly	Ala	Val	Val	Gly	Ala	Ser	
					565					570					575		
	Thr	Arg	Met	Pro	Gly	Gly	Asp	Thr	Leu	Ser	Leu	Gly	Phe	Ala	Gln	Leu	
				580					585					590			
50	Phe	Ala	Arg	Asp	Lys	Asp	Tyr	Phe	Met	Asn	Thr	Asn	Phe	Ala	Lys	Thr	
					595					600					605		
	Tyr	Ala	Gly	Ser	Leu	Arg	Leu	Gln	His	Asp	Ala	Ser	Leu	Tyr	Ser	Val	
					610					615					620		
	Val	Ser	Ile	Leu	Leu	Gly	Glu	Gly	Gly	Leu	Arg	Glu	Ile	Leu	Leu	Pro	
				625					630					635			
60	Tyr	Val	Ser	Lys	Thr	Leu	Pro	Cys	Ser	Phe	Tyr	Gly	Gln	Leu	Ser	Tyr	
					645					650					655		
	Gly	His	Thr	Asp	His	Arg	Met	Lys	Thr	Glu	Ser	Leu	Pro	Pro	Pro	Pro	
					660					665					670		
	Pro	Thr	Leu	Ser	Thr	Asp	His	Thr	Ser	Trp	Gly	Gly	Tyr	Val	Trp	Ala	
				675					680					685			
70	Gly	Glu	Leu	Gly	Thr	Arg	Val	Ala	Val	Glu	Asn	Thr	Ser	Gly	Arg	Gly	
					690					695					700		
	Phe	Phe	Gln	Glu	Tyr	Thr	Pro	Phe	Val	Lys	Val	Gln	Ala	Val	Tyr	Ala	
				705					710					715			
				720					725					730			

46/83

	Arg	Gln	Asp	Ser	Phe	Val	Glu	Leu	Gly	Ala	Ile	Ser	Arg	Asp	Phe	Ser
					725					730					735	
	Asp	Ser	His	Leu	Tyr	Asn	Leu	Ala	Ile	Pro	Leu	Gly	Ile	Lys	Leu	Glu
				740					745					750		
10	Lys	Arg	Phe	Ala	Glu	Gln	Tyr	Tyr	His	Val	Val	Ala	Met	Tyr	Ser	Pro
			755					760					765			
	Asp	Val	Cys	Arg	Ser	Asn	Pro	Lys	Cys	Thr	Thr	Thr	Leu	Leu	Ser	Asn
		770					775					780				
	Gln	Gly	Ser	Trp	Lys	Thr	Lys	Gly	Ser	Asn	Leu	Ala	Arg	Gln	Ala	Gly
	785					790					795					800
	Ile	Val	Gln	Ala	Ser	Gly	Phe	Arg	Ser	Leu	Gly	Ala	Ala	Ala	Glu	Leu
20					805					810					815	
	Phe	Gly	Asn	Phe	Gly	Phe	Glu	Trp	Arg	Gly	Ser	Ser	Arg	Ser	Tyr	Asn
				820					825					830		
	Val	Asp	Ala	Gly	Ser	Lys	Ile	Lys	Phe							
			835					840								
	<210>	28														
30	<211>	841														
	<212>	PRT														
	<213>	Chlamydia pneumoniae														
	<400>	28														
	Met	Lys	Ile	Pro	Leu	Arg	Phe	Leu	Leu	Ile	Ser	Leu	Val	Pro	Thr	Leu
	1				5					10					15	
	Ser	Met	Ser	Asn	Leu	Leu	Gly	Ala	Ala	Thr	Thr	Glu	Glu	Leu	Ser	Ala
				20					25					30		
40	Ser	Asn	Ser	Phe	Asp	Gly	Thr	Thr	Ser	Thr	Thr	Ser	Phe	Ser	Ser	Lys
			35					40					45			
	Thr	Ser	Ser	Ala	Thr	Asp	Gly	Thr	Asn	Tyr	Val	Phe	Lys	Asp	Ser	Val
		50					55					60				
	Val	Ile	Glu	Asn	Val	Pro	Lys	Thr	Gly	Glu	Thr	Gln	Ser	Thr	Ser	Cys
	65					70					75					80
	Phe	Lys	Asn	Asp	Ala	Ala	Ala	Gly	Asp	Leu	Asn	Phe	Leu	Gly	Gly	Gly
50					85					90					95	
	Phe	Ser	Phe	Thr	Phe	Ser	Asn	Ile	Asp	Ala	Thr	Thr	Ala	Ser	Gly	Ala
				100					105					110		
	Ala	Ile	Gly	Ser	Glu	Ala	Ala	Asn	Lys	Thr	Val	Thr	Leu	Ser	Gly	Phe
			115					120					125			
	Ser	Ala	Leu	Ser	Phe	Leu	Lys	Ser	Pro	Ala	Ser	Thr	Val	Thr	Asn	Gly
60		130					135					140				

47/83

10	Leu 145	Gly	Ala	Ile	Asn	Val 150	Lys	Gly	Asn	Leu	Ser 155	Leu	Leu	Asp	Asn	Asp 160
	Lys	Val	Leu	Ile	Gln 165	Asp	Asn	Phe	Ser	Thr 170	Gly	Asp	Gly	Gly	Ala 175	Ile
	Asn	Cys	Ala	Gly 180	Ser	Leu	Lys	Ile	Ala 185	Asn	Asn	Lys	Ser	Leu 190	Ser	Phe
	Ile	Gly	Asn 195	Ser	Ser	Ser	Thr	Arg 200	Gly	Gly	Ala	Ile	His 205	Thr	Lys	Asn
	Leu	Thr 210	Leu	Ser	Ser	Gly	Gly 215	Glu	Thr	Leu	Phe	Gln 220	Gly	Asn	Thr	Ala
20	Pro 225	Thr	Ala	Ala	Gly	Lys 230	Gly	Gly	Ala	Ile	Ala 235	Ile	Ala	Asp	Ser	Gly 240
	Thr	Leu	Ser	Ile	Ser 245	Gly	Asp	Ser	Gly	Asp 250	Ile	Ile	Phe	Glu	Gly	Asn 255
	Thr	Ile	Gly	Ala 260	Thr	Gly	Thr	Val	Ser 265	His	Ser	Ala	Ile	Asp 270	Leu	Gly
	Thr	Ser	Ala 275	Lys	Ile	Thr	Ala	Leu	Arg 280	Ala	Ala	Gln	Gly 285	His	Thr	Ile
30	Tyr 290	Phe	Tyr	Asp	Pro	Ile	Thr 295	Val	Thr	Gly	Ser 300	Thr	Ser	Val	Ala	Asp
	Ala 305	Leu	Asn	Ile	Asn	Ser 310	Pro	Asp	Thr	Gly	Asp 315	Asn	Lys	Glu	Tyr	Thr 320
	Gly	Thr	Ile	Val	Phe 325	Ser	Gly	Glu	Lys	Leu 330	Thr	Glu	Ala	Glu	Ala 335	Lys
40	Asp	Glu	Lys	Asn 340	Arg	Thr	Ser	Lys	Leu 345	Leu	Gln	Asn	Val	Ala 350	Phe	Lys
	Asn	Gly	Thr 355	Val	Val	Leu	Lys	Gly	Asp 360	Val	Val	Leu	Ser 365	Ala	Asn	Gly
	Phe 370	Ser	Gln	Asp	Ala	Asn 375	Ser	Lys	Leu	Ile	Met 380	Asp	Leu	Gly	Thr	Ser
50	Leu 385	Val	Ala	Asn	Thr	Glu 390	Ser	Ile	Glu	Leu	Thr 395	Asn	Leu	Glu	Ile	Asn 400
	Ile	Asp	Ser	Leu	Arg 405	Asn	Gly	Lys	Lys	Ile 410	Lys	Leu	Ser	Ala 415	Ala	Thr
	Ala	Gln	Lys	Asp 420	Ile	Arg	Ile	Asp	Arg 425	Pro	Val	Val	Leu	Ala 430	Ile	Ser
	Asp	Glu	Ser 435	Phe	Tyr	Gln	Asn	Gly 440	Phe	Leu	Asn	Glu	Asp 445	His	Ser	Tyr
60	Asp 450	Gly	Ile	Leu	Glu	Leu	Asp 455	Ala	Gly	Lys	Asp 460	Ile	Val	Ile	Ser	Ala

48 / 83

10	Asp 465	Ser	Arg	Ser	Ile	Asp 470	Ala	Val	Gln	Ser	Pro 475	Tyr	Gly	Tyr	Gln	Gly 480
	Lys	Trp	Thr	Ile	Asn 485	Trp	Ser	Thr	Asp	Asp 490	Lys	Lys	Ala	Thr	Val	Ser 495
	Trp	Ala	Lys	Gln 500	Ser	Phe	Asn	Pro	Thr 505	Ala	Glu	Gln	Glu	Ala 510	Pro	Leu
	Val	Pro	Asn 515	Leu	Leu	Trp	Gly	Ser	Phe 520	Ile	Asp	Val	Arg 525	Ser	Phe	Gln
	Asn 530	Phe	Ile	Glu	Leu	Gly	Thr 535	Glu	Gly	Ala	Pro	Tyr 540	Glu	Lys	Arg	Phe
20	Trp 545	Val	Ala	Gly	Ile	Ser 550	Asn	Val	Leu	His	Arg 555	Ser	Gly	Arg	Glu	Asn 560
	Gln	Arg	Lys	Phe	Arg 565	His	Val	Ser	Gly	Gly 570	Ala	Val	Val	Gly	Ala 575	Ser
	Thr	Arg	Met	Pro 580	Gly	Gly	Asp	Thr	Leu 585	Ser	Leu	Gly	Phe	Ala 590	Gln	Leu
30	Phe	Ala	Arg 595	Asp	Lys	Asp	Tyr	Phe 600	Met	Asn	Thr	Asn	Phe 605	Ala	Lys	Thr
	Tyr	Ala 610	Gly	Ser	Leu	Arg 615	Leu	Gln	His	Asp	Ala 620	Ser	Leu	Tyr	Ser	Val
	Val 625	Ser	Ile	Leu	Leu	Gly 630	Glu	Gly	Gly	Leu	Arg 635	Glu	Ile	Leu	Leu	Pro 640
40	Tyr	Val	Ser	Lys	Thr 645	Leu	Pro	Cys	Ser	Phe 650	Tyr	Gly	Gln	Leu	Ser 655	Tyr
	Gly	His	Thr	Asp 660	His	Arg	Met	Lys	Thr 665	Glu	Ser	Leu	Pro	Pro 670	Pro	Pro
	Pro	Thr	Leu 675	Ser	Thr	Asp	His	Thr 680	Ser	Trp	Gly	Gly	Tyr 685	Val	Trp	Ala
50	Gly 690	Glu	Leu	Gly	Thr	Arg 695	Val	Ala	Val	Glu	Asn 700	Thr	Ser	Gly	Arg	Gly
	Phe 705	Phe	Gln	Glu	Tyr	Thr 710	Pro	Phe	Val	Lys	Val 715	Gln	Ala	Val	Tyr	Ala 720
	Arg	Gln	Asp	Ser	Phe 725	Val	Glu	Leu	Gly	Ala 730	Ile	Ser	Arg	Asp	Phe 735	Ser
	Asp	Ser	His	Leu 740	Tyr	Asn	Leu	Ala	Ile 745	Pro	Leu	Gly	Ile	Lys 750	Leu	Glu
	Lys	Arg	Phe 755	Ala	Glu	Gln	Tyr	Tyr 760	His	Val	Val	Ala	Met 765	Tyr	Ser	Pro
60	Asp 770	Val	Cys	Arg	Ser	Asn 775	Pro	Lys	Cys	Thr	Thr 780	Thr	Leu	Leu	Ser	Asn

52/83

Gly Gly Thr Lys Gly Phe Phe Asn Pro Thr Pro Tyr Thr Lys Asn Ala
 260 265 270
 Leu Glu Ala Lys Lys Ala Glu Gly Ala Ala Ala Asp Lys Glu Lys Lys
 275 280 285
 10 Glu Asp Ala Asp Ser Gln Gly Glu Ser Lys Asn Ala Glu Thr Ser Asp
 290 295 300
 Lys Asp Ser Ser Asp Lys Asp Ala Pro Glu Gly Ser Asn Glu Ile Glu
 305 310 315 320
 Gly Ala

 <210> 32
 <211> 226
 20 <212> PRT
 <213> Chlamydia pneumoniae

 <400> 32
 Met Thr Ile Arg Val Arg Asn Leu Ala Tyr Ser Val Asn Lys Lys Lys
 1 5 10 15
 Ile Leu Asp Gly Val Thr Phe Ser Leu Glu Arg Gly His Ile Thr Leu
 20 25 30
 30 Phe Val Gly Lys Ser Gly Ser Gly Lys Thr Met Ile Leu Arg Ala Leu
 35 40 45
 Ala Gly Leu Val Gln Pro Thr Gln Gly Asp Ile Trp Ile Glu Gly Glu
 50 55 60
 Ala Pro Ala Leu Val Phe Gln Gln Pro Glu Leu Phe Ser His Met Thr
 65 70 75 80
 Val Leu Gly Asn Cys Thr His Pro Gln Ile His Ile Lys Gly Arg Ser
 40 85 90 95
 Thr Glu Glu Ala Arg Glu Lys Ala Phe Glu Leu Leu His Leu Leu Asp
 100 105 110
 Ile Glu Glu Val Ala Lys Asn Tyr Pro Asp Gln Leu Ser Gly Gly Gln
 115 120 125
 Lys Gln Arg Val Ala Ile Val Arg Ser Leu Cys Met Asp Lys His Thr
 130 135 140
 50 Leu Leu Phe Asp Glu Pro Thr Ser Ala Leu Asp Pro Phe Ala Thr Ala
 145 150 155 160
 Ser Phe Arg His Leu Leu Glu Thr Leu Arg Asp Gln Glu Leu Thr Val
 165 170 175
 Gly Leu Thr Thr His Asp Met Gln Phe Val His Ser Cys Leu Asp Arg
 180 185 190
 60 Ile Tyr Leu Ile Asp Gln Gly Thr Val Ala Gly Val Tyr Asp Lys Arg
 195 200 205

55/83

Lys Lys Gln Ser Gly Tyr Arg Ser Pro Pro His Trp Leu Glu Thr Asp
 60 65 70 75
 Gly Ser Thr Ile Gln Leu His Leu Arg Glu Glu Leu Leu Gly Trp Asp
 80 85 90
 10 Leu Phe His Ala Leu Leu Val Cys Ser Ala Asn Asp Ala Ala Asn Val
 95 100 105
 Leu Ala Met Ala Cys Cys Gly Ser Val Glu Lys Phe Met Asp Lys Leu
 110 115 120
 Asn Phe Phe Leu Lys Glu Glu Ile Gly Cys Thr His Thr His Phe Asn
 125 130 135
 20 Asn Pro His Gly Leu His His Pro Asn His Tyr Thr Thr Thr Arg Asp
 140 145 150 155
 Leu Ile Ser Ile Met Arg Cys Ala Leu Lys Glu Pro Pro Phe Arg Gly
 160 165 170
 Val Ile Ser Thr Thr Ser Tyr Lys Ile Gly Ala Thr Asn Leu His Gly
 175 180 185
 Glu Arg Ile Leu Ser Pro Thr Asn Lys Leu Leu Leu Pro Gly Ser Thr
 190 195 200
 30 Tyr His Tyr Pro Pro Ala Leu Gly Gly Lys Thr Gly Thr Thr Lys Thr
 205 210 215
 Ala Gly Lys Asn Leu Ile Met Ala Ala Glu Lys Asn Asn Arg Leu Leu
 220 225 230 235
 Val Thr Ile Ala Thr Gly Tyr Ser Gly Pro
 240 245
 40 <210> 35
 <211> 645
 <212> PRT
 <213> Chlamydia pneumoniae
 <400> 35
 Met Ala Ser Asn Pro Ile Leu Gln Ile Glu Asp Leu Ser Ile Thr Leu
 1 5 10 15
 50 Ala Lys Gln Arg Gln Gln Tyr Pro Ile Val Gln Ser Leu Ser Phe Thr
 20 25 30
 Ile Asn Glu Gly Gln Thr Leu Ala Ile Ile Gly Glu Ser Gly Ser Gly
 35 40 45
 Lys Ser Val Ser Ala His Ala Ile Leu Arg Leu Leu Pro Cys Pro Pro
 50 55 60
 60 Phe Ser Val Ser Gly Gln Val Asn Phe Gln Gly His Asn Leu Leu Thr
 65 70 75 80

60/83

	Lys	Ser	Glu	Glu	Glu	Lys	Val	Lys	Glu	Arg	Leu	Thr	Lys	Arg	Glu	Leu	
				20					25					30			
	Thr	Cys	Glu	Asp	Leu	Lys	Asp	Asn	Gly	Tyr	Thr	Val	Asn	Phe	Glu	Asp	
			35					40					45				
10	Ile	Ser	Ile	Leu	Glu	Leu	Leu	Gln	Phe	Val	Ser	Lys	Ile	Ser	Gly	Thr	
		50					55					60					
	Asn	Phe	Val	Phe	Asp	Ser	Asn	Asp	Leu	Gln	Phe	Asn	Val	Thr	Ile	Val	
	65					70					75					80	
	Ser	His	Asp	Pro	Thr	Ser	Val	Asp	Asp	Leu	Ser	Thr	Ile	Leu	Leu	Gln	
					85					90					95		
	Val	Leu	Lys	Met	His	Asp	Leu	Lys	Val	Val	Glu	Gln	Gly	Asn	Asn	Val	
20				100					105					110			
	Leu	Ile	Tyr	Arg	Asn	Pro	His	Leu	Ser	Lys	Leu	Ser	Thr	Val	Val	Thr	
			115					120					125				
	Asp	Ser	Ser	Leu	Lys	Glu	Thr	Cys	Glu	Ala	Val	Val	Val	Thr	Arg	Val	
		130					135					140					
	Phe	Arg	Leu	Tyr	Arg	Arg	Gln	Pro	Ser	Ala	Ala	Val	Asn	Ile	Ile	Gln	
	145					150					155					160	
30	Pro	Leu	Leu	Ser	His	Asp	Ala	Ile	Val	Ser	Ala	Ser	Glu	Ala	Thr	Arg	
					165					170					175		
	His	Val	Ile	Ile	Ser	Asp	Ile	Ala	Gly	Asn	Val	Asp	Lys	Val	Ser	Asp	
				180					185					190			
	Leu	Leu	Ala	Ala	Leu	Asp	Cys	Pro	Gly	Thr	Ser	Val	Asp	Met	Thr	Glu	
			195				200						205				
40	Tyr	Glu	Val	Lys	Tyr	Ala	Asn	Pro	Ala	Ala	Leu	Val	Ser	Tyr	Cys	Gln	
		210					215					220					
	Asp	Val	Leu	Gly	Thr	Leu	Ala	Glu	Asp	Asp	Ala	Phe	Gln	Met	Phe	Ile	
	225					230					235					240	
	Gln	Pro	Gly	Thr	Asn	Lys	Ile	Phe	Val	Val	Ser	Ser	Pro	Arg	Leu	Ala	
					245					250					255		
	Asn	Lys	Ala	Glu	Gln	Leu	Leu	Lys	Ser	Leu	Asp	Val	Pro	Glu	Met	Ala	
50				260					265					270			
	His	Thr	Leu	Asp	Asp	Pro	Ala	Ser	Thr	Ala	Leu	Ala	Leu	Gly	Gly	Thr	
			275					280					285				
	Gly	Thr	Thr	Ser	Pro	Lys	Ser	Leu	Arg	Phe	Phe	Met	Tyr	Lys	Leu	Lys	
		290					295					300					
	Tyr	Gln	Asn	Gly	Glu	Val	Ile	Ala	Asn	Ala	Leu	Gln	Asp	Ile	Gly	Tyr	
	305					310					315					320	
60	Asn	Leu	Tyr	Val	Thr	Thr	Ala	Met	Asp	Glu	Asp	Phe	Ile	Asn	Thr	Leu	
					325					330					335		

62/83

Tyr Arg Tyr Asn Trp Glu Ala Asp Glu Gly Ser Met Gln Val Ala Pro
660 665 670

Arg His Ala Pro Glu Cys Gln Gly Pro Pro Ser Leu Gln Ala Glu Ser
675 680 685

10 Asp Phe Lys Ile Ile Glu Ile Glu Ala Gln
690 695

<210> 38

<211> 547

<212> PRT

<213> Chlamydia pneumoniae

<400> 38

Met Ser Arg Lys Asp Asn Glu Val Ser Leu Ala Arg Ser Ile Phe Asn
20 1 5 10 15

Ile Leu Ser Gly Thr Phe Cys Ser Arg Ile Thr Gly Ile Phe Arg Glu
20 25 30

Ile Ala Met Ala Thr Tyr Phe Gly Ala Asp Pro Ile Val Ala Ala Phe
35 40 45

Trp Leu Gly Phe Arg Thr Val Phe Phe Leu Arg Lys Ile Leu Gly Gly
50 55 60

30 Leu Ile Leu Glu Gln Ala Phe Ile Pro His Phe Glu Phe Leu Arg Ala
65 70 75 80

Gln Ser Leu Asp Arg Ala Ala Phe Phe Phe Arg Arg Phe Ser Arg Leu
85 90 95

Ile Lys Gly Ser Thr Ile Ile Phe Thr Leu Leu Ile Glu Ala Val Leu
100 105 110

40 Trp Val Phe Phe Asn Asn Val Glu Glu Gly Thr Tyr Asp Met Ile Leu
115 120 125

Leu Thr Met Ile Leu Leu Pro Cys Gly Ile Phe Leu Met Met Tyr Asn
130 135 140

Val Asn Gly Ala Leu Leu His Cys Gly Asn Lys Phe Phe Gly Val Gly
145 150 155 160

Leu Ala Pro Val Val Val Asn Ile Ile Trp Ile Phe Phe Val Ile Ala
50 165 170 175

Ala Arg His Ser Asp Pro Arg Glu Arg Ile Ile Gly Leu Ser Val Ala
180 185 190

Leu Val Ile Gly Phe Phe Phe Glu Trp Leu Ile Thr Val Pro Gly Val
195 200 205

Trp Lys Phe Leu Leu Glu Ala Lys Ser Pro Pro Gln Glu His Asp Ser
210 215 220

60

67/83

	Gly	Ile	Ala	Ala	Phe	Asp	Asn	Asn	Thr	Ala	Ala	Arg	Asp	Gly	Gly	Ala	
	305					310					315					320	
	Ile	Cys	Thr	Gln	Ser	Leu	Thr	Ile	Gln	Asp	Ser	Gly	Pro	Val	Tyr	Phe	
					325					330					335		
10	Thr	Asn	Asn	Gln	Gly	Thr	Trp	Gly	Gly	Ala	Ile	Met	Leu	Arg	Gln	Asp	
				340					345					350			
	Gly	Ala	Cys	Thr	Leu	Phe	Ala	Asp	Gln	Gly	Asp	Ile	Ile	Phe	Tyr	Asn	
			355					360					365				
	Asn	Arg	His	Phe	Lys	Asp	Thr	Phe	Ser	Asn	His	Val	Ser	Val	Asn	Cys	
		370					375					380					
	Thr	Arg	Asn	Val	Ser	Leu	Thr	Val	Gly	Ala	Ser	Gln	Gly	His	Ser	Ala	
20	385					390				395						400	
	Thr	Phe	Tyr	Asp	Pro	Ile	Leu	Gln	Arg	Tyr	Thr	Ile	Gln	Asn	Ser	Ile	
					405					410					415		
	Gln	Lys	Phe	Asn	Pro	Asn	Pro	Glu	His	Leu	Gly	Thr	Ile	Leu	Phe	Ser	
				420					425					430			
	Ser	Thr	Tyr	Ile	Pro	Asp	Thr	Ser	Thr	Ser	Arg	Asp	Asp	Phe	Ile	Ser	
			435				440					445					
30	His	Phe	Arg	Asn	His	Ile	Gly	Leu	Tyr	Asn	Gly	Thr	Leu	Ala	Leu	Glu	
		450					455					460					
	Asp	Arg	Ala	Glu	Trp	Lys	Val	Tyr	Lys	Phe	Asp	Gln	Phe	Gly	Gly	Thr	
	465					470					475					480	
	Leu	Arg	Leu	Gly	Ser	Arg	Ala	Val	Phe	Ser	Thr	Thr	Asp	Glu	Glu	Gln	
					485					490					495		
40	Ser	Ser	Ser	Ser	Val	Gly	Ser	Val	Ile	Asn	Ile	Asn	Asn	Leu	Ala	Ile	
				500					505					510			
	Asn	Leu	Pro	Ser	Ile	Leu	Gly	Asn	Arg	Val	Ala	Pro	Lys	Leu	Trp	Ile	
			515					520					525				
	Arg	Pro	Thr	Gly	Ser	Ser	Ala	Pro	Tyr	Ser	Glu	Asp	Asn	Asn	Pro	Ile	
		530					535					540					
	Ile	Asn	Leu	Ser	Gly	Pro	Leu	Ser	Leu	Leu	Asp	Asp	Glu	Asn	Leu	Asp	
50	545					550					555					560	
	Pro	Tyr	Asp	Thr	Ala	Asp	Leu	Ala	Gln	Pro	Ile	Ala	Glu	Val	Pro	Leu	
					565					570					575		
	Leu	Tyr	Leu	Leu	Asp	Val	Thr	Ala	Lys	His	Ile	Asn	Thr	Asp	Asn	Phe	
				580					585					590			
	Tyr	Pro	Glu	Gly	Leu	Asn	Thr	Thr	Gln	His	Tyr	Gly	Tyr	Gln	Gly	Val	
		595						600					605				
60	Trp	Ser	Pro	Tyr	Trp	Ile	Glu	Thr	Ile	Thr	Thr	Ser	Asp	Thr	Ser	Ser	
		610					615					620					

70/83

	Gln	Lys	Phe	Asn	Pro	Asn	Pro	Glu	His	Leu	Gly	Thr	Ile	Leu	Phe	Ser	
					255					260					265		
	Ser	Thr	Tyr	Ile	Pro	Asp	Thr	Ser	Thr	Ser	Arg	Asp	Asp	Phe	Ile	Ser	
				270					275					280			
10	His	Phe	Arg	Asn	His	Ile	Gly	Leu	Tyr	Asn	Gly	Thr	Leu	Ala	Leu	Glu	
			285					290					295				
	Asp	Arg	Ala	Glu	Trp	Lys	Val	Tyr	Lys	Phe	Asp	Gln	Phe	Gly	Gly	Thr	
		300					305					310					
	Leu	Arg	Leu	Gly	Ser	Arg	Ala	Val	Phe	Ser	Thr	Thr	Asp	Glu	Glu	Gln	
	315					320					325					330	
	Ser	Ser	Ser	Ser	Val	Gly	Ser	Val	Ile	Asn	Ile	Asn	Asn	Leu	Ala	Ile	
20					335					340					345		
	Asn	Leu	Pro	Ser	Ile	Leu	Gly	Asn	Arg	Val	Ala	Pro	Lys	Leu	Trp	Ile	
				350					355					360			
	Arg	Pro	Thr	Gly	Ser	Ser	Ala	Pro	Tyr	Ser	Glu	Asp	Asn	Asn	Pro	Ile	
			365					370					375				
	Ile	Asn	Leu	Ser	Gly	Pro	Leu	Ser	Leu	Leu	Asp	Asp	Glu	Asn	Leu	Asp	
	380					385						390					
30	Pro	Tyr	Asp	Thr	Ala	Asp	Leu	Ala	Gln	Pro	Ile	Ala	Glu	Val	Pro	Leu	
	395					400					405					410	
	Leu	Tyr	Leu	Leu	Asp	Val	Thr	Ala	Lys	His	Ile	Asn	Thr	Asp	Asn	Phe	
				415						420					425		
	Tyr	Pro	Glu	Gly	Leu	Asn	Thr	Thr	Gln	His	Tyr	Gly	Tyr	Gln	Gly	Val	
				430					435					440			
40	Trp	Ser	Pro	Tyr	Trp	Ile	Glu	Thr	Ile	Thr	Thr	Ser	Asp	Thr	Ser	Ser	
			445				450						455				
	Glu	Asp	Thr	Val	Asn	Thr	Leu	His	Arg	Gln	Leu	Tyr	Gly	Asp	Trp	Thr	
	460						465					470					
	Pro	Thr	Gly	Tyr	Lys	Val	Asn	Pro	Glu	Asn	Lys	Gly	Asp	Ile	Ala	Leu	
	475					480					485					490	
	Ser	Ala	Phe	Trp	Gln	Ser	Phe	His	Asn	Leu	Phe	Ala	Thr	Leu	Arg	Tyr	
50				495						500					505		
	Gln	Thr	Gln	Gln	Gly	Gln	Ile	Ala	Pro	Thr	Ala	Ser	Gly	Glu	Ala	Thr	
				510					515					520			
	Arg	Leu	Phe	Val	His	Gln	Asn	Ser	Asn	Asn	Asp	Ala	Lys	Gly	Phe	His	
			525					530					535				
	Met	Glu	Ala	Thr	Gly	Tyr	Ser	Leu	Gly	Thr	Thr	Ser	Asn	Thr	Ala	Ser	
	540						545					550					
60	Asn	His	Ser	Phe	Gly	Val	Asn	Phe	Ser	Gln	Leu	Phe	Ser	Asn	Leu	Tyr	
	555					560					565					570	

75/83

<210> 43
 <211> 931
 <212> PRT
 <213> Chlamydia pneumoniae

<400> 43

10	Met	Leu	Leu	Pro	Phe	Thr	Phe	Val	Leu	Ala	Asn	Glu	Gly	Leu	Gln	Leu	1	5	10	15
	Pro	Leu	Glu	Thr	Tyr	Ile	Thr	Leu	Ser	Pro	Glu	Tyr	Gln	Ala	Ala	Pro	20	25	30	
	Gln	Val	Gly	Phe	Thr	His	Asn	Gln	Asn	Gln	Asp	Leu	Ala	Ile	Val	Gly	35	40	45	
	Asn	His	Asn	Asp	Phe	Ile	Leu	Asp	Tyr	Lys	Tyr	Tyr	Arg	Ser	Asn	Gly	50	55	60	
20	Gly	Ala	Leu	Thr	Cys	Lys	Asn	Leu	Leu	Ile	Ser	Glu	Asn	Ile	Gly	Asn	65	70	75	80
	Val	Phe	Phe	Glu	Lys	Asn	Val	Cys	Pro	Asn	Ser	Gly	Gly	Ala	Ile	Tyr	85	90	95	
	Ala	Ala	Gln	Asn	Cys	Thr	Ile	Ser	Lys	Asn	Gln	Asn	Tyr	Ala	Phe	Thr	100	105	110	
30	Thr	Asn	Leu	Val	Ser	Asp	Asn	Pro	Thr	Ala	Thr	Ala	Gly	Ser	Leu	Leu	115	120	125	
	Gly	Gly	Ala	Leu	Phe	Ala	Ile	Asn	Cys	Ser	Ile	Thr	Asn	Asn	Leu	Gly	130	135	140	
	Gln	Gly	Thr	Phe	Val	Asp	Asn	Leu	Ala	Leu	Asn	Lys	Gly	Gly	Ala	Leu	145	150	155	160
40	Tyr	Thr	Glu	Thr	Asn	Leu	Ser	Ile	Lys	Asp	Asn	Lys	Gly	Pro	Ile	Ile	165	170	175	
	Ile	Lys	Gln	Asn	Arg	Ala	Leu	Asn	Ser	Asp	Ser	Leu	Gly	Gly	Gly	Ile	180	185	190	
	Tyr	Ser	Gly	Asn	Ser	Leu	Asn	Ile	Glu	Gly	Asn	Ser	Gly	Ala	Ile	Gln	195	200	205	
	Ile	Thr	Ser	Asn	Ser	Ser	Gly	Ser	Gly	Gly	Gly	Ile	Phe	Ser	Thr	Gln	210	215	220	
50	Thr	Leu	Thr	Ile	Ser	Ser	Asn	Lys	Lys	Leu	Ile	Glu	Ile	Ser	Glu	Asn	225	230	235	240
	Ser	Ala	Phe	Ala	Asn	Asn	Tyr	Gly	Ser	Asn	Phe	Asn	Pro	Gly	Gly	Gly	245	250	255	
	Gly	Leu	Thr	Thr	Thr	Phe	Cys	Thr	Ile	Leu	Asn	Asn	Arg	Glu	Gly	Val	260	265	270	
60	Leu	Phe	Asn	Asn	Asn	Gln	Ser	Gln	Ser	Asn	Gly	Gly	Ala	Ile	His	Ala	275	280	285	

79/83

	Thr	Pro	Ser	Ser	Gly	Thr	Tyr	Ala	Leu	Gly	Ser	Gly	Gly	Ala	Ile	Cys	
				260					265					270			
	Ile	Pro	Thr	Gly	Thr	Phe	Glu	Leu	Lys	Asn	Asn	Gln	Gly	Lys	Cys	Thr	
			275					280					285				
10	Phe	Ser	Tyr	Asn	Gly	Thr	Pro	Asn	Asp	Ala	Gly	Ala	Ile	Tyr	Ala	Glu	
		290					295					300					
	Thr	Cys	Asn	Ile	Val	Gly	Asn	Gln	Gly	Ala	Leu	Leu	Leu	Asp	Ser	Asn	
	305					310					315					320	
	Thr	Ala	Ala	Arg	Asn	Gly	Gly	Ala	Ile	Cys	Ala	Lys	Val	Leu	Asn	Ile	
				325						330					335		
	Gln	Gly	Arg	Gly	Pro	Ile	Glu	Phe	Ser	Arg	Asn	Arg	Ala	Glu	Lys	Gly	
				340					345					350			
20	Gly	Ala	Ile	Phe	Ile	Gly	Pro	Ser	Val	Gly	Asp	Pro	Ala	Lys	Gln	Thr	
			355					360					365				
	Ser	Thr	Leu	Thr	Ile	Leu	Ala	Ser	Glu	Gly	Asp	Ile	Ala	Phe	Gln	Gly	
		370					375					380					
	Asn	Met	Leu	Asn	Thr	Lys	Pro	Gly	Ile	Arg	Asn	Ala	Ile	Thr	Val	Glu	
	385					390					395					400	
30	Ala	Gly	Gly	Glu	Ile	Val	Ser	Leu	Ser	Ala	Gln	Gly	Gly	Ser	Arg	Leu	
					405					410					415		
	Val	Phe	Tyr	Asp	Pro	Ile	Thr	His	Ser	Leu	Pro	Thr	Thr	Ser	Pro	Ser	
				420					425					430			
	Asn	Lys	Asp	Ile	Thr	Ile	Asn	Ala	Asn	Gly	Ala	Ser	Gly	Ser	Val	Val	
			435					440					445				
40	Phe	Thr	Ser	Lys	Gly	Leu	Ser	Ser	Thr	Glu	Leu	Leu	Leu	Pro	Ala	Asn	
		450					455					460					
	Thr	Thr	Thr	Ile	Leu	Leu	Gly	Thr	Val	Lys	Ile	Ala	Ser	Gly	Glu	Leu	
	465					470					475					480	
	Lys	Ile	Thr	Asp	Asn	Ala	Val	Val	Asn	Val	Ala	Gly	Phe	Ala	Thr	Gln	
					485					490					495		
	Gly	Ser	Gly	Gln	Leu	Thr	Leu	Gly	Ser	Gly	Gly	Thr	Leu	Gly	Leu	Ala	
				500					505					510			
50	Thr	Pro	Thr	Gly	Ala	Pro	Ala	Ala	Val	Asp	Phe	Thr	Ile	Gly	Lys	Leu	
			515					520					525				
	Ala	Phe	Asp	Pro	Phe	Ser	Phe	Leu	Lys	Arg	Asp	Phe	Val	Ser	Ala	Ser	
		530					535					540					
	Val	Asn	Ala	Gly	Thr	Lys	Asn	Val	Thr	Leu	Thr	Gly	Ala	Leu	Val	Leu	
	545					550					555					560	
60	Asp	Glu	His	Asp	Val	Thr	Asp	Leu	Tyr	Asp	Met	Val	Ser	Leu	Gln	Ser	
					565					570					575		

80/83

	Pro	Val	Ala	Ile	Pro	Ile	Ala	Val	Phe	Lys	Gly	Ala	Thr	Val	Thr	Lys
				580					585					590		
	Thr	Gly	Phe	Pro	Asp	Gly	Glu	Ile	Ala	Thr	Pro	Ser	His	Tyr	Gly	Tyr
			595					600					605			
10	Gln	Gly	Lys	Trp	Ser	Tyr	Thr	Trp	Ser	Arg	Pro	Leu	Leu	Ile	Pro	Ala
		610					615					620				
	Pro	Asp	Gly	Gly	Phe	Pro	Gly	Gly	Pro	Ser	Pro	Ser	Ala	Asn	Thr	Leu
	625					630					635					640
	Tyr	Ala	Val	Trp	Asn	Ser	Asp	Thr	Leu	Val	Arg	Ser	Thr	Tyr	Ile	Leu
					645					650					655	
	Asp	Pro	Glu	Arg	Tyr	Gly	Glu	Ile	Val	Ser	Asn	Ser	Leu	Trp	Ile	Ser
20				660					665					670		
	Phe	Leu	Gly	Asn	Gln	Ala	Phe	Ser	Asp	Ile	Leu	Gln	Asp	Val	Leu	Leu
			675					680					685			
	Ile	Asp	His	Pro	Gly	Leu	Ser	Ile	Thr	Ala	Lys	Ala	Leu	Gly	Ala	Tyr
		690					695					700				
	Val	Glu	His	Thr	Pro	Arg	Gln	Gly	His	Glu	Gly	Phe	Ser	Gly	Arg	Tyr
	705					710					715					720
30	Gly	Gly	Tyr	Gln	Ala	Ala	Leu	Ser	Met	Asn	Tyr	Thr	Asp	His	Thr	Thr
					725					730					735	
	Leu	Gly	Leu	Ser	Phe	Gly	Gln	Leu	Tyr	Gly	Lys	Thr	Asn	Ala	Asn	Pro
				740					745					750		
	Tyr	Asp	Ser	Arg	Cys	Ser	Glu	Gln	Met	Tyr	Leu	Leu	Ser	Phe	Phe	Gly
			755					760					765			
40	Gln	Phe	Pro	Ile	Val	Thr	Gln	Lys	Ser	Glu	Ala	Leu	Ile	Ser	Trp	Lys
		770					775					780				
	Ala	Ala	Tyr	Gly	Tyr	Ser	Lys	Asn	His	Leu	Asn	Thr	Thr	Tyr	Leu	Arg
	785					790					795					800
	Pro	Asp	Lys	Ala	Pro	Lys	Ser	Gln	Gly	Gln	Trp	His	Asn	Asn	Ser	Tyr
					805					810					815	
	Tyr	Val	Leu	Ile	Ser	Ala	Glu	His	Pro	Phe	Leu	Asn	Trp	Cys	Leu	Leu
50				820					825					830		
	Thr	Arg	Pro	Leu	Ala	Gln	Ala	Trp	Asp	Leu	Ser	Gly	Phe	Ile	Ser	Ala
			835					840					845			
	Glu	Phe	Leu	Gly	Gly	Trp	Gln	Ser	Lys	Phe	Thr	Glu	Thr	Gly	Asp	Leu
		850					855					860				
	Gln	Arg	Ser	Phe	Ser	Arg	Gly	Lys	Gly	Tyr	Asn	Val	Ser	Leu	Pro	Ile
	865					870					875					880
60	Gly	Cys	Ser	Ser	Gln	Trp	Phe	Thr	Pro	Phe	Lys	Lys	Ala	Pro	Ser	Thr
					885					890					895	

81/83

	Leu	Thr	Ile	Lys	Leu	Ala	Tyr	Lys	Pro	Asp	Ile	Tyr	Arg	Val	Asn	Pro
				900					905					910		
	His	Asn	Ile	Val	Thr	Val	Val	Ser	Asn	Gln	Glu	Ser	Thr	Ser	Ile	Ser
			915					920					925			
10	Gly	Ala	Asn	Leu	Arg	Arg	His	Gly	Leu	Phe	Val	Gln	Ile	His	Asp	Val
		930					935					940				
	Val	Asp	Leu	Thr	Glu	Asp	Thr	Gln	Ala	Phe	Leu	Asn	Tyr	Thr	Phe	Asp
	945					950					955					960
	Gly	Lys	Asn	Gly	Phe	Thr	Asn	His	Arg	Val	Ser	Thr	Gly	Leu	Lys	Ser
					965					970					975	
	Thr	Phe														
20																
	<210>	45														
	<211>	813														
	<212>	PRT														
	<213>	Chlamydia pneumoniae														
	<400>	45														
	Ser	Ala	Leu	Gln	Pro	Thr	Asp	Ser	Leu	Thr	Val					
	1				5					10						
30	Glu	Asn	Ile	Ser	Gln	Ser	Ile	Lys	Phe	Phe	Gly	Asn	Leu	Ala	Asn	Phe
				15					20					25		
	Gly	Ser	Ala	Ile	Ser	Ser	Ser	Pro	Thr	Ala	Val	Val	Lys	Phe	Ile	Asn
			30					35					40			
	Asn	Thr	Ala	Thr	Met	Ser	Phe	Ser	His	Asn	Phe	Thr	Ser	Ser	Gly	Gly
		45					50					55				
40	Gly	Val	Ile	Tyr	Gly	Gly	Ser	Ser	Leu	Leu	Phe	Glu	Asn	Asn	Ser	Gly
	60					65					70					75
	Cys	Ile	Ile	Phe	Thr	Ala	Asn	Ser	Cys	Val	Asn	Ser	Leu	Lys	Gly	Val
					80					85					90	
	Thr	Pro	Ser	Ser	Gly	Thr	Tyr	Ala	Leu	Gly	Ser	Gly	Gly	Ala	Ile	Cys
				95					100					105		
	Ile	Pro	Thr	Gly	Thr	Phe	Glu	Leu	Lys	Asn	Asn	Gln	Gly	Lys	Cys	Thr
			110					115					120			
50	Phe	Ser	Tyr	Asn	Gly	Thr	Pro	Asn	Asp	Ala	Gly	Ala	Ile	Tyr	Ala	Glu
		125					130					135				
	Thr	Cys	Asn	Ile	Val	Gly	Asn	Gln	Gly	Ala	Leu	Leu	Leu	Asp	Ser	Asn
	140					145					150					155
	Thr	Ala	Ala	Arg	Asn	Gly	Gly	Ala	Ile	Cys	Ala	Lys	Val	Leu	Asn	Ile
				160						165					170	
60	Gln	Gly	Arg	Gly	Pro	Ile	Glu	Phe	Ser	Arg	Asn	Arg	Ala	Glu	Lys	Gly
				175					180					185		

82/83

	Gly	Ala	Ile	Phe	Ile	Gly	Pro	Ser	Val	Gly	Asp	Pro	Ala	Lys	Gln	Thr
			190					195					200			
	Ser	Thr	Leu	Thr	Ile	Leu	Ala	Ser	Glu	Gly	Asp	Ile	Ala	Phe	Gln	Gly
		205					210					215				
10	Asn	Met	Leu	Asn	Thr	Lys	Pro	Gly	Ile	Arg	Asn	Ala	Ile	Thr	Val	Glu
	220					225					230					235
	Ala	Gly	Gly	Glu	Ile	Val	Ser	Leu	Ser	Ala	Gln	Gly	Gly	Ser	Arg	Leu
					240					245					250	
	Val	Phe	Tyr	Asp	Pro	Ile	Thr	His	Ser	Leu	Pro	Thr	Thr	Ser	Pro	Ser
				255					260					265		
	Asn	Lys	Asp	Ile	Thr	Ile	Asn	Ala	Asn	Gly	Ala	Ser	Gly	Ser	Val	Val
20			270					275					280			
	Phe	Thr	Ser	Lys	Gly	Leu	Ser	Ser	Thr	Glu	Leu	Leu	Leu	Pro	Ala	Asn
		285					290					295				
	Thr	Thr	Thr	Ile	Leu	Leu	Gly	Thr	Val	Lys	Ile	Ala	Ser	Gly	Glu	Leu
	300					305					310					315
	Lys	Ile	Thr	Asp	Asn	Ala	Val	Val	Asn	Val	Ala	Gly	Phe	Ala	Thr	Gln
					320					325					330	
30	Gly	Ser	Gly	Gln	Leu	Thr	Leu	Gly	Ser	Gly	Gly	Thr	Leu	Gly	Leu	Ala
				335					340					345		
	Thr	Pro	Thr	Gly	Ala	Pro	Ala	Ala	Val	Asp	Phe	Thr	Ile	Gly	Lys	Leu
			350					355					360			
	Ala	Phe	Asp	Pro	Phe	Ser	Phe	Leu	Lys	Arg	Asp	Phe	Val	Ser	Ala	Ser
		365					370					375				
40	Val	Asn	Ala	Gly	Thr	Lys	Asn	Val	Thr	Leu	Thr	Gly	Ala	Leu	Val	Leu
	380					385					390					395
	Asp	Glu	His	Asp	Val	Thr	Asp	Leu	Tyr	Asp	Met	Val	Ser	Leu	Gln	Ser
					400					405					410	
	Pro	Val	Ala	Ile	Pro	Ile	Ala	Val	Phe	Lys	Gly	Ala	Thr	Val	Thr	Lys
				445					420					425		
	Thr	Gly	Phe	Pro	Asp	Gly	Glu	Ile	Ala	Thr	Pro	Ser	His	Tyr	Gly	Tyr
			430					435					440			
50	Gln	Gly	Lys	Trp	Ser	Tyr	Thr	Trp	Ser	Arg	Pro	Leu	Leu	Ile	Pro	Ala
		445					450					455				
	Pro	Asp	Gly	Gly	Phe	Pro	Gly	Gly	Pro	Ser	Pro	Ser	Ala	Asn	Thr	Leu
	460					465					470					475
	Tyr	Ala	Val	Trp	Asn	Ser	Asp	Thr	Leu	Val	Arg	Ser	Thr	Tyr	Ile	Leu
					480					485					490	
60	Asp	Pro	Glu	Arg	Tyr	Gly	Glu	Ile	Val	Ser	Asn	Ser	Leu	Trp	Ile	Ser
				495					500					505		

83 / 83

[illegible]